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Despite the prevalence of musculoskeletal disorders, one of the leading causes of work-
related disability in the United States, effective therapeutic delivery to the affected 
musculoskeletal tissues such as bone, cartilage, and muscle remains a significant 
challenge.  Thus, the long term goal of this research was to develop a tunable 
biomaterial-based system for the delivery of regenerative therapeutics to musculoskeletal 
tissues.  This goal was approached through the engineering of a heparin-based 
microparticle (MP) system with tunable heparin sulfation, heparin content, and hydrolytic 
degradation, which was subsequently employed for in vitro release of an osteoinductive 
growth factor and in vivo delivery of a chondroprotective anti-inflammatory protein and a 
chemokine capable of recruiting pro-regenerative cells to muscle.   
In aim 1, hydrolytically-degradable, heparin-based MPs were fabricated 
containing heparin derivatives of varying levels of sulfation, and N-desulfated heparin 
MPs were found to efficiently load and release an osteoinductive growth factor, bone 
morphogenetic protein-2 (BMP-2), in vitro.  In aim 2, heparin-based MPs were loaded 
with tumor necrosis factor- stimulated gene-6 (TSG-6), an anti-inflammatory protein 
known to inhibit plasmin, and delivered via intra-articular injection to rat knees in the 
context of post-traumatic osteoarthritis.  After 21 days, TSG-6 loaded MPs reduced 
cartilage damage following injury, whereas a 3X higher dose of soluble TSG-6 did not, 
suggesting that Hep-N can enhance TSG-6 bioactivity in vivo and that Hep-N-based MPs 
can effectively deliver a chondroprotective protein for cartilage regeneration.  Finally, in 
aim 3, heparin-based MPs were loaded with the chemokine stromal cell-derived factor-
1 (SDF-1) and delivered via local injection to the supraspinatus muscle in combination 
 xvii 
with systemic delivery of the bone marrow mobilizing agent, VPC01091, following 
severe rotator cuff injury in rats.  Co-delivery of SDF-1 loaded MPs and VPC01091 led 
to significant modulation of the inflammatory cellular milieu and mesenchymal stem cell 
population in muscle 3 and 7 days following injury, along with significantly more 
regenerating muscle fibers compared to either treatment alone.   
Overall, in this thesis, heparin-based MPs were utilized to deliver therapeutics 
capable of stimulating endogenous healing processes in two unique contexts of cartilage 
and muscle degeneration.  Given the tunability of the MP system and the ability for 
heparin to bind and interact with a myriad of proteins, the application of heparin-based 
MPs extends beyond cartilage and muscle, and may be used for a wide range of 









Despite the prevalence of musculoskeletal disorders, one of the leading causes of work-
related disability in the United States [1], effective therapeutic delivery to the affected 
musculoskeletal tissues such as bone, cartilage, and muscle remains a significant 
challenge [2].  Though systemic drug delivery may be an option for some conditions, 
supraphysiological doses are often required which can be costly and result in adverse side 
effects for the patient [3–6].  Local delivery strategies may alleviate these shortcomings, 
but methods that require additional invasive surgical procedures may have limited 
clinical application as well.  Moreover, in many musculoskeletal disorders, the affected 
and degenerating musculoskeletal tissues lie within the joint space, which presents an 
additional challenge to effectively target and treat these tissues [7].   
Once delivered to the site of injury or disease, controlled and sustained release of 
drugs for many musculoskeletal conditions is also critical.  Though dependent on many 
factors, soluble proteins and small molecules are often rapidly cleared from the site of 
delivery [6–8], limiting therapeutic efficacy, and for chronic and progressive disorders, 
sustained release of therapeutics may be beneficial and reduce the number of repeat 
injections required.  For these reasons, among others, treatment strategies are in high 
demand for degenerating tissues in many musculoskeletal conditions. 
The research presented in this thesis strives to develop a tunable biomaterial-based 
platform for the facile delivery of regenerative therapeutics for musculoskeletal tissues 
including bone, cartilage, and muscle.  Though a myriad of hydrogel-based drug delivery 
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systems exist [9–12], microparticles are advantageous as they are injectable using 
standard needles and syringes without an invasive surgical procedure, which may 
facilitate clinical translation of these biomaterials [13–16].  Furthermore, particularly 
advantageous for musculoskeletal diseases, microparticles can be injected directly into 
muscle, tendon, or into the joint space for treatment of articular cartilage and bone. 
Furthermore, our laboratory and others have focused on the development of 
microparticles containing heparin, a highly sulfated glycosaminoglycan (GAG) that can 
bind with a myriad of positively-charged proteins through sequence-specific interactions 
and, primarily due to heparin’s sulfate groups, electrostatic interactions [9,14,17–19].  
That said, though we and others have previously employed heparin-based biomaterials to 
load and release positively-charged proteins, varying heparin sulfation may be a method 
to further tune heparin-protein electrostatic interactions and, in turn, modulate protein 
release.  Thus, alteration and assessment of heparin sulfation level, as well as heparin 
content and hydrolytic degradation of microparticles, may be a novel approach to develop 
a more tunable therapeutic delivery platform. 
Through binding and interacting with proteins, heparin has also shown to protect 
and even enhance protein bioactivity, potentially enhancing their therapeutic efficacy in 
vivo [20–22].  However, few studies have investigated how heparin sulfation affects 
protein bioactivity, especially in the context of musculoskeletal tissue regeneration.  
Furthermore, varying heparin content and heparin sulfation within microparticles may 
further modulate protein release and bioactivity, which has never been assessed 
previously.  Thus, the development of a heparin-based microparticle platform may 
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facilitate systematic evaluation of how heparin sulfation, among other variables, affects 
therapeutic release and bioactivity when delivered in vitro and in vivo. 
 
1.2 RESEARCH OBJECTIVES 
Overall, the long term goal of this research was to develop a tunable biomaterial-based 
system for the delivery of regenerative therapeutics for musculoskeletal tissue including 
bone, cartilage, and muscle.  This goal was achieved through the engineering of a 
heparin-based microparticle system with tunable heparin sulfation, heparin content, and 
hydrolytic degradation, which was subsequently employed for in vitro release of an 
osteoinductive growth factor and in vivo delivery of a chondroprotective anti-
inflammatory protein and a chemokine capable of recruiting pro-regenerative cells to 
muscle. 
First, a tunable heparin-based microparticle system was developed through the 
modulation of hydrolytic degradation, heparin sulfation, and heparin content within 
microparticles to, in turn, vary the in vitro loading, release, and bioactivity of an 
osteoinductive growth factor, BMP-2.  Then, a single formulation, hydrolytically 
degradable N-desulfated heparin-based microparticles, was assessed as an in vivo 
delivery vehicle for two musculoskeletal tissues, cartilage and muscle, in two unique 
injury contexts.  First, heparin-based microparticles were utilized to deliver the anti-
inflammatory protein TSG-6 to reduce cartilage degeneration in a rat model of post-
traumatic osteoarthritis and second, to deliver the chemokine SDF-1 alone or in 
combination with systemic delivery of a bone marrow mobilizing agent, VPC01091, to 
recruit pro-regenerative cells to muscle in a rat model of severe rotator cuff tear. 
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The overarching rationale for this project is that the engineering of a heparin-
based drug delivery platform can be utilized to deliver bioactive therapeutics for 
musculoskeletal tissues including cartilage and muscle.  The overall hypothesis of this 
work is that heparin-based microparticles can be tuned to efficiently deliver bioactive 
proteins in vitro and in vivo, thereby preventing cartilage degeneration in the context of 
post-traumatic osteoarthritis via an anti-inflammatory protein and promoting a pro-
regenerative cellular milieu within muscle in the context of rotator cuff tear via a 
chemokine.  This hypothesis was investigated in the following three specific aims:  
 
Specific Aim 1: Develop hydrolytically-degradable heparin-based microparticles 
and evaluate their ability to act as a drug delivery vehicle for a positively-charged 
osteoinductive protein in vitro.   
The hypothesis for this aim is that altering heparin sulfation level, heparin content, and 
degradation properties of heparin-based microparticles, three approaches to control BMP-
2 release from microparticles, will allow for tunable growth factor delivery kinetics from 
these materials.  The rationale for this aim is that heparin has been shown to bind 
positively-charged BMP-2 in part through its negatively-charged sulfate groups [15].  
Thus, release of BMP-2 from microparticles may be tuned by systematically altering 
heparin sulfation and content within microparticles, as well as hydrolytic degradation rate 
of microparticles.  First, hydrolytically-degradable heparin-based microparticles of 
varying sulfation levels (fully sulfated, N-desulfated, 6O,N-desulfated, and fully 
desulfated), heparin content (1 and 10 wt%), and hydrolytic degradation rate (7 to 14 
days) were fabricated.  Subsequently, loading and release of BMP-2 from microparticles 
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was assessed over 10 days via ELISA, followed by evaluation of the bioactivity of 
released BMP-2 via a cell-based C2C12 alkaline phosphatase (ALP) bioactivity assay.  
Lastly, to further probe the effect of heparin sulfation on BMP-2 denaturation, BMP-2 
was incubated with each soluble heparin derivative of varying total sulfation and 
analyzed via ELISA. 
 
Specific Aim 2: Evaluate the ability of an anti-inflammatory protein delivered via 
heparin-based microparticles to reduce cartilage degeneration in a rat model of 
post-traumatic osteoarthritis. 
The hypothesis for this aim is that heparin of greater total sulfation will enhance TSG-6 
bioactivity and, subsequently, TSG-6 loaded onto heparin-based microparticles with the 
appropriate sulfation level and delivered via intra-articular injection will reduce cartilage 
damage significantly more than soluble TSG-6 treatment in a model of post-traumatic 
osteoarthritis (OA).  The rationale for this aim is, first, that heparin has previously shown 
to bind and enhance TSG-6 bioactivity, potentially by maintaining TSG-6 in a “closed” 
conformation [22,23], though the effect of heparin sulfation on TSG-6 bioactivity has yet 
to be assessed.  Second, TSG-6 has been shown to possess anti-inflammatory properties 
through the inhibition of plasmin, an enzyme present in OA joints and capable of 
activating matrix metalloproteinases (MMPs) and degrading extracellular matrix (ECM) 
[24–27].  Therefore, as plasmin may be a key factor in the cartilage degeneration seen in 
OA joints, TSG-6 delivery may be a method to ameliorate the cartilage degeneration 
observed.  To that end, heparin derivatives of varying sulfation level between 0-100% 
total sulfation were incubated with TSG-6 to assess their effect on TSG-6 bioactivity 
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using a plasmin inhibition assay.  The results of the in vitro studies subsequently 
informed the development of degradable, N-desulfated heparin-based microparticles to 
release bioactive TSG-6 via intra-articular injection to the knee of rats following post-
traumatic OA injury.  Medial meniscal transection (MMT) injury was induced in the knee 
of rats at day 0, followed by 3 weekly injections of TSG-6 loaded microparticles, soluble 
TSG-6, or no treatment.  After 21 days, animals were euthanized to assess cartilage 
proteoglycan content (histology and safranin-O staining) and cartilage thickness, volume, 
and attenuation (Equilibrium Partitioning of an Ionic Contrast agent via µCT analysis, 
EPIC-µCT). 
 
Specific Aim 3: Evaluate the ability for bone marrow-derived cell mobilization and 
subsequent bone marrow-derived cell recruitment to synergistically increase the 
pro-regenerative cellular milieu within muscle following rotator cuff injury. 
The hypothesis for this aim is that systemic delivery of a bone marrow mobilizing agent, 
VPC01091, in combination with intra-muscular delivery of a chemokine, SDF-1α, loaded 
onto microparticles, will synergistically enhance the number of pro-regenerative bone 
marrow-derived cells in the muscle compared to either treatment alone.  The rationale for 
this aim is that SDF-1 has previously shown to attract immune cells such as monocytes 
7,8, stem cells such as hematopoietic [30] and mesenchymal stem cells (MSCs) [31], and 
progenitor cell populations [12,32], among others [33,34].  Furthermore, through 
sphingosine 1 phosphate receptor 1 (S1PR1) agonism and S1PR3 antagonism [35], 
VPC01091 has previously shown to increase  LSK cell (LinnegSca-1+c-Kit+, early 
hematopoietic stem cells) and MSC migration [36], ultimately resulting in significantly 
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more CXCR4+ cells (cells possessing the primary receptor for SDF-1) in circulation 
[36].  Thus, through VPC01091-mediated mobilization of CXCR4+ cells, and subsequent 
SDF-1-mediated recruitment of CXCR4+ cells into the muscle, co-delivery of 
VPC01091 and SDF-1 may be a method to recruit pro-regenerative cell populations to 
the muscle following severe rotator cuff injury and prevent muscle degeneration.  First, 
SDF-1 release kinetics from heparin-based microparticles was monitored in vitro via 
ELISA and in vivo via near-infrared protein tracking.  Next, VPC01091 was delivered via 
intraperitoneal injection and SDF-1 loaded microparticles were delivered via intra-
muscular injection immediately following tendon transection and denervation in rats.  
Following injury and treatment, pro-regenerative cell mobilization was assessed in blood 
over 7 days and cell recruitment was assessed in muscle at day 3 and 7 via flow 
cytometry.  Finally, muscle fiber regeneration and angiogenesis were assessed at day 7 
and 14 via immunohistochemistry for embryonic myosin heavy chain (eMHC and H&E) 
and CD31, respectively.  Finally, after 14 days muscle degeneration was assessed via 
muscle fiber regeneration (eMHC and H&E), muscle atrophy (muscle weight), functional 
testing (isometric torque testing). 
 
1.3 SIGNIFICANCE AND SCIENTIFIC CONTRIBUTION 
Musculoskeletal disorders, including arthritis and rotator cuff tears, are among the 
most common chronic conditions affecting the US population today [1,37], yet methods 
to effectively treat the associated degenerating tissues remains an unsolved problem.  
Thus, to develop a delivery method for therapeutics following musculoskeletal injuries, a 
heparin-based microparticle system was first engineered and assessed in vitro.  The 
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tunability of the microparticle system was validated by modulating heparin content (1 and 
10 wt%), heparin sulfation (0 to 100% total sulfation), and hydrolytic degradation (8 to 
30 days) of microparticles to, in turn, modulate the in vitro loading, release, and 
bioactivity of a positively-charged protein, BMP-2.  Though BMP-2 loading was 
unaffected by these variables, microparticles with greater heparin content and greater 
heparin sulfation released significantly more BMP-2 and enhanced BMP-2 bioactivity in 
vitro.  Finally, given the diminished anti-coagulant properties of desulfated heparin 
derivatives compared to fully sulfated heparin (Hep), N-desulfated heparin (Hep-N, 80% 
sulfation compared to Hep) was chosen for the fabrication of microparticles used for 
subsequent in vivo therapeutic delivery. 
Next, heparin-based microparticles were employed to deliver a anti-inflammatory 
protein, TSG-6, in the context of osteoarthritis, a condition which affects more than 60% 
of Americans over 65 years of age and is characterized by significant articular cartilage 
degeneration [4,38,39].  While OA is a multi-factorial disease, at stages of disease 
progression both cartilage-resident chondrocytes and synoviocytes in the joint capsule 
have been found to secrete increased levels of inflammatory factors known to promote or 
be directly involved in cartilage degradation [39–41].  Additionally, components of the 
plasminogen activation pathway [24–27] have been shown to be upregulated in OA 
joints, which can in turn activate MMPs and degrade ECM [42,43].  Thus, TSG-6, which 
exhibits both anti-inflammatory and anti-plasmin activity, was delivered as a method to 
ameliorate the cartilage degeneration exhibited in OA joints [26,44].  Degradable, 10 
wt% Hep-N microparticles were found to release and enhance TSG-6 bioactivity in vitro, 
and in vivo TSG-6 was significantly more chondroprotective than a 3x dose of soluble 
 9 
TSG-6.  Ultimately, a novel, heparin-based biomaterial system was developed and 
validated as a method to load, release, and enhance the therapeutic efficacy of a 
therapeutic for musculoskeletal tissue. 
Finally, heparin-based microparticles were validated as a method to delivery 
therapeutics to muscle in the context of severe rotator cuff injury.  Though nearly 
300,000+ rotator cuff repairs occur annually [45], the current standard of surgical 
treatment involves only the reattachment of the tendons to the humeral head, resulting in 
continued degeneration of the supraspinatus and infraspinatus muscles of the rotator cuff, 
an increased likelihood of re-tear, and poor patient prognoses.  Thus, the work described 
in this thesis is significant, first, because the timeline of cell inflammatory cell and stem 
cell recruitment following rotator cuff injury is investigated using an animal model of 
severe rotator cuff injury.  Using a rat model of severe rotator cuff tear, though no 
significant changes in inflammatory cells were observed 3 days following injury, a 
significant increase in total leukocytes and macrophages were observed in injured 
supraspinatus muscles compared to uninjured contralateral controls after 7 days.  
Subsequently, though no significant differences were observed at 1 week, by 3 and 6 
weeks significant muscle atrophy and fibrosis was observed in injured supraspinatus 
muscles compared to uninjured muscles.  Fatty infiltration was also investigated via 
histology, though no significant differences were observed between injured and uninjured 
supraspinatus muscles in our studies.  Ultimately, the results of this work elucidated the 
timeline of inflammatory and stem cell recruitment following tendon transection and 
denervation in rats, providing a platform to further investigate and modulate the cellular 
milieu following rotator cuff injury. 
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Following characterization of muscle degeneration in the animal model, 10 wt% 
Hep-N microparticles were ultimately employed to deliver the chemokine SDF-1 to the 
supraspinatus muscle alone and in combination with systemic delivery of a bone marrow 
mobilizing agent, VPC01091, following rotator cuff tear.  After 7 days post-injury and 
treatment, significantly more anti-inflammatory, M2-like macrophages and MSCs were 
detected with SDF-1 MPs alone, and when in combination with VPC010191, the 
M2:M1 macrophage ratio was also significantly increased compared to injury by day 3 
and 7 in muscle.  By day 7 significantly more eMHC+ regenerating muscle fibers were 
observed in the dual treatment group than any treatment or injury alone.  Thus, this work 
is significant in that our novel microparticle platform was utilized to deliver therapeutics 
to modulate the cellular milieu of muscle toward a more pro-regenerative state following 
rotator cuff injury. 
Overall, in this thesis, a biomaterial-based drug delivery system was developed to 
effectively treat degenerating musculoskeletal tissues following injury or disease.  A 
naturally derived glycosaminoglycan, heparin, and poly (ethylene glycol) (PEG), a 
polymer that is FDA-approved as PEG-conjugated drugs, were utilized to reduce the 
likelihood of an undesired immune response and to increase the potential for clinical 
translation in the future.  Furthermore, injectable biomaterial-based microparticles were 
fabricated, enabling delivery of therapeutics to the articular cartilage and muscle without 
invasive surgical procedures.  Once developed, heparin-based microparticles were 
assessed as a drug delivery vehicle, and were shown to release multiple positively-
charged proteins over several days in vitro and in vivo and enhance the bioactivity of 
each protein compared to soluble controls.  Finally, the ability of the microparticle 
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system to treat degenerating musculoskeletal tissues was validated through the delivery 
of an anti-inflammatory protein to reduce articular cartilage damage following post-
traumatic OA and through the delivery of a chemotactic protein to recruit pro-healing 
cells to the muscle following rotator cuff tear.  Given the tunability of the microparticle 
system and the ability for heparin to bind and interact with a myriad of proteins, the 
application of heparin-based microparticles extends far beyond cartilage and muscle, and 
may be used for a wide range of applications where controlled release of bioactive 




















2.1 BIOMATERIALS FOR DRUG DELIVERY 
2.1.1 MICROPARTICLES FOR DRUG DELIVERY 
For biomaterial-based drug delivery strategies, a wide range of microparticle (MP) 
systems have been developed and exhibit significant advantages compared to bulk 
hydrogels.  First, MPs are advantageous as they are injectable using standard needles and 
syringes, allowing for clinical translation in the future [13–16].  Though some hydrogel 
systems are also injectable, the free radicals or initiators required for crosslinking once in 
the body may be detrimental to the patient or denature the delivered protein [46–48].  
Particularly advantageous for certain musculoskeletal diseases, MPs can also be injected 
directly into muscle, tendon, or into the joint space for treatment of articular cartilage 
[49] and bone [50].  Finally, MPs can be made with a myriad of materials, including 
synthetic, bioinert polymers such as poly (ethylene glycol) (PEG) and naturally-derived 
materials [15,51]. 
2.1.2 HEPARIN-BASED BIOMATERIALS 
Though MPs have been fabricated with a variety of materials, a major consideration in 
the use of MPs for drug delivery is their ability to efficiently load and release the 
therapeutic of interest in a controlled manner.  Previously, materials including chitosan, 
collagen, gelatin, and PEG have been used to deliver a myriad of proteins [52–55].  
However, our laboratory and others have explored the use of glycosaminoglycans 
(GAGs) within our biomaterials to better control the loading and release kinetics of each 
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therapeutic [9,14,21,56]. GAGs are linear polysaccharides found within the extracellular 
matrix (ECM) either as free chains or covalently bound to a polypeptide core, collectively 
known as proteoglycans [57,58].  Heparin in particular is a highly sulfated GAG species 
found mainly in mast cells of connective tissues, although heparan sulfate, a similar GAG 
species, is abundantly found on cell surfaces throughout the body [59].  Native heparin is 
well-known for its anti-coagulant properties, but other biological functions include tumor 
growth inhibition and antiviral activity [60].  Furthermore, heparin is capable of binding 
with proteins through carbohydrate sequence-specific interactions and through 
electrostatic interactions with positively-charged proteins, primarily due to heparin’s 
negatively-charged sulfate groups [58,61,62].   
Harnessing these protein-binding properties, significant research has focused on 
the development of heparin-based drug delivery systems [63–67].  As bulk hydrogels, 
heparin-based materials have been used to deliver basic fibroblast growth factor (bFGF) 
[68], bone morphogenetic protein-2 (BMP-2) [69–71], epidermal growth factor (EGF) 
[72], human growth hormone (HGH) [73], stromal cell-derived factor-1alpha (SDF-1) 
[11], and vascular endothelial growth factor (VEGF), among others.  In our lab 
specifically, heparin-based hydrogels have been used to release proteins and small 
molecules in vitro  [17] and in vivo [9,10], as well as to encapsulate mesenchymal stem 
cells (MSCs) [56].  Though fewer systems exist to date, injectable heparin-based 
biomaterials have become increasingly more prevalent for a wide variety of applications.  
Injectable heparin-based hydrogel systems have been used to encapsulate cells including 
primary chondrocytes [74], hepatocytes [75] and fibroblasts [76] and to release a model 
protein as a proof-of-concept study [77], hepatocyte growth factor (HGF) [75], and FGF-
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2 [78].  Finally, though heparin-decorated hyaluronic particles exhibited near zero order 
release of BMP-2 after an initial burst release [16], few other heparin-based MP systems 
currently exist.   
In our work, we have collaborated with other labs to develop 100% heparin MPs, 
which have previously shown to modulate release of BMP-2 in vitro [15] and bone 
regeneration in vivo [50,79].  Furthermore, 100% heparin MPs have been incorporated 
within core-shell MPs to modulate BMP-2 release [13], while 10 wt% heparin-based MPs 
have been incorporated within ATDC5 cell aggregates to control cell differentiation [80].  
Ultimately, several heparin-based drug delivery systems have been developed with 
varying levels of success, and these results indicate that heparin-based materials may be 
an effective and tunable drug delivery method. 
2.1.3 HEPARIN SULFATION 
To further probe the interactions between heparin and heparin-binding proteins, heparin 
sulfation has been investigated in several contexts.  Given that heparin’s negatively-
charged sulfate groups are primarily responsible for the electrostatic interactions between 
heparin and positively-charged molecules, several labs have investigated how altering 
heparin sulfation levels and patterns may affect binding to proteins.  In the Werner lab, 
hydrogels composed of heparin derivatives of varying sulfation level were used to tune 
loading and release of several proteins from the biomaterial [66,81].   For VEGF, the less 
sulfated, less negatively-charged heparin hydrogels were found to load significantly less 
protein.  However, these less sulfated heparin-based hydrogels released a significantly 
higher percentage of their loaded cargo, indicating that these hydrogels may have had 
decreased affinity toward the positively-charged VEGF.  Similar results were also seen 
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using FGF-2, whereby the amount of protein released from heparin-based hydrogels 
increased as the heparin was more desulfated [81].  In our lab as well, heparin can be 
systematically desulfated resulting in fully sulfated (Hep), N-desulfated (Hep-N), 6O,N-
desulfated (Hep-6O,N) and fully desulfated (Hep-) heparin derivatives with 100, 80, 20, 
and 0% total sulfation, respectively [21].  When these heparin derivatives were 
incorporated within 10 wt% heparin hydrogels, it was found that significantly more 
crystal violet, a cationic small molecule, was loaded onto the more sulfated Hep and Hep-
N hydrogels compared to the more desulfated heparin hydrogels.  Furthermore, the release 
of crystal violet from the more sulfated heparin hydrogels was more linear and sustained 
than from the more desulfated heparin hydrogels, where significantly more burst release 
was observed.  Thus, utilizing heparin within biomaterials has shown to enable efficient 
protein loading and release, and altering heparin sulfation may offer a means to further 
tune this loading and release. 
HEPARIN AND BMP-2 
Aside from altering binding and release, heparin sulfation has shown to play a 
significant role in the bioactivity of proteins as well [14,21,82,83].  As described above, 
heparin’s negatively charged sulfate groups allow for binding to many positively-charged 
proteins, but heparin sulfation also contributes to heparin’s sequence-specific binding to 
certain proteins [58].  These interactions have been studied extensively for many proteins.  
For example, with BMP-2 it was found that heparin likely can bind to two locations on an 
electropositive surface of BMP-2, where specific sulfate groups are involved, and 
possibly required, for complete binding between heparin and BMP-2 [62,84].  It has also 
been determined that heparin does not affect BMP-2 binding to its receptor, which 
eliminates this possible mechanism by which heparin can enhance BMP-2 bioactivity.  
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However, other hypotheses have been published, including the conjecture that heparin 
acts as a continuous ligand for BMP-2 [85].  In in vitro culture, heparin suppressed the 
accumulation of BMP-2 onto the cell layer, and rather maintained the BMP-2 and BMP-2 
bioactivity within the culture media and overall these studies indicates that heparin could 
protect BMP-2 homodimer and heterodimer activity.  It has also has been shown that 
heparin sulfate proteoglycans increase the recruitment of type II receptor units to BMP-2 
type 1 receptor heteromeric complexes, which can subsequently regulate signaling [84].   
In another study, BMP-2 was able to prolong the half-life of BMP-2 by 20-fold, 
indicating that heparin can protect BMP-2 from denaturation.  Furthermore, when in the 
presence of heparin, noggin failed to inhibit BMP-2 activity, which also suggests that 
heparin may out-compete for binding to BMP-2 compared to certain inhibitors, further 
enhancing BMP-2 activity [86].  Finally, the effect of selective desulfation of heparin on 
BMP-2 bioactivity was assessed in vitro and in vivo [87].  2O-desulfated heparin was the 
most effective in enhancing BMP-2-mediated MSC proliferation, whereas 6O-desulfated 
heparin was least effective, and 2O-desulfate heparin enhanced BMP-2-mediated bone 
formation in vivo significantly more than native heparin.   A similar pattern was found 
with BMP-2 binding to heparin, whereby 2O-desulfated heparin bound the most BMP-2 
and 6O-desulfated heparin bound the least, which all collectively suggest that specific 
sulfate groups are differentially required for protein binding and modulation of protein 
bioactivity. 
HEPARIN AND TSG-6 
Heparin interactions with the anti-inflammatory protein tumor necrosis factor-alpha 
stimulated gene-6 (TSG-6) have also been studied.  TSG-6 is comprised primarily of link 
and complement C1r/C1s-, uEGF-, BMP-1-like (CUB) modules, and the link module in 
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particular has shown to bind to GAGs such as chondroitin-4 sulfate (C4S),14 chondroitin-
6 sulfate (C6S), dermatan sulfate, heparin 18,19, and the non-sulfated GAG, hyaluronic 
acid (HA) 15-17.  Though several GAG species bind within the link modules of TSG-6, the 
binding domains for heparin and HA, for example, were found to be distinct and non-
overlapping 14,18,23.  Unlike HA which binds to the link module of TSG-6 at a 1:1 molar 
ratio, the stoichiometry for heparin and TSG-6 was found to be ~0.46±0.06.  As this 
value is close to 0.5, it is hypothesized that two TSG-6 link modules may bind to heparin 
to form a protein dimer 23.  Importantly, once bound to heparin, TSG-6 does not undergo 
a conformational change as with HA, and therefore remains in a “closed” state 20,23.  
Furthermore, TSG-6 binding to heparin has previously shown to enhance TSG-6 anti-
plasmin activity in vitro, whereas TSG-6 anti-plasmin activity was unaffected or even 
inhibited by HA 23.  Thus, it is hypothesized that heparin’s ability to maintain TSG-6 in a 
closed conformation may be a contributing factor to the enhanced bioactivity observed.  
To begin to understand the role of heparin sulfation, one study investigated chondroitin 
sulfate (CS) derivatives with varying sulfation patterns.  It was found that chondroitin-4-
sulfate (C4S) could bind to TSG-6 while chondroitin-6-sulfate (C6S) could not [88], 
suggesting that specific sulfate groups may significantly affect GAG binding to TSG-6 
and subsequent bioactivity.  However, heparin sulfation has yet to be studied any further 
in the context of TSG-6 binding and bioactivity. 
HEPARIN AND SDF-1 
The binding site and importance of heparin sulfation has also been investigated for SDF-
1.  It has been shown that SDF-1 dimerizes when crystallized, and the number of 
SDF-1 molecules capable of binding to a single 9 kDa heparin chain, 6 in total, also 
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suggests that SDF-1 may dimerize when bound to heparin [89,90].  In fact, heparin has 
shown to enable and stabilize dimerization of SDF-1 which may be one method by 
which heparin enables SDF-1 bioactivity in vivo [91].  It was also determined that 
heparin binding involves the N-terminus of SDF-1, which is critical for SDF-1’s 
bioactivity [89].  Furthermore, in one study heparin was also shown to bind the C-
terminus of SDF-1, which in turn enhanced the biological activity of the SDF-1 N-
terminus [92].  Thus, it has been hypothesized that heparin may stabilize the SDF-1 N-
terminus, thereby protecting or enhancing SDF-1 bioactivity.  Finally, it was also found 
that heparin binding to SDF-1 decreased with 2O [93] and N-desulfated heparin, 
whereas only a modest decrease in binding was exhibited with 6O-desulfated heparin, 
which indicates that 2O and N-sulfate groups may be more critical to complete heparin 
binding to SDF-1 [89].   
HEPARIN AND OTHER PROTEINS 
Though heparin interactions have been examined with many proteins, the importance of 
heparin sulfation is not as well established and the most characterized example is with the 
FGF family of proteins.  First, it has previously been found that the transmembrane 
tyrosine kinase for FGF is activated by heparin, which induces FGF-2 and activates FGF-
2 bioactivity [58].  In understanding the role of heparin sulfation in this process, it has 
been found that 6O-desulfated heparin promoted FGF-2 binding while 2O-sulfate groups 
were essential for FGF-2/heparin binding.  However, in other work it was found that 
partially 2O and 6O-sulfated heparin was the minimum binding motif for FGF-1 and 
FGF-4, which suggests that heparin binding may be slightly different dependent on the 
specific FGF protein [58,94].  Finally, it was also found that FGF-2 incubated with 6O-
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desulfated heparin showed significantly diminished bioactivity compared to FGF-2 
incubated with fully sulfated heparin, which indicates that incomplete heparin binding to 
proteins, through loss of specific sulfate groups, may result in diminished protein 
bioactivity as well [95].  Overall, this work collectively indicates that heparin binds 
differentially to many proteins, and heparin sulfation plays a unique and critical role in 
binding and protecting or enhancing protein bioactivity. 
2.1.4 HEPARIN IN VIVO 
Finally, when using heparin materials in vivo it is important to consider its anti-
coagulation properties, which have been observed and utilized clinically since as early as 
1935 [60].  Normally, anti-thrombin, a serine protease inhibitor, is inactive in the body 
[60].  Once bound to heparin or heparan sulfate, however, anti-thrombin undergoes a 
conformational change, binds to serine protease thrombin and factor Xa, another serine 
protease inhibitor, and this complex is free to activate additional anti-thrombin.  This 
pathway of binding ultimately results in an anti-coagulation cascade, and is beneficial in 
many clinical applications.  However, if implanted in vivo, the heparin-mediated anti-
coagulation may cause excessive bleeding and ultimately prevent successful drug 
delivery.  Instead, it has been found that desulfated heparin derivatives have significantly 
diminished anti-coagulation properties compared to the natively sulfated heparin 
[57,66,96,97].  In fact, even Hep-N, which has ~80% total sulfation compared to native 
heparin, exhibited significantly less anti-coagulant activity using a standard in vitro assay 
[66].  In our lab, Hep and Hep-N-based biomaterials have also exhibited similar loading 
and release efficiency of BMP-2 and crystal violet, and both have been shown to protect 
BMP-2 bioactivity [14].  Overall, when incorporated into biomaterial systems, heparin 
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derivatives which possess reduced anti-coagulant properties while maintaining the ability 





Osteoarthritis (OA) affects more than 60% of Americans over 65 years of age and is 
characterized by significant articular cartilage and subchondral bone degeneration 
[4,38,39].  Though complete etiology has yet to be fully understood, OA is correlated 
with increasing age, increased body mass index, and is more commonly observed in 
women [98].  Furthermore, while OA most commonly affects the knee joint, hands, feet, 
hips, and the spine may also be affected [99].  Ultimately, OA is the leading cause of 
disability in the United States [99], highlighting the significant healthcare burden and the 
need for effective treatment strategies. 
2.2.2 CARTILAGE DEGENERATION IN OSTEOARTHRITIC JOINTS 
CARTILAGE DEGENERATION 
OA is characterized by significant cartilage degeneration within the joint space, which 
evolves as the disease progresses.  In early stages of OA, cartilage thickness decreases 
and cartilage fibrillation develops on the cartilage surface.  Chondrocytes in OA joints do 
exhibit slightly elevated levels of proliferation when compared to healthy patients, which 
may be the cause of chondrocyte clustering often exhibited in OA joints [100].  However, 
chondrocyte apoptosis has also been observed in many studies to varying degrees, which 
is at least partially responsible for the decreased chondrocyte population within the 
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cartilage tissue [101,102].  Due to the decreased chondrocyte population, proteoglycan 
and collagen synthesis decreases as well, leading to thinning of cartilage and decreased 
cartilage integrity [103].  As OA progresses, factors such as matrix metalloproteinases 
(MMPs) and pro-inflammatory cytokines including interleukins and tumor necrosis 
factor-alpha [39–41], among others, have been shown to be upregulated in OA joints, 
which likely further contributes to cartilage degradation and erosion.  Ultimately, 
hallmarks of articular cartilage degeneration in OA joints include cartilage fibrillation, 
fissures, and loss of proteoglycan and collagen content within the cartilage ECM, 
ultimately leading to significant pain and poor joint function [4,38,39].   
SCORING METHODS OF CARTILAGE DEGENERATION IN OSTEOARTHRITIS 
Many scoring methods exist to evaluate cartilage degeneration in the context of 
OA.  Of the more commonly utilized systems, Mankin scoring (also known as 
Histological/Histochemical Grading System (HHGS) was developed earliest in the 1971.  
The Mankin scoring approach utilized histological images to identify cartilage structure, 
cell distribution, safranin-O proteoglycan staining, and cartilage tidemark integrity.  Also 
commonly used, the Osteoarthritis Research Society International (OARSI) created a 
scoring system that, unlike other systems, emphasized the extent of cartilage damage over 
the articular surface.  OARSI scoring includes evaluation of cartilage matrix architecture, 
including fibrillation and proteoglycan depletion, cartilage cell viability, including 
proliferation, hypertrophy, and death, and bone remodeling, including the development of 
microfractures and osteophyte formation [104–106].   
With the development of more sophisticated analysis techniques such as magnetic 
resonance imaging (MRI) and computed tomography (CT), these techniques have been 
used increasingly more frequently to assess cartilage degeneration in patients [107].  
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With MRI-based methods, certain systems are semi-quantitative and assess cartilage 
volume, thickness, surface area, percent cartilaginous joint surface area, cartilage surface 
curvature, among others [107].  With CT imaging, contrast agents are employed to better 
visualize cartilage compared to bone and surrounding air, which allows for scoring of 
cartilage contour and the level of contrast agent penetration into the cartilage, indicative 
of cartilage degeneration [108]. 
2.2.3 PLASMINOGEN ACTIVATION PATHWAY IN OSTEOARTHRITIC JOINTS 
Central to the fibrinolytic system is the plasminogen activation pathway, in which the 
proenzyme plasminogen is converted to the fibrin-degrading enzyme plasmin [24].  In 
addition to fibrin, plasmin is capable of cleaving and degrading most other extracellular 
matrix (ECM) proteins, and has previously shown to activate both metalloproteinase 
precursors and matrix metalloproteinases (MMPs) [42,43,109].  As components of the 
plasminogen activation pathway including plasminogen and plasminogen activators, 
receptors, and inhibitors [24–27] have all shown to be upregulated in OA joints when 
compared to healthy patients [26,44], it is postulated that the plasminogen activation 
pathway may play a significant role in the cartilage degeneration exhibited in OA joints 
[25,27].  Thus, plasmin-inhibiting therapeutics may be a promising method to ameliorate 
cartilage degeneration in the context of OA. 
2.2.4 CURRENT CLINICAL TREATMENT STRATEGIES 
As no disease modifying OA drugs (DMOADs) are clinically approved, current treatment 
strategies first include exercise and weight loss [106], followed by pain reduction with 
non-steroidal anti-inflammatory drugs (NSAIDs) [110], COX-2 selective inhibitors [111], 
or corticosteroid injections, all of which often provide only temporary relief [106,112].  
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More recently, intra-articular injections of HA, a non-sulfated GAG, have become a more 
common treatment option [112].  HA was FDA-approved as a method to increase the 
viscosity of synovial fluid, and though some clinical trials have shown efficacy compared 
to placebo controls, others have not [112].  Furthermore, for intra-articular delivery of 
these treatments, injections are typically limited to ~4 injections per year given the 
invasiveness of the procedure, and the rapid clearance of these treatments from the joint 
space likely limits their therapeutic efficacy [4].  Finally, in advanced cases of OA, 
surgery may be required and is most commonly a full joint replacement which, though 
costly, has shown to be cost effective compared to recurring drug alternatives [113]. 
2.2.5 TREATMENT STRATEGIES IN DEVELOPMENT 
THERAPEUTICS IN CLINICAL TRIALS 
Given the lack of FDA-approved DMOADs, significant research has focused on 
development of such treatments.  Treatments targeting inflammatory mediators that are 
upregulated in OA joints may be one approach, and options such as doxycycline and 
diacerein which inhibit MMPs and interleukin-1 (IL-1), respectively, and have shown to  
lower OA progression when analyzed via x-ray imaging in human trials [111].  In other 
cases, however, MMP inhibitors have shown to cause musculoskeletal side effects 
leading to failure in their clinical trials.  Alternatively, other work has investigated the use 
of drugs which promote chondrocyte activity or MSC differentiation toward a 
chondrogenic phenotype. The GAG CS, which stimulates chondrocyte RNA synthesis, 
has previously shown to lower OA progression in human trials [99] and a small molecule 
inhibitor of the Wnt pathway, SM04690, has shown to induce MSC differentiation into 
functional chondrocytes and is now in a Phase 2 clinical trial [114].  Despite these 
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promising options, these treatment strategies are still in development, and important 
considerations such as the frequency of injections, side effects, and cost have yet to be 
fully assessed.   
PARTICLE-BASED DELIVERY STRATEGIES 
Micro and nano-scale biomaterials have also been employed for drug delivery to the 
osteoarthritic joint space, particularly due to their injectability into the joint space.  
Biomaterials including gelatin [115,116], C6S [117], chitosan [118], polymers [119,120], 
and others have been used alone and in combination with drugs primarily to enhance their 
retention in the joint space [121,122].  In several cases, gelatin hydrogel microspheres 
were used to deliver platelet rich plasma (PRP)  and FGF into OA-induced rabbit knees 
[115,116].  OA score was significantly lower in PRP microsphere animals than animals 
treated with PRP alone [115], and microspheres retained FGF within the joint space for at 
least 7 days, leading to a reduction in OA progression compared to soluble FGF [116].  
Diclofenac sodium loaded albumin microspheres were also injected into OA-induced 
rabbit knees [123], while gelatin/C6S microspheres were injected into OA-induced 
mouse knees [117],  and results indicated that microspheres could retain the drug of 
interest locally within the joint [123] with minimal inflammatory response [117].  
Poly(lactic-co glycolic acid) (PLGA) microspheres loaded with paclitaxel were delivered 
into the knee or rats with antigen induced arthritis, and it was found that indicators of 
cartilage degeneration were diminished with specific sized microspheres [120].  
Nanoparticle systems composed of copolymers [119,124], chitosan [49], 
superparamagnetic iron oxide [125], among others, have also been used for delivery of 
IL-1receptor agonist (IL-1Ra) [124], bethamethasone sodium phosphate [119], kartogenin 
[49], and dexamethasone 21-acetate [125], respectively.  In many cases, nanoparticles 
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improved the retention of drug in the joint space [49,124] and maintained drug bioactivity 
in vivo [119,126].  Thus, both microparticle and nanoparticle systems may enable 
controlled delivery of therapeutics to OA joints and these systems primarily focus on the 
delivery of corticosteroids [119,125] and anti-inflammatory proteins/molecules 
[123,124].  
2.2.6 ANIMAL MODELS OF OSTEOARTHRITIS  
Due to the moderate cost and relatively rapid onset of degenerative changes compared to 
other animals, rat models of osteoarthritis have become prevalent for research purposes.  
Chemically induced OA models are one option, and the most common approach is the 
injection of monosodium iodoacetate (MIA), which induces chondrocyte apoptosis and 
joint inflammation [127,128].  However, it is difficult to compare chemically-induced 
OA models to the human condition, as each chemical works through a particular pathway 
to induce degeneration [129].  Instead, the knee joint can also be surgically destabilized 
by transecting tissues including the anterior cruciate ligament (ACL), medial collateral 
ligament (MCL), meniscus, or a combination, the most common of which includes 
medial meniscal transection, often referred to as the MMT model [4].  In this model, 
cartilage degeneration is commonly observed through proteoglycan loss, fibrillation, and 
osteophyte formation within 3 to 6 weeks following the initial injury [38,127,130,131]. 
In these animal models, cartilage degeneration has been historically assessed via 
histological scoring using the Osteoarthritis Research Society International (OARSI) 
scoring system.  However, with the development of more sophisticated analysis 
techniques such as microcomputed tomography (µCT) in combination with contrast 
agents, the Guldberg and Willett labs have established Equilibrium Partitioning of an 
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Ionic Contrast agent via µCT (EPIC-µCT) as another method to evaluate cartilage 
degeneration in OA joints [38,127,131–134].  In one study, histological analysis with 
OARSI scoring and EPIC-µCT were directly compared using the MMT rat model of 
post-traumatic OA [131].  In this work, it was determined that EPIC-µCT and 
histological scoring provided similar results, but using power analysis it was found that 
EPIC-µCT was more powerful and sensitive than histology, requiring fewer animals to 
achieve significant results.  Therefore, EPIC-µCT is an alternative approach to the 
assessment of articular cartilage in animal models of OA. 
2.2.7 TSG-6 AS A THERAPEUTIC FOR OSTEOARTHRITIS 
TNF--stimulated gene-6 (TSG-6) is a positively charged 35 kDa protein with 
anti-plasmin and anti-inflammatory properties [42].  In particular, TSG-6 has been 
studied extensively for its ability to potentiate inter-alpha-inhibitor (IalphaI)-mediated 
inhibition of plasmin [42,43] and more recently, its ability to suppress the response of 
chondrocytes to inflammatory factors such as interleukin-1 and TNF- [135].  In the 
context of OA, while little constitutively expressed TSG-6 has been observed in healthy 
patients, TSG-6 protein expression was found to be upregulated in OA joints and greater 
TSG-6 levels were observed in patients where OA symptoms had advanced over a three 
year period compared to non-progressing OA patients [136–138]. 
 Despite the increased production of endogenous TSG-6, however, tissues within 
OA joints continue to degenerate, leading to studies on the effect of adding exogenous 
TSG-6 on arthritis progression.  In rheumatoid arthritis (RA) mouse models, soluble 
TSG-6 treatment led to a significant improvement in joint swelling [139] and cartilage 
damage [139,140], assessed via joint diameter and histology, respectively; but these 
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effects were often short-lived, and by day 12 [139] or day 35 [140] no differences were 
observed between treated and untreated animals.  Most recently, soluble TSG-6 treatment 
was also investigated in a rat OA model induced by anterior cruciate ligament and 
meniscus transection [135].  In this work, a portion of the TSG-6 molecule was delivered 
via intra-articular injection weekly up to 21 days following injury.  After 28 days, 
histology indicated that cartilage fibrillation and ulceration were significantly diminished 
with TSG-6 treatment compared to untreated controls, indicating that TSG-6 or TSG-6 
derivatives may be an effective OA treatment strategy [135].  
 
2.3 ROTATOR CUFF INJURY 
2.3.1 ROTATOR CUFF 
The rotator cuff is made up of the subscapularis, supraspinatus, infraspinatus, and teres 
minor muscles, all of which originate at the scapula and insert onto the humeral head 
[141].  Each muscle is functionally unique, allowing for specific movements including 
abduction and rotation of the humerus.  Collectively, the tendons of these muscles also 
form the rotator cuff around the humeral head, and ultimately stabilize the glenohumeral 
joint.  Unlike other ball and socket joints, the socket of the glenoid is shallow, leading to 
decreased stability of the humeral head within the glenohumeral joint space [142].  Thus, 
functionally the rotator cuff provides both stability to the glenohumeral joint, as well 
range of motion to the shoulder [142,143]. 
2.3.2 SEVERE ROTATOR CUFF INJURY 
Rotator cuff tear is one of the most common injuries of the shoulder, accounting for 
nearly 50% of major shoulder injuries [141,144,145].  Moreover, the prevalence of 
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rotator cuff tears continues to increase with age, as up to 50% of adults over 70 will 
suffer from some degree of rotator cuff injury [145,146].  In severe rotator cuff injury, 
which involves a significant tear of the rotator cuff, the size or shape of the tear is 
typically used to classify the injury through arthroscopic examination or imaging 
modalities such as ultrasonography and MRI [147].  While small to medium-sized tears 
can range between 0 to 3 cm, large and massive tears, indicative of a severe rotator cuff 
injury, are generally characterized as greater than 3 to 4 cm [141,147].  After such injury, 
symptoms typically include substantial pain and poor shoulder function, and these 
symptoms often progress with time [148,149].  Furthermore, the surrounding tissue of the 
joint space including cartilage, bone, and muscle have all shown to be significantly 
affected after severe rotator cuff injury, which surgical interventions for rotator cuff 
injury do not currently address.  Specifically, Mankin scoring of cartilage tissue has 
indicated increased structural disorganization, hypocellularity, decreased GAG content 
and tide marks crossed by blood vessels, all of which are indicators of cartilage 
degeneration [148].  For the surrounding bone tissue, the disrupted kinematics of the 
glenohumeral joint after rotator cuff injury can often lead to osteoarthritis, where the 
subchondral bone of the humeral head collapses and the surrounding bone tissue erodes 
[148].  Finally, severe rotator cuff tears are often accompanied by supraspinatus and 
infraspinatus muscle atrophy and fatty infiltration, often referred to as “fatty 
degeneration” [149,150]. 
2.3.3 MUSCLE DEGENERATION FOLLOWING ROTATOR CUFF TEAR  
The unique degeneration of the supraspinatus and infraspinatus muscles after rotator cuff 
tear has been investigated extensively in humans.  Conventionally, muscle atrophy is 
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assessed using sagittal plane MRI of the supraspinatus and infraspinatus to appropriately 
measure the size, and therefore the atrophy, of each muscle [150].  To assess fatty 
infiltration, a system first established by Goutallier et al. is often used, where either CT 
scans or MRI are used to measure fatty streaking within the muscle belly [147,151].  
Using these methods, supraspinatus and infraspinatus muscle atrophy and fatty 
infiltration have been established as hallmarks of rotator cuff injury, and have shown to 
negatively correlate with range of motion [152] and muscle strength [153] and positively 
correlate with the size of the tear [146,149,150,152,154,155].  Muscle fibrosis, though 
not as well characterized in rotator cuff injuries due to limitations in imaging techniques, 
is a hallmark of skeletal muscle injury and disease, and leads to decreased muscle fiber 
diameter, contractility and function in other muscle injury contexts [152,156].  In the 
context of rotator cuff tears, muscle fibrosis has been observed in many animal studies, 
and certain work has even correlated poor muscle function with increased expression of 
fibrotic markers [157,158].  Ultimately, though initially a tendon injury, rotator cuff tears 
result in a unique profile of supraspinatus and infraspinatus muscle degeneration, which 
includes muscle atrophy, fatty infiltrate, and fibrous infiltrate, that ultimately leads to 
decreased muscle function [159]. 
2.3.4 CURRENT CLINICAL TREATMENT STRATEGIES 
TREATMENT STRATEGIES PRIOR TO SURGICAL INTERVENTION 
Among non-operative treatment options for rotator cuff injuries, NSAIDS, physical 
therapy, subacromial corticosteroid injections, and other more moderate options such as 
heat and ice are common [146].  However, in a longitudinal study of patients receiving 
non-operative care for their injury, over half of patients with a full-thickness tear 
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exhibited an increase in tear size over 1 year despite their treatment [160].  Thus, surgical 
intervention is more commonly suggested as the size and severity of the tear increases.  
PRP injections have also become a popular option, as PRP contains numerous factors that 
are essential for recruitment and proliferation of cells required for healing [161].  In one 
meta-analysis study, 70% of patients self-reported either mostly complete or completely 
improved perceived symptoms of their injury, but other studies indicated no difference 
between PRP-treated and placebo patients [161].  Thus, non-operative treatment options 
may be promising, but provide either highly variable results or may become ineffective as 
the severity of the tear increases.  
SURGICAL INTERVENTION 
Due to the limitations of non-operative treatment strategies for massive rotator cuff tears, 
surgical treatment has continued to increase as much as 140% from 1996 to 2006, with 
over 250,000 surgeries now occurring every year in the United States [146,155].  When 
surgery is performed, two options exist to reattach the torn tendons back to the humeral 
head; in traditional open surgery, a surgical incision is made through the shoulder to 
access the tendon and view the humeral head [162].  Alternatively, an arthroscopic 
procedure may be used, where a camera is inserted into a small incision in the skin, along 
with the tools necessary to repair the tendon.  In both open and arthroscopic procedures, 
anchors are screwed into the humeral head, while sutures attached to these anchors are 
threaded through the tendon tissue and tightened to reapproximate the tendons and 
humeral head [163]. 
MUSCLE DEGENERATION BEFORE AND AFTER SURGICAL INTERVENTION 
Historically, significant improvement in range of motion and strength has been 
observed in patients following tendon reattachment, and thus surgical rotator cuff repair 
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has become the standard of care for severe tears [37,162,164].  However, it has also been 
observed that surgical prognosis diminishes with increasing muscle degeneration and tear 
size [165–167], leading to a re-tear rate of up to 94% according to one study [168]. In 
another study, it was observed that supraspinatus muscle fatty infiltration and atrophy 
positively correlated with tear size (R2 values of 0.745 and 0.819, respectively), and 
ultimately those patients with moderate to severe muscle fatty infiltration or atrophy had 
a ~70% probability of re-tear, significantly greater than the ~30% probability for patients 
with mild or no muscle degeneration [150].  Moreover, significant muscle degeneration 
has now been used to indicate irreparability of the rotator cuff tear even prior to surgery 
[169].  Fatty infiltrate affecting more than 50% of the musculature or MRI indicating 
fatty infiltrate of the supraspinatus muscle are both predictors that a patient should not 
receive surgery, primarily due to the unlikelihood that the shoulder will heal [169].  Thus, 
treatment strategies targeting muscle degeneration before or after surgical intervention 
may be a method to improve patient prognoses. 
2.3.5 ANIMAL MODELS OF SEVERE ROTATOR CUFF TEAR 
ANIMAL MODELS OF ACUTE, SEVERE ROTATOR CUFF INJURY 
To mimic acute, severe rotator cuff injury, tendon transection is the most common 
surgical technique used.  In 1996, the Soslowsky lab investigated 33 animal species and, 
based on the similarity in anatomy and range of motion of the rotator cuff as well as ease 
of use and care, the rat was chosen as the most appropriate animal to mimic the human 
condition of rotator cuff injury [170].  Several labs have since developed tendon 
transection models, often in rats and mice, and several variations of the procedure exist.  
In the Soslowsky lab, only the supraspinatus tendon is transected [171], whereas in the 
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Feeley [172–174] and Mendias [175,176] labs both the supra and infraspinatus tendons 
are transected.  In one instance, the Feeley lab also transected an additional tendon, the 
teres minor [177].  To avoid spontaneous reattachment, in certain cases the Feeley lab has 
removed a 5 mm portion of each tendon [177] and in other labs tubing is sutured around 
the transected ends of each transected tendon [178]. 
In rats with transection of 2 tendons, significant muscle weight loss was observed 
after ~4 weeks in supraspinatus and infraspinatus muscle, and in the infraspinatus muscle 
fiber cross sectional area was significantly reduced as well as fiber contractility 
[175,176].  In a separate study, supraspinatus muscle length significantly decreased and 
the number of Evans Blue Dye + muscle fibers, indicative of permeable and nonviable 
fibers, significantly increased compared to uninjured controls [179].  Similar results were 
observed in mice, whereby supraspinatus muscle fiber cross-sectional area was 
significantly reduced after 3 and 14 weeks compared to sham contralateral controls [174].  
In rats with transection of 3 tendons, significant muscle weight loss was observed after 2 
and 6 weeks in both the supra and infraspinatus muscles and a significant increase in fatty 
infiltrate was observed after 6 weeks in the infraspinatus muscle [177].   
To add to the degeneration observed, in many studies the suprascapular nerve was 
also transected in addition to tendon transection [172,173,180–182].  Though 
concomitant suprascapular denervation is relatively uncommon in humans, suprascapular 
neuropathy due to compression or impingement has been observed [152,183,184].  With 
this surgical procedure, an additional significant decrease in muscle weight of the 
supraspinatus was observed, though infraspinatus muscle weight and fatty infiltrate did 
not differ from a tendon transection only group [177].  In a separate study, significant 
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muscle weight loss was observed after 6 weeks compared to sham contralateral controls, 
and fibrous and fatty infiltrate was observed via histological imaging [173].  Ultimately, 
these models recapitulate several hallmarks of muscle degeneration following rotator cuff 
injury, including muscle atrophy, fatty and fibrous infiltration, and allow for a testbed to 
ameliorate the muscle degeneration commonly observed after rotator cuff tears.  
REATTACHMENT MODELS 
To recapitulate the current standard of care, several labs have adapted a reattachment 
procedure following tendon transection in their animal models.  In the Rodeo and 
Mendias labs, two crossing bone tunnels are made through the humerus, and sutures 
attached to the transected supraspinatus tendon are fed through these bone tunnels and 
pulled taught [163,179,185–187].  In some cases, the tendon(s) may be reattached 
immediately or after several weeks to allow for tissue degeneration to occur.  In one such 
study with mice, mechanical testing of the transected and immediately reattached tendon 
indicated that while tendon failure force and stiffness was decreased after 2 weeks 
compared to uninjured tendon, both measurements improved over time.  Similarly, in our 
own work both muscle weight, indicative of atrophy, and fibrosis, both improved 
following reattachment, suggesting that some level of tissue healing occurs as a result of 
tendon repair (data not published).  It is important to note, however, that tissue 
regeneration, particularly of the muscle, is not common in human rotator cuff repairs, 
indicating that animal models of rotator cuff repair may not fully recapitulate the human 
conditions. 
2.3.6 THERAPEUTIC INTERVENTIONS FOR ROTATOR CUFF TEAR 
THERAPEUTIC INTERVENTIONS IN ANIMAL MODELS OF ROTATOR CUFF TEAR 
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Utilizing variations of the tendon transection animal model, many studies have focused 
on treatment strategies for severe rotator cuff injuries.  However, these studies primarily 
focus on the treatment and regeneration of the bone, cartilage, tendon, and enthesis.  For 
example, platelet derived growth factor – BB (PDGF-BB) has been combined with type 1 
collagen scaffolds [188], gelatin hydrogel sheets, or fiberwire sutures [189] and placed 
near the tendon-to-bone insertion following rotator cuff injury in sheep and rat animal 
models.  In these studies, higher ultimate load to failure measurements were observed in 
some cases [188] but not others [189].  FGF-2 has also been delivered via gelatin 
hydrogel sheets or electrospun PLGA fibrous membrane in rat and rabbit models, which 
resulted in significantly improved mechanical strength [190] of the tendon-to-bone 
insertion as well as improved collagen organization.  Other therapeutics including a 
COX-1, COX-2, and LOX-5 inhibitor, which are fundamental enzymes in the 
inflammatory cascade, and a MMP inhibitor, doxycycline, significantly increased the 
load to failure of the enthesis compared to uninjured controls [186,191].  Focusing on 
bone regeneration, BMP-2 and an antibody to sclerostin, a negative regulator of bone 
formation, have been delivered within rat and rabbit animal models.  Both treatment 
strategies resulted in significantly more humerus bone formation and significantly 
increased ultimate tensile load of the tendon-to bone insertion [192].  Ultimately, many 
therapeutics have been utilized with or without scaffolds to augment rotator cuff repair, 
but the focus of these treatment strategies included cartilage, tendon, and the enthesis 
[193,194]. 
THERAPEUTIC INTERVENTIONS FOR OTHER MUSCLE INJURIES: CELL-BASED STRATEGIES 
Many therapies have been investigated to improve muscle healing after injury, albeit not 
typically in the unique context of rotator cuff injury.  For example, cell-based therapies 
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have included the use of MSCs [185,195–197], embryonic stem cells (ESCs) [198], 
muscle-derived stem cells (MDSCs) [199], and satellite cells [200], among others [201] 
in a variety of animal models for muscle injury, and MDSCs have have even been tested 
in clinical trials with patients [195].  In a mouse model of Duchenne muscular dystrophy 
(DMD), MSCs derived from the synovial membrane restored sarcolemmal expression of 
dystrophin, reduced central nucleation, and returned the expression of mechano growth 
factor within muscle [197].  In other work, highly myogenic ESCs were first identified as 
Pax3+, PDGF-alpha receptor+, and Flk-1neg [198].  Then, this ESC subpopulation was 
transplanted into dmx mice, resulting in enhanced contractile function of the tibialis 
anterior muscle without formation of teratomas [198].  Finally, other work has 
investigated the induction of myogenic differentiation in bone marrow stromal cells, also 
referred to as MSCs, through a 14 day in vitro process, after which time the induced 
“skeletal muscle cells” were implanted in vivo and resulted in the generation of muscle 
fibers in mdx mice [196]. 
THERAPEUTIC INTERVENTIONS FOR OTHER MUSCLE INJURIES: VOLUMETRIC MUSCLE LOSS 
Though certain cell-based therapies are promising, these methods are often 
accompanied by significant disadvantages, including locating an abundant and viable cell 
source, heterogeneity and characterization of the cell populations, and significant time 
and cost [202].  Thus, significant work has focused on engineering drug-based therapies 
instead, including the stimulation of existing muscle cells and tissue to regenerate.  
Several growth factors have shown to improve muscle regeneration through a variety of 
mechanisms: insulin-like growth factor-1 (IGF-1) is highly mitogenic for myoblasts and 
may be a key player in mediating skeletal muscle growth, while FGF, PDGF, and nerve 
growth factor (NGF) are capable of stimulating satellite cell proliferation [203,204].  In 
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the context of volumetric muscle loss specifically, experimental treatments primarily 
focus on scaffolds  [205–208], and examples include muscle-derived decellularized ECM 
scaffolds [205], porcine-derived small intestinal submucosa (SIS)-ECM scaffolds [207], 
bladder-derived acellular matrices[206,209], and skeletal muscle autografts [208].  
Furthermore, minced or fragments options were also investigated including adipose-
derived microvascular fragments [210] and a minced form of skeletal muscle autografts 
[208].  Though less common, drug-based strategies have included losartan administration 
[211], which reduced fibrosis but did not improve functional recovery, and delivery of 
hepatocyte growth factor (HGF) on fibrin matrices, which improved muscle force 
production after 60 days following injury and treatment [212].  
THERAPEUTIC INTERVENTIONS FOR OTHER MUSCLE INJURIES: ISCHEMIC MUSCLE INJURY 
In ischemic muscle injury, a primary focus is the development of new vasculature to, in 
turn, promote muscle regeneration.  Therefore, current treatment strategies have included 
the delivery of VEGF alone [213] and in combination with IGF-1 [214], FGF gene 
delivery [215], and transplantation of human adipose stromal cells and bone marrow 
stromal cells to promote neovascularization [216,217].  The combinatorial delivery of 
VEGF and IGF-1 lead to angiogenesis reinnervation, and myogenesis, specifically 
stimulating satellite cells proliferation [214], while certain cell-based treatment strategies 
resulted in improved blood flow in the ischemic muscle [216]. 
THERAPEUTIC INTERVENTIONS FOR MUSCLE FOLLOWING ROTATOR CUFF INJURY  
In one study, a HIF prolyl 4-hydroxylases (PHD) inhibitor was used to enhance the 
activity of HIF-1α, a transcription factor that activates many genes important to skeletal 
muscle regeneration [178].  The supraspinatus tendon was transected and reattached after 
4 weeks in rats, with daily oral delivery of the PHD inhibitor and after 2 weeks post-
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reattachment, muscle mass was significantly higher in the PHD inhibitor treated groups, 
but maximum isometric force of the muscle had significantly decreased compared to 
injury alone  [178].  In separate studies, a TGF-B small molecule inhibitor, SB431542 
[218], and simvastatin [158], were both utilized for their potential to reduce muscle 
fibrosis, among other factors.  After daily IP injection of the TGF-B inhibitor for 2 or 6 
weeks following tendon transection and denervation in mice, a significant decrease in 
muscle fibrosis was observed compared to injured controls [218], though treated muscles 
were still only ~25% the weight of uninjured controls [218].  Furthermore, with daily oral 
delivery of simvastatin, though a significant increase in specific force (maximum 
isometric force / muscle fiber cross sectional area) after 4 weeks, no significant difference 
in absolute maximum isometric force was observed with treatment [158].  Ultimately, 
though these studies offer some promise, novel delivery strategies and therapeutics for 
muscle healing in the context of rotator cuff injury are in high demand. 
2.3.7 THERAPEUTICS TO MODULATE CELLULAR MILIEU IN ROTATOR CUFF MUSCLE 
CHEMOTACTIC PROTEINS 
One potential approach for muscle regeneration is chemotactic therapeutics such as SDF-
1 have previously been used to recruit endogenous, pro-regenerative cell populations in 
the context of other muscle injuries.  Primarily through its G protein-coupled receptor, 
CXC chemokine receptor type 4 (CXCR4), SDF-1 has previously shown to attract a 
myriad of cell populations including monocytes [28,29], lymphocytes [29,219], stem 
cells such as hematopoietic [30] and MSCs [31], and progenitor cell populations [12,32], 
among others [33,34].  Previously in our laboratory, we subcutaneously implanted SDF-
1 loaded hydrogels into a murine dorsal skinfold window chamber model to enable the 
 38 
visualization of cell recruitment and vascular remodeling and after 2-3 days, more bone 
marrow-derived cells [9] and significantly more anti-inflammatory monocytes were 
detected near the SDF-1 loaded hydrogels [9,10] compared to unloaded gels.  After 7 
days, significantly more anti-inflammatory, M2-like macrophages, were observed near 
SDF-1 loaded gels compared to unloaded controls [10], which suggests that SDF-1 
delivery may be an effective approach to modulate the cellular milieu during disease 
states involving tissue degeneration. 
BONE MARROW MOBILIZING AGENTS 
Bone marrow mobilizing agents, including clinically approved granulocyte colony 
stimulating factor (G-CSF) and AMD3100, are most commonly used to treat neutropenia 
or lymphopenia following chemotherapy treatment [220–223].  Through indirect 
signaling, G-CSF has been shown to promote chemotaxis of hematopoietic stem and 
progenitor cells (HSPCs) from the bone marrow into circulation, and increased progenitor 
cells of all lineages have been subsequently detected in the spleen of G-CSF treated mice 
[224].  Furthermore, through initial studies utilizing AMD3100 as a human 
immunodeficiency virus (HIV) inhibitor, significantly more circulating leukocytes were 
also observed in treated patients, leading to the approval of AM3100 as a hematopoietic 
cell mobilization agent in 2008 [222].  Among other mechanisms of actions, both G-CSF 
and AMD3100 have shown to antagonize CXCR4, an essential mediator of cell 
trafficking [33], which may also disrupt CXCR4 signaling with SDF-1 [221].  Despite 
these promising effects, G-CSF and AMD3100 can lead to significant complications and 
specifically through CXCR4 inhibition, AMD3100 has shown to impair the ability for 
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cells to return to the bone marrow niche.  Thus, bone marrow mobilizing agents with 
non-CXCR4 targets may be advantageous [36,225,226].   
Sphingosine-1-phosphate (S1P) is a structurally simple lipid with a class of 
corresponding G-protein coupled receptors (GPCRs) S1PR1-5, found in abundance in the 
plasma and serum [226].  During homeostasis, a steep gradient of S1P is maintained 
between the blood and bone marrow [227], and the disruption of this gradient leads to the 
sequestration of HSPCs, indicating the importance of S1P in the mobilization of bone 
marrow-derived cell populations.  Though structurally similar, S1PR1-5 possess unique 
functions, both related and unrelated to cell mobilization.  For example, S1PR1 is 
required for the egress of lymphocytes from secondary lymphoid organs and antagonism 
of S1PR1 has been shown to induce lymphopenia [35,228–230].  In contrast, antagonism 
of S1PR3 has been shown to promote egress of HSPCs from bone marrow to peripheral 
blood, ultimately suggesting that S1PR1 agonists and S1PR3 antagonists may be methods 
to promote cell mobilization. 
Among a host of drugs targeting S1P receptors, VPC01091 is both an S1PR1 
agonist and S1PR3 antagonist [35,231].  In vitro, VPC01091 induced a reduction in LSK 
(LinnegSca-1+c-Kit+, early hematopoietic stem cells) cell adhesion and an increase in LSK 
cell migration.  Furthermore, when delivered via intraperitoneal (I.P.) injection in rats, 
significantly more MSCs were observed in blood 1.5 and 24 hours after delivery [232] 
while in mice, significantly more circulating LSK cells were observed in blood 1.5 hours 
after delivery [36].  Interestingly, of the mobilized LSK cells, significantly more cells 
were CXCR4+, the primary receptor for SDF-1, compared to untreated controls [36].  
 40 
Thus, SDF-1 and VPC01091 may synergistically increase the number of pro-
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Bone morphogenetic protein-2 (BMP-2) is an osteoinductive growth factor that is FDA-
approved for use in specific orthopaedic procedures including spinal fusions and tibial 
fracture repairs [3,233].  Currently supraphysiological levels of BMP-2 are required to 
induce bone repair, primarily due to the inability of biomaterial delivery vehicles to 
maintain growth factor bioactivity or spatiotemporally control growth factor release 
[234,235].  These high and costly doses of BMP-2 ultimately result in undesirable side 
effects, including inflammation and bone formation with cyst-like voids or poor 
mechanical properties [236,237].  Therefore, a novel strategy to maintain BMP-2 
bioactivity while releasing it in a controlled manner is in high demand. 
 Previous efforts to fabricate BMP-2 delivery vehicles have employed alginate, 
chitosan, collagen, gelatin, and synthetic polymers derived from polyethylene glycol 
(PEG) or poly(lactic acid) [53,238–241].  However, we and other laboratories [56,242–
245] are exploring the use of glycosaminoglycans (GAGs) to potentially reduce burst 
release of BMP-2 and prolong growth factor bioactivity [239,241,246].  GAGs are linear 
polysaccharides found within the extracellular matrix (ECM) either as free chains or, 
more often, covalently bound to a polypeptide core, collectively known as proteoglycans 
[57,58].  GAGs can bind growth factor through carbohydrate sequence-specific 
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interactions and sulfated GAGs can also bind positively-charged growth factors via their 
negatively-charged sulfate groups [58].  Therefore, sulfation pattern can be adjusted 
experimentally to further alter the binding and release of growth factor from GAG 
molecules [96,97,247,248].  Ultimately, GAGs can immobilize growth factors near cells 
and prevent growth factor degradation, making GAGs a promising biomaterial for growth 
factor delivery [56,61,249]. 
 Heparin is a highly sulfated GAG species found mainly in mast cells, although 
heparan sulfate, a similar GAG species, is abundantly found on cell surfaces throughout 
the body [59].  Heparin is capable of non-covalent and reversible binding to a wide 
variety of positively charged growth factors including BMP-2, transforming growth 
factor-β (TGF-β), vascular endothelial growth factor (VEGF), fibroblast growth factors 
(FGFs) and insulin-like growth factors (IGFs) [58,61,62].  Our laboratory and others have 
incorporated heparin into bulk hydrogels for improved BMP-2 loading and release 
[56,242–245], but microparticles (MPs) are advantageous to efficiently load growth 
factors with little excess material due to the MP’s high surface area-to-volume ratio 
[239,250]. Therefore, microgels and MPs with heparin have also been fabricated as 
BMP-2 carriers [16,251,252], and we have demonstrated that 100 wt% heparin MPs can 
bind significant amounts of BMP-2 with up to 95-100% loading efficiency and enhanced 
BMP-2 bioactivity [15].  
 The potential drawback of including large amounts of heparin in MPs, however, is 
that little BMP-2 release was observed from 100% heparin MPs due to sequestration of 
growth factor, limiting the efficiency of these MPs as soluble growth factor delivery 
vehicles [15,16].  Therefore, in this study we explored two methods to facilitate more 
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complete growth factor release from MPs while maintaining their ability to bind and 
preserve growth factor bioactivity. First, by incorporating a hydrolytically degradable 
crosslinker and varying heparin content within heparin-based MPs, we hypothesized that 
the release of growth factor could be enhanced as the MP degrades.  Secondly, given that 
heparin sulfation is primarily responsible for electrostatic growth factor-GAG binding 
and release, we hypothesized that systematically reducing the degree of heparin sulfation 
may promote the release of BMP-2 from heparin MPs.  Furthermore, since desulfated 
GAGs have been shown to have diminished anti-coagulation properties, desulfated 
heparin MPs may be safer for future in vivo therapies [57,96,253].  Therefore, we 
fabricated a series of MPs with selectively desulfated heparin derivatives to further 
control BMP-2 release.  Overall, we hypothesized that altering the degradation properties 
and sulfation pattern of heparin MPs, two orthogonal approaches to control BMP-2 
release from MPs, would allow for tunable growth factor delivery kinetics from these 
materials.   
 
3.2 MATERIALS AND METHODS 
3.2.1 PREPARATION OF HEPARIN DERIVATIVES 
Preparation of desulfated Hep-N, Hep-6O,N, and Hep- species was carried out as described 
previously [21].  Briefly, heparin sodium salt from porcine intestinal mucosa (Sigma 
Aldrich, St. Louis, MO) was reconstituted at ~10 mg/mL in water and passed through 
Dowex 50WX4 resin (mesh size 100-200, Sigma Aldrich).  Pyridine was added drop-
wise to the desalted heparin until the pH of the solution was ~6.0.  Excess water and 
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pyridine were removed on a rotary evaporator (Buchi).  The heparin pyridinium salt 
solution was flash frozen in liquid nitrogen, lyophilized to a powder, and stored at -20°C. 
 For Hep-N preparation, heparin pyridinium salt was dissolved at 1 mg/mL in 90% 
DMSO/10% water (v/v) and mixed at 50°C for 2 hours [254,255]. For Hep-6O,N, heparin 
pyridine was dissolved at 10 mg/mL in 90% N-methylpyrrolidone (NMP, Acros 
Organics, Belgium)/10% water (v/v) and maintained at 90°C for 48 hours [247].  Hep- 
was prepared under identical conditions to Hep-6O,N but the reaction proceeded at 100°C 
for 24 hours. Following each reaction, each heparin solution was cooled on ice and 
precipitated with 95% ethanol saturated with sodium acetate. The heparin precipitates 
were stirred for 2 hours on ice and centrifuged to remove excess ethanol and water. The 
resulting material was dissolved in water, dialyzed for 3 days, lyophilized to a powder, 
and stored at -20°C.  
3.2.2 THIOLATION OF HEPARIN DERIVATIVES 
400 mg of each heparin derivative was dissolved in water with 0.2-4.0 molar excess 
hydroxybenzotriazole (HOBt, Ark Pharm, Libertyville, IL) and cystamine.  After 
adjusting the pH to 5.0, 0.2-4.0 molar excess 1-Ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDC, Sigma Aldrich) was added and the reaction was allowed to proceed 
for 2 hours (see Table 3.1).  Following the reaction, the solution was dialyzed for 3 days, 
lyophilized to a powder, and stored at -20°C [76,256]. 
 
Table 3.1. Molar excesses of reagents used for thiolation of heparin derivatives.  
 






Hep 0.2 0.2 0.2 
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Hep-N 1.0 1.0 1.0 
Hep-6O,N 2.0 2.0 2.0 
Hep- 4.0 4.0 2.0 
 
 
3.2.3 MATERIAL CHARACTERIZATION 
Proton nuclear magnetic resonance (1H NMR) was performed to determine the degree of 
thiolation and sulfation of the various chemically modified heparin species. Heparin 
derivatives were dissolved in deuterated water (10 mg/mL) and 1H NMR spectra were 
recorded on a Bruker Avance III 400 spectrometer at 400 MHz as described previously 
[21]. 
3.2.4 MICROPARTICLE FABRICATION AND SIZE ANALYSIS 
To functionalize 4-arm polyethylene glycol (PEG, 10 kDa, Creative PEGWorks, Chapel 
Hill, NC), PEG was reacted with acryloyl chloride (AcCl, Sigma Aldrich) in an 8:1 AcCl 
to PEG molar ratio in dichloromethane (DCM) solution [257].  Triethylamine (TEA, 
Sigma Aldrich) was added drop-wise in a 1:1 TEA to AcCl molar ratio as a catalyst to 
yield 4-arm PEG acrylate (PEG-4Ac).  To prepare the aqueous phase for 10 wt% heparin 
MPs, 5.6 mg thiolated heparin, 50 mg PEG-4Ac, and 16 μL 50 mM tris-(2-carboxyethyl)-
phosphine (TCEP, pH 9, Calbiochem, Germany) were dissolved in 200 μL water.  For 1 
wt% heparin MPs, 0.6 mg thiolated heparin, 55 mg PEG-4Ac, and 16 μL 50 mM TCEP 
were dissolved in 220 μL water.  After all heparin/PEG-4Ac solutions incubated for 15 
minutes at 37°C, water (pH 3) and 25 mM D,L-dithiothreitol (DTT, Sigma Aldrich) were 
added to yield a final aqueous phase volume of 320 μL. 
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 A homogenizer (Polytron PT 3100, Kinematica, Bohemia, NY) was set to 3,100 
RPM and a water bath set to 26°C was configured underneath the homogenizer probe.  
The oil phase, 15 mL mineral oil (Amresco, Solon, OH) + 0.05% v/v Span 80 (TCI, 
Cambridge, MA), was placed under the homogenizer and the aqueous phase was 
subsequently added via pipette.  After 2 minutes, 5 mL mineral oil containing between 5-
13 μL TEA was added to the emulsion via syringe and homogenized for 10 minutes 
(Table 3.2).  
 
Table 3.2. TEA amounts added for each MP formulation. 
 
MP formulation TEA (µl) 
10 wt% Hep 13.0 
10 wt% Hep-N 12.0 
10 wt% Hep-6O,N 9.5 
10 wt% Hep- 13.0 
1 wt% Hep 8.0 
1 wt% Hep-N 7.4 
1 wt% Hep-6O,N 5.2 
1 wt% Hep- 8.0 
 
 
 After homogenizing, 25 mL 0.8 mM Pluronic F 127 (Pluronic buffer, Sigma 
Aldrich) + 0.5% v/v acetic acid (VWR) was added to the emulsion and this solution was 
centrifuged at 4100 RPM for 10 minutes.  The oil phase was removed, MPs were washed 
with Pluronic buffer two additional times and then stored at 4°C.  MP average size and 
distribution analysis were performed on newly formed MPs via phase contrast imaging 
(Nikon i80 microscope), with Image J and Origin 9 software.  A minimum of 150 MPs 
were measured per experimental group. 
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3.2.5 MICROPARTICLE DEGRADATION 
MP degradation was monitored by incubating 0.1 mg of all MP formulations in 0.5 mL 
0.5% v/v BSA (Thermo Scientific, Norcross, GA) + 0.5% NaN3 (Alfa Aesar, Ward Hill, 
MA) phosphate buffered saline (PBS) solution at 37°C.  To capture MP degradation over 
time, 30 μL of each sample was removed and imaged via phase microscopy at day 1, 2, 4, 
7, 10, and 14.  Approximately 25 MPs were captured per image at Day 1 and a minimum 
of 12 images were taken per group at each time point. 
3.2.6 BMP-2 LOADING AND RELEASE 
Recombinant human BMP-2 (R&D Systems, Minneapolis, MN) was dissolved at 100 
μg/mL in sterile water and single-use aliquots were frozen until use. For loading and 
release studies, 0.1 mg of each MP formulation and 100 ng BMP-2 were incubated in 0.5 
mL 0.5% BSA PBS solution for 16 h at 4°C. The amount of BMP-2 was chosen to ensure 
that the concentration of BMP-2 released from the MPs falls within the linear range of 
the BMP-2 bioactivity assay.  After 16 hours, MPs were centrifuged at 15,000 RCF for 
3 min, the supernatant was removed, and MPs were re-suspended in 0.5 mL fresh 0.5% 
BSA solution.  The supernatant removed at 16 and 19 h was used to quantify loading 
onto MPs via BMP-2 ELISA (R&D Systems).  Assuming that BMP-2 released over the 
initial 3 h was not specifically bound to the MPs, the BMP-2 in the supernatant at 16 and 
19 h was subtracted from the amount of BMP-2 in BMP-2 samples that had been 
incubated for the same time without MPs to determine the amount of BMP-2 
bound/loaded onto MPs.  Following this loading procedure, MPs were incubated at 37°C 
and supernatant was collected on days 1, 2, 4, 7, and 10 to quantify BMP-2 release (n = 
3-5). 
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3.2.7 BMP-2 BIOACTIVITY AFTER MICROPARTICLE LOADING AND RELEASE 
Using an established cell-based BMP-2 bioactivity assay, 1.92 x104 C2C12 
myoblasts/cm2 (ATCC) were plated into 96-well plates with 100 μL media consisting of 
4.5 g/mL glucose Dulbecco’s Modified Eagle Medium (DMEM, Cellgro, Manassas, 
VA), 10% v/v fetal bovine serum (FBS, Atlanta Biologics, Atlanta, GA), 1% v/v 10000 
IU penicillin/10000 μg/mL streptomycin (Mediatech, Manassas, VA), and 1% v/v 200 
mM L-glutamine (Cellgro) [258].  After 6 h of attachment, cells were treated with media 
only, 75 ng soluble BMP-2, 0.1 mg unloaded 10% Hep MPs, or 0.1 mg of all MP 
formulations loaded with BMP-2.  After MPs were loaded with BMP-2 as described 
above, all groups were maintained for 3 days at 37°C and 95% O2, 5% CO2, after which 
cells were lysed with 100 μL lysis buffer for alkaline phosphatase (ALP) activity and 
double stranded DNA (dsDNA) quantification. 
 ALP activity in C2C12 cells was assessed via production of p-nitrophenol (Sigma 
Aldrich).  All lysed cell samples were frozen, thawed and sonicated three times to 
completely dissociate the cells.  20 μL of sample or p-nitrophenol standards was 
combined with 5 μL 1.5 M 2-amino-2-methyl-1-propanol (pH 10.25, Sigma Aldrich) in 
each well of a 96-well plate.  Then, 100 μL of a 1:1 mixture 20 mM p-nitrophenol 
phosphate disodium salt hexahydrate (Sigma Aldrich) and 10 mM MgCl2 was added to 
each well.  All samples and standards were incubated for 1 hour at 37°C, at which point 
the reaction was terminated by adding 100 μL 1 M NaOH and absorbance was read at 
405 nm (n = 3-5).  The ALP activity (nmol of p-nitrophenol/mL/min) of each sample was 
normalized to its respective dsDNA concentration (μg/mL, Figure A.1). 
3.2.8 STATISTICAL ANALYSIS 
 49 
All data are presented as mean ± standard deviation. One-way analysis of variance 
(ANOVA) and Tukey’s post hoc multiple comparison test with a significance value set at 
p ≤ 0.05 were used to identify significant differences. Statistical analysis was performed 
with Minitab (v15.1). 
 
3.3 RESULTS 
3.3.1 HEPARIN MP FABRICATION AND CHARACTERIZATION 
Prior to MP fabrication, four heparin derivatives were prepared through desulfation, 
including fully sulfated (Hep), N-desulfated (Hep-N), 6O,N-desulfated (Hep-6O,N), and 
fully desulfated (Hep-) heparin.  Total sulfation was quantified via 1H NMR for each 
heparin derivative and ranged from 0% for Hep- to 100% for Hep (Table 3.3).  
Additionally, 1H NMR indicated that all heparin derivatives were successfully thiolated 
with 10-14% thiolation per disaccharide unit (Table 3.3).   
 
Table 3.3. Sulfation and thiolation degrees of synthesized heparin derivatives. 
 
Heparin species Total sulfation [%] Thiolation [%] per 
disaccharide units 
Hep 100 ± 1 14 ± 2 
Hep-N 87 ± 2 14 ± 2 
Hep-6O,N 20 ± 2 10 ± 1 
Hep- 0 ± 0 12 ± 2 
 
10 wt% heparin and 1 wt% heparin MPs were formed with each heparin derivative 
(Figure 3.1) and based upon phase contrast imaging, most MP formulations appeared 
similar in size, transparency and spherical morphology (Figure 3.2).  Size distribution 
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analysis indicated that a majority of MPs in all formulations were less than 20 μm in 
diameter and specifically for 1% Hep-N MPs, most were less than 10 μm in diameter 
(Figure 3.2Aii).  The average diameter of all MPs ranged between 11-14 μm and 1% Hep-
N MPs were only significantly smaller than 10% Hep-6O,N MPs (Table 3.4). 
 
 
Figure 3.1. Schematic of microparticle fabrication with thiolated heparin, 4-arm PEG 




Figure 3.2. Heparin microparticle size distribution. Microparticles contain either 10 wt% 
heparin (A) or 1 wt% heparin (B) of differing sulfation patterns (i-iv). Scale bar is 100 
μm. 
 
Table 3.4. Average size of microparticle formulations. $Significantly different from each 
other; p ≤ 0.05; n > 150. 
 
 Hep Hep-N Hep-6O,N Hep- 
10 wt% heparin MPs 12.3 ± 7.7 13.2 ± 11.4 13.5 ± 9.7$ 12.3 ± 7.0 
1 wt% heparin MPs 11.3 ± 9.3 11.8 ± 10.9$ 12.8 ± 6.4 13.3 ± 6.8 
 
3.3.2 HEPARIN MP DEGRADATION 
In the MP degradation study, all MP formulations remained present at day 4 (Figure 3.3).  
By day 7, 10% Hep MPs had degraded and all other 10% heparin MPs appeared to have 
swelled.  Finally by day 10, all remaining 10% heparin MP formulations had degraded.  
In contrast, though 1% Hep- MPs degraded by day 10, all other 1% heparin MP 





























on the phase-contrast microscopy images, all MPs appeared to remain similar in shape 
over time. 
 
Figure 3.3. Microparticle degradation time course.  First row shows representative images 
that were similar for 1 wt% Hep, 1 % Hep-N and 1% Hep-6ON microparticles.  Second row 
shows representative images that were similar for 10 wt% Hep-N, 10% Hep-6ON, 10% 
Hep- microparticles, and 1% Hep- microparticles.  White arrows indicate microparticles 
and scale bar is 100 μm. 
 
 
Table 3.5. Degradation time (days) for all microparticle formulations. 
 
 Hep Hep-N Hep-6O,N Hep- 
10 wt% heparin MPs 7 10 10 10 
1 wt% heparin MPs 14 14 14 10 
 
3.3.3 BMP-2 LOADING AND RELEASE FROM MPS 
All MP formulations loaded 46-50% of the 100 ng BMP-2, except 1% Hep- MPs, which 
loaded 56% (Figure 3.4A).  Furthermore, all heparin MPs loaded significantly more 
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found to be significantly different dependent on heparin sulfation pattern and amount of 
heparin in MPs.  10% and 1% heparin MPs with more sulfated heparin derivatives, Hep 
and Hep-N, released significantly more BMP-2 (at least five-fold) than 10% and 1% 
heparin MPs with Hep-6O,N and Hep- (Figure 3.4B-C).  Moreover, the 10% Hep and 10%   
Hep-N MPs released significantly more BMP-2 than 1% Hep and 1% Hep-N MPs.  
However, similar release kinetics were observed from all MP formulations.  More than 
95% of the cumulative release occurred between days 1-4 for all MPs, and after day 7 no 
detectable levels of additional BMP-2 were observed in any MP group. 
 
Figure 3.4. BMP-2 loading and release from all microparticle formulations.  (A) BMP-2 
loading was similar for most microparticle formulations whereas (B-C) BMP-2 release 
was significantly higher for more sulfated heparin microparticles with higher heparin 
content. $Significantly different than all other groups; p ≤ 0.05. %Significantly different 
than 10 wt% Hep, 10% Hep-6O,N, and 1% Hep-6O,N microparticle groups; p ≤ 0.05.  #All 
groups significantly different from each other; p ≤ 0.05.  &Significantly different from 1% 















































































































































3.3.4 CELL-BASED BMP-2 BIOACTIVITY ASSAY 
For these experiments, the ALP activity of each group was normalized to its dsDNA 
content (Figure A.1).  After 3 days, BMP-2-loaded 10% Hep and 10% Hep-N MPs 
stimulated significantly more ALP activity than all other groups, including control groups 
of unloaded 10% Hep MPs (no observable ALP activity; data not shown) and 75 ng 
soluble BMP-2 (Figure 3.5).  Moreover, since the release studies indicated that 10% Hep 
and 10% Hep-N MPs released less than 20 ng BMP-2 of the ~50 ng loaded over 3 days, 
these results suggested that BMP-2 bioactivity was enhanced compared to soluble BMP-
2.  Similarly, 1% Hep and 1% Hep-N MPs stimulated comparable levels of ALP activity 
to 75 ng soluble BMP-2, though the release studies indicated that these MPs had released 
less than 10 ng BMP-2 over 3 days.  In contrast, the more desulfated heparin MPs, 
including Hep-6O,N and Hep- MPs, stimulated little to no ALP activity over the 3 day time 
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Figure 3.5. C2C12 ALP assay for BMP-2 bioactivity.  BMP-2 bioactivity is significantly 
enhanced in the more sulfated heparin microparticle groups.  $Significantly different than 




In these studies, a series of heparin-based MPs were fabricated for the purpose of 
controlling release of bioactive BMP-2.  In future in vivo applications we envision that 
these MPs could be combined with gels or mesh-like carriers as an effective orthopaedic 
therapy.  Towards this goal, we investigated (1) the incorporation of hydrolytically 
degradable crosslinker and alteration of heparin content in MPs to vary MP degradation 
and (2) the desulfation of heparin within MPs to vary the release of BMP-2 from MPs.  
Though we have previously developed 100 wt% heparin MPs, to our knowledge the 
incorporation of degradable crosslinker and desulfated heparin into MPs to further 
control BMP-2 release has yet to be investigated.  Furthermore, the use of Michael Type 
addition crosslinking within MPs is a novel approach and allows for controlled 
crosslinking by tuning pH (Figure 3.1).  We deliberately chose to incorporate heparin 
within PEG MPs because the PEG could be functionalized to include a degradable 
crosslinker, as well as the fact that it is relatively inert [259].  Altogether, we examined 
eight different MP formulations, including 10 wt% heparin and 1 wt% heparin MPs with 
four heparin species.   
 After fabrication, all MPs exhibited spherical morphology, little MP aggregation, 
and similar size distributions (Figure 3.2).  Overall, the size of our MPs were similar to 
those made previously with 100 wt% heparin [15] to facilitate direct comparisons of 
growth factor loading and release.  To vary MP degradation, we initially sought to 
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modify the DTT concentration in MPs, but found that MPs only formed within a small 
range of DTT concentrations (15-25 mM DTT) and MP degradation was not significantly 
altered by DTT content.  Instead, we modified the heparin content in MPs and found that 
10% heparin MPs degraded sooner than most 1% heparin MPs (Figure 3.3).  With 10-
fold less negatively charged heparin within 1% heparin MPs, this may have resulted in 
less water attraction into the MPs and subsequently slower hydrolysis of the MPs.  
Similarly, other studies have found that with increasing sulfation, the hydrolytic 
degradation of sulfated cellulose fibers occurred at lower temperatures, suggesting that 
more negatively charged materials are increasingly susceptible to hydrolytic degradation 
[260].  Finally, it was observed that the 10% Hep MPs were first to degrade of the 10% 
heparin MPs whereas 1% Hep- MPs were the first to degrade of the 1% heparin MPs.  
The faster degradation of 1% Hep- MPs may indicate that these MPs were not as stable or 
did not crosslink as well, and therefore degraded more quickly.  Ultimately, we have 
demonstrated that by reducing the heparin content within MPs the time course of MP 
degradation was increased by ~4 days for most formulations, thus providing a means to 
modulate the degradation time of these materials.    
 In order to produce degradable MPs, the heparin content was reduced compared 
to the 100 wt% heparin MPs fabricated previously in our laboratory [15].  However, even 
with significantly reduced heparin content, most MP formulations exhibited a loading 
efficiency of ~50% (Figure 3.4A).  Based on these results and previous data from our 
laboratory, 100%, 10%, and 1% heparin MPs loaded 90, 500, and 5000 ng BMP-2 per 0.1 
mg heparin, respectively, though the efficiency of loading can vary depending upon the 
amounts of growth factor and MPs used [15].  These differences in growth factor-to-
 57 
heparin loading efficiency may result from the increasing availability of heparin as the 
heparin content within MPs is reduced.  For 100% heparin MPs, the high density of 
heparin binding sites may sterically hinder some sites from being occupied, whereas 
within 10% and 1% heparin MPs, the increased distance between heparin binding sites 
could potentially allow for more efficient BMP-2 binding.  Previous studies in our 
laboratory found that positively charged protein penetration into heparin-based hydrogels 
decreased with increasing heparin content, again supporting the idea that MPs with less 
heparin could load growth factors more efficiently than 100% heparin MPs [56].  Taken 
together, these results suggest that reduced heparin content within MPs is still adequate 
for efficient BMP-2 loading. 
 Over 10 days, nearly 60% of loaded BMP-2 was released from 10% Hep MPs, 
substantially more than 100% Hep MPs, which released only 20% in previous studies 
from our laboratory (Figure 3.4B) [15].  In our system, it is possible that the 100% Hep 
MPs, which are crosslinked along the heparin backbone, are more tightly crosslinked than 
the 10% Hep MPs, which crosslink only at the ends of each PEG-4Ac arm.  Therefore, 
one rationale for the difference in BMP-2 release is the less tightly crosslinked network 
of 10% Hep MPs in comparison to 100% Hep MPs, allowing for greater diffusion and 
more abundant release of BMP-2.  Prior studies with heparin-containing hydrogels 
resulted in a large range of release, between 20-80% of loaded BMP-2 [70,71,245].  In 
studies more similar to our system, heparin-containing MPs released 40-60% of loaded 
BMP-2 [16,252], which is consistent with our findings from 10% Hep MPs.  In these 
cases, however, heparin was either covalently attached to hyaluronic acid MPs or coated 
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onto the alginate MP surface, rather than crosslinked into PEG-based MPs as in our 
system. 
 To further tune BMP-2 release from MPs we varied the degradation of MPs 
between ~10-14 days.  However, regardless of the time course of MP degradation, similar 
release kinetics were observed from all MPs (Figure 3.4).  These findings suggest that 
BMP-2 release was governed by diffusion rather than exclusively on the degradation of 
the MPs and led us to simultaneously alter sulfation pattern within the degradable MPs.  
Specifically, we hypothesized that with decreased heparin sulfation and concomitant 
reduction in electrostatic interactions within the MPs, more desulfated heparin MPs 
would release greater amounts of BMP-2 and thus provide a means to further tune BMP-
2 release.  Instead, as heparin sulfation levels within MPs decreased, the total BMP-2 
release recorded also significantly decreased (Figure 3.4B-C).  Additionally, C2C12 ALP 
activity indicated that MPs with more sulfated heparin derivatives, Hep and Hep-N, 
enhanced the bioactivity of BMP-2 over soluble BMP-2, whereas little ALP activity was 
stimulated by less sulfated heparin MPs.  For the MPs that had not fully degraded by Day 
10 (1 wt% Hep, Hep-N, and Hep-6O,N) it is possible that some BMP-2 was still entrapped 
beyond the timeframe of the 10 day release study, however, this does not explain the 
trends in ALP activity and BMP-2 release observed in the majority of the MP 
formulations.  Interpreting our BMP-2 release and bioactivity results collectively, we 
hypothesized that BMP-2 was significantly more protected by more sulfated heparin 
MPs, resulting in greater detected levels of BMP-2 and enhanced BMP-2 bioactivity in 
these MP groups.  This interpretation also applies to the differences between 10% and 1% 
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heparin MPs, whereby the MPs with greater amounts of heparin (10 wt%) protected more 
BMP-2 than 1 wt% MPs with the same heparin species. 
 To test our hypothesis, we incubated all the heparin derivatives with BMP-2 in 
solution to investigate the effect of heparin on BMP-2 detection.  After 24 hours at 4°C, 
the detected levels of BMP-2 remained between 90-100 ng in Hep and Hep-N samples but 
decreased significantly in Hep-6O,N,  Hep-, and no heparin samples, suggesting that more 
sulfated heparin derivatives may protect BMP-2 from denaturation in this time frame 
(Figure A.2).  Similar trends were also seen previously in our laboratory after heat 
treatment, where more BMP-2 protection was found with more sulfated soluble heparin 
derivatives, although these experiments were carried out with non-glycosylated BMP-2, 
unlike the glycosylated form used in these studies [21].  It is important to note, however, 
that even in the most sulfated heparin MP groups, some BMP-2 denaturation may have 
occurred over time, resulting in less than 100% detected release of loaded BMP-2 
 Applying our bioactivity results to our MP studies, more desulfated heparin MPs 
were likely unable to protect the bound BMP-2, resulting in little release of detectable 
BMP-2 and minimal BMP-2 bioactivity after as little as 24 hours.  In contrast, more 
sulfated heparin MPs, and particularly those with higher heparin content, were able to 
maintain BMP-2 bioactivity during release.  However, in our MP experiments it is still 
unclear whether the source of BMP-2 protection lies in BMP-2 interactions with heparin 
within and on the surface of MPs or interactions with soluble heparin released from MPs.  
Therefore, quantifying the amount of heparin released from MPs over time may shed 
light on how BMP-2 is protected in this system. 
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 Previous experiments have demonstrated that the FGF family of growth factors is 
protected by heparin [82,83].  However, compared with FGF, relatively few studies have 
investigated how sulfation pattern may contribute to heparin’s role in protecting BMP-2 
bioactivity, and the results have been inconsistent [21,85].  One group has demonstrated 
that BMP-2 bioactivity was enhanced after incubating with a desulfated heparin 
derivative. This work used soluble 2O-desulfated heparin, which is distinct from any of 
our derivatives, and mesenchymal stem cells (MSCs) were used to assess BMP-2 
bioactivity rather than C2C12 cells [87].  On the other hand, a separate set of studies have 
corroborated our findings where BMP-2 was bioactive after incubation with fully sulfated 
heparin and inactive with fully desulfated heparin, as determined via C2C12 ALP activity 
47.  It should be noted, however, that only soluble heparin was used and the fully 
desulfated heparin was further altered to be N-acetylated or N-sulfated, unlike the Hep- 
used for our studies.  In our studies, because multiple sulfate groups were removed 
simultaneously, we were unable to completely decouple the effects of sulfation level and 
sulfation pattern, although this may be an interesting avenue for future investigation.   
Thus, based on reported results as well as our findings in these experiments, heparin 
sulfation pattern/level may be an important consideration in fabrication of GAG-based 
delivery systems for BMP-2 in the future. 
 
3.5 CONCLUSIONS 
Hydrolytically-degradable, heparin-based MPs were fabricated containing heparin 
derivatives with varying levels of sulfation.  It was demonstrated that MP degradation 
time in vitro can be adjusted by varying the heparin content (weight %) within MPs.  
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Furthermore, our results indicate that most MP formulations load equivalent amounts of 
BMP-2, whereas more sulfated heparin MPs, Hep and Hep-N, are able to release 
significantly greater detectable levels of intact BMP-2 than more desulfated heparin MPs, 
Hep-6O,N and Hep-.  Similarly, presentation of BMP-2 from more sulfated heparin MPs 
can enhance BMP-2 bioactivity compared to growth factor in solution, whereas heavily 
desulfated heparin MPs maintain little to no BMP-2 bioactivity.  Therefore, we have 
identified 10 wt% Hep and Hep-N MPs as viable growth factor carriers capable of 
efficient loading and release of bioactive BMP-2, and demonstrated that heparin sulfation 
level may be an important consideration for any future heparin-based biomaterials 


























INTRA-ARTICULAR TSG-6 DELIVERY FROM HEPARIN-BASED MICROPARTICLES 




Osteoarthritis (OA) affects more than 60% of Americans over 65 years of age and is 
characterized by significant articular cartilage degeneration including cartilage 
fibrillation, fissures, and loss of proteoglycan and collagen content within the cartilage 
extracellular matrix  (ECM) [4,38,39].  While OA is a multi-factorial disease, at stages of 
disease progression both cartilage-resident chondrocytes and synoviocytes in the joint 
capsule have been found to secrete increased levels of soluble factors including 
interleukins, tumor necrosis factor-alpha (TNF-), and matrix metalloproteinases 
(MMPs), among others, which are known to promote or be directly involved in cartilage 
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degradation [39–41].  Additionally, components of the plasminogen activation pathway 
including plasminogen and plasminogen activators, receptors, and inhibitors [24–27] 
have also been shown to be upregulated in OA joints when compared to healthy patients 
[26,44].  As plasmin, the active form of plasminogen, has been shown to activate MMPs 
and degrade ECM [42,43], it is postulated that the plasminogen activation pathway plays 
a significant role in the cartilage degeneration exhibited in OA joints [25,27].  Thus, 
plasmin-inhibiting therapeutics may be a promising method to ameliorate cartilage 
degeneration in the context of OA. 
TNF--stimulated gene-6 (TSG-6) is a positively charged 35 kDa protein with 
anti-plasmin and anti-inflammatory properties [42].  In particular, TSG-6 has been 
studied extensively for its ability to potentiate inter-alpha-inhibitor (IalphaI)-mediated 
inhibition of plasmin [42,43] and more recently, its ability to suppress the response of 
chondrocytes to inflammatory factors such as interleukin-1 and TNF- [135].  In the 
context of OA, while little constitutively expressed TSG-6 has been observed in healthy 
patients, TSG-6 protein expression was found to be upregulated in OA joints and greater 
TSG-6 levels were observed in patients where OA symptoms had advanced over a three 
year period compared to non-progressing OA patients [136–138]. 
 Despite the increased production of endogenous TSG-6, however, tissues within 
OA joints continue to degenerate, leading to studies on the effect of adding exogenous 
TSG-6 on arthritis progression.  In rheumatoid arthritis (RA) mouse models, soluble 
TSG-6 treatment led to a significant improvement in joint swelling [139] and cartilage 
damage [139,140], assessed via joint diameter and histology, respectively; but these 
effects were often short-lived, and by day 12 [139] or day 35 [140] no differences were 
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observed between treated and untreated animals.  Most recently, soluble TSG-6 treatment 
was also investigated in a rat OA model induced by anterior cruciate ligament and 
meniscus transection [135].  In this work, a portion of the TSG-6 molecule was delivered 
via intra-articular injection weekly up to 21 days following injury.  After 28 days, 
histology indicated that cartilage fibrillation and ulceration were significantly diminished 
with TSG-6 treatment compared to untreated controls, indicating that TSG-6 or TSG-6 
derivatives may be an effective OA treatment strategy [135].   
Despite these promising results, one drawback to soluble treatments are the high 
doses often required and short retention due to rapid clearance from the joint space [4,5]. 
Therefore, in this study we explored the use of heparin, a naturally derived and highly 
sulfated GAG that can bind to a myriad of positively charged proteins including TSG-6 
[10,12,14,16,17,20], as an injectable biomaterial carrier.  Heparin is of particular interest 
in this application because previous work has demonstrated that soluble complexes of 
heparin and TSG-6 resulted in enhanced TSG-6 anti-plasmin activity [22,43].  Although 
desulfated heparin derivatives have been explored as a safer in vivo therapeutic delivery 
strategy due to their diminished anti-coagulant properties compared to fully sulfated 
heparin [14,17,66,96], the effect of heparin desulfation on TSG-6 binding and bioactivity 
has yet to be determined.  Therefore, investigating the ability for desulfated heparin 
derivatives to maintain or enhance TSG-6 bioactivity is important to the development of 
an efficacious delivery strategy for TSG-6. 
 In this work, we first assessed the ability for desulfated heparin derivatives 
ranging from 0 to 100% total sulfation to enhance TSG-6 bioactivity in vitro.  Next, 
though heparin-based hydrogels have been utilized extensively for protein delivery 
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[65,66,81,262–265], hydrogel volume may be prohibitive for drug delivery to joint 
spaces,[4].  Therefore, we have developed hydrolytically degradable heparin-based 
microparticles (MPs) based on our in vitro results and delivered TSG-6 loaded heparin-
based MPs via intra-articular injection following medial meniscal transection (MMT) 
injury in a rat model. We hypothesized that heparin of greater total sulfation would 
enhance TSG-6 bioactivity and, ultimately, that TSG-6 loaded on MPs with the 
appropriate sulfation level and delivered via intra-articular injection would reduce 
cartilage damage following MMT injury significantly more than soluble TSG-6 
treatment. 
 
4.2 MATERIALS AND METHODS 
4.2.1 HEPARIN MODIFICATIONS 
N-desulfated (Hep-N) and fully desulfated (Hep-) heparin were prepared as described 
previously, whereby 10 mg/mL heparin sodium salt (Hep) from porcine intestinal mucosa 
(Sigma) was dissolved in dH2O and passed through Dowex 50WX4 resin (mesh size 100-
200, Sigma) [14,21].  Pyridine was added until the heparin solution reached pH 6, after 
which time excess dH2O and pyridine were removed via rotatory evaporator (Buchi), 
flash frozen, and lyophilized.  For Hep-N, the heparin pyridinium was then dissolved at 1 
mg/mL in 9:1 v/v dimethyl sulfoxide (DMSO)/ dH2O at 50°C for 2 hours.[254,255]  For 
Hep-, heparin pyridinium was dissolved at 10 mg/mL in 9:1 v/v N-methylpyrrolidone 
(NMP, Acros Organics)/ dH2O at 100°C for 24 hours [247].  Subsequently, Hep-N and 
Hep- were precipitated with 95% ethanol saturated with sodium acetate, collected via 
centrifuge, dissolved in dH2O, dialyzed, lyophilized, and stored at -20°C.   
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Hep-N methacrylamide (Hep-N MAm) functionalization was performed as described 
previously.[13]  Briefly, 1.1 mM Hep-N, 83.0 mM N-hydroxysulfosuccinimide (sulfo-
NHS, Sigma), 101.0 mM N-(3-Aminopropyl) methacrylamide hydrochloride (APMAm, 
Polysciences Inc.), and 156.0 mM (N-3-Dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC, Sigma) were combined in 10 mL phosphate buffer saline (PBS, 
Teknova).  After stirring on ice for 6 hours, Hep-N MAm was dialyzed, lyophilized, and 
stored at -20°C. 
 
4.2.2 POLY (ETHYLENE GLYCOL) DIACRYLATE SYNTHESIS 
Poly (ethylene glycol) (PEG, 3.4 kDa, Sigma) was reacted in a 8:1 molar ratio of acryloyl 
chloride (AcCl, Sigma) to PEG in dichloromethane (DCM) solution.33  Next, a 1:1 molar 
ratio of triethylamine (TEA, Sigma) to AcCl was added as a catalyst resulting in linear 
PEG-diacrylate (PEGDA). 
4.2.3 PROTON NUCLEAR MAGNETIC RESONANCE 
Proton nuclear magnetic resonance (1H NMR) was performed whereby 10 mg/mL Hep-N 
MAm and PEGDA samples were each dissolved in deuterated H2O (Sigma), run on a 
Bruker Avance III spectrometer at 400 Hz, and analyzed using iNMR software [21].  
Percent modification was determined by dividing the integral of the methacrylamide peak 
by the heparin peak for Hep-N MAm and the acrylate peaks by the PEG peak for PEGDA. 
4.2.4 PLASMIN INHIBITION ASSAY 
Plasmin inhibition via TSG-6 was determined as described previously.[43]  Briefly, clear 
96-well plates were blocked for 1 hour with 0.5 wt% bovine serum albumin (BSA, 
Thermo) PBS solution.  For TSG-6 with soluble heparin derivatives, 108 nM TSG-6 was 
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added with 108 nM of Hep, Hep-N or Hep- in a pH 7.4 buffer of 10 mM HEPES, 150 mM 
NaCl, and 0.02% v/v Tween20 in dH2O for 30 mins at 37°C.  Next, 24 nM IalphaI 
(Athens Research & Technology) was added and allowed to incubate for an additional 30 
mins at 37°C.  Finally, 3.4 nM plasmin (Sigma) and 197 μM plasmin substrate (N-p-
Tosyl-Gly-Pro-Lys 4-nitroanilide acetate salt, Sigma) were added and incubated for 20 
mins at RT and 20 mins at 37°C, at which time the plate was analyzed on a plate reader at 
405 nm every ~40 mins for a total of 180 mins; n = 3. 
4.2.5 MICROPARTICLE FABRICATION 
To fabricate 10 wt% Hep-N MPs, 50.0 mg PEGDA and 1.61 mg dithiothreitol (DTT, 35 
mM, Sigma) were added to 273 μL 10 wt% BSA PBS solution and incubated at 37°C for 
30 mins to allow for Michael Type addition between PEGDA and DTT.  Then, 5.6 mg 
Hep-N MAm was added and the aqueous solution was incubated again at 37°C for 30 
mins. 
Next, an oil phase of 5 mL mineral oil (Amresco) with 3.0-3.2 μL Span80 (TCI) 
was placed under a homogenizer (Polytron PT 3100, Kinematica) set to 4000 RPM.  
After adding 27 μL of 0.05 wt% Irgacure 2959 photoinitiator (Ciba) to the aqueous 
phase, the solution was added drop-wise to the oil phase and the water-and-oil emulsion 
was allowed to homogenize for 5 mins.  Subsequently, the water-and-oil emulsion was 
nitrogen purged for 1 min and crosslinked under UV (~15 mW/cm2) via free radical 
polymerization between PEGDA and Hep-N MAm.  MPs were then washed through 3 
iterations of the following procedure: MPs were combined with 35 mL dH2O, centrifuged 
at 4000 RPM for 5 mins, and the supernatant consisting of water and oil was removed.  In 
the final wash, MPs were pipetted through 40 μm cell strainers to remove MPs under 40 
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μm in diameter.  To sterilize MPs, each MP batch was incubated with 70% ethanol on 
rotary platform at 4°C for 30 mins, followed by 3 30-min washes in sterile PBS.  Phase 
microscopy and ImageJ software were used to image and determine the size distribution 
of each MP batch.  MPs were stored in sterile PBS at 4°C until use. 
4.2.6 TSG-6 LOADING AND RELEASE FROM MICROPARTICLES 
To load TSG-6 onto MPs, 1.0 μg human TSG-6 (R&D Systems) was added to 0.6 mg 
MPs in 50 μL 0.1 wt% BSA solution.  TSG-6 and MPs were incubated for 2 hours at 
4°C, after which time MPs were rinsed by adding an additional 450 μL 0.1 wt% BSA 
solution.  The MPs were centrifuged for 3 mins at 10,000 RCF and 495 μL supernatant 
was removed.  For all in vitro and in vivo studies, MP loading was completed on the day 
of the experiment to reduce variability and avoid potential protein denaturation prior to 
the start of the experiment. 
 For in vitro TSG-6 release studies, the removed supernatant was replaced with 
495 μL fresh 0.1 wt% BSA solution and samples were incubated at 37°C.  MPs were 
centrifuged and 495 μL supernatant was removed and replaced 3 hours, 1, 3, 7, and 10 
days following TSG-6 loading until MPs degraded.  TSG-6 protein levels were quantified 
using a human TSG-6 sandwich ELISA with the following steps: 10 μg/mL monoclonal 
capture antibody (Santa Cruz Biotechnology) overnight, 100-10,000 pg/mL recombinant 
human TSG-6 used as standards and samples for 2 hours, 0.5 μg/mL biotinylated 
secondary detection antibody (R&D Systems) for 2 hours, streptavidin-horseradish 
peroxidase enzyme (R&D Systems) for 20 mins, substrate solution (R&D Systems) for 
20 mins, and lastly a stop solution of 2 N sulfuric acid (Ricca) that was read at 450 nm; n 
= 3-5. 
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 To assess TSG-6 bioactivity after release from MPs, the plasmin inhibition assay 
protocol was followed with day 1 TSG-6 release supernatant (11 ng/mL) and compared 
to a soluble TSG-6 control at the same concentration (11 ng/mL); n= 3-5. 
4.2.7 MEDIAL MENISCAL TRANSECTION MODEL 
Animal use was reviewed and approved by the Georgia Institute of Technology 
Institutional Animal Care and Use Committee which follows the “Public Health Service 
Policy on Humane Care and Use of Laboratory Animals” and uses the National 
Guidelines outlined in the “Guide for the Care and Use of Laboratory Animals, 8th Ed.” 
as its basis.  In addition, experiments followed all institutional guidelines, personnel were 
enrolled in the Georgia Institute of Technology Occupational Health & Safety Program 
and experiments were reviewed by Environmental Health & Safety and Radiation Safety 
Committee.  MMT injury was induced using a similar method to previously established 
protocols with male Sprague-Dawley rats (11 total animals used for all in vivo 
experiments, 250-300 g initial weight, 8-10 weeks old from Charles River).[38]  Prior to 
surgery animals were anesthetized by 5% isoflurane (Isothesia), followed by 2-3% 
isoflurane during surgery and were administered sustained release buprenorphine as an 
analgesic.  Next, a small incision was made through the skin on the medial aspect of the 
left femoro-tibial joint. The medial collateral ligament was exposed by blunt dissection 
and transected to visualize the joint space and medial meniscus. The meniscus was then 
transected completely at its narrowest point. The skin was sutured with 4.0 silk sutures 
(Ethicon) and then closed using wound clips. 
4.2.8 IN VIVO TSG-6 DELIVERY  
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For TSG-6 loaded MP treatment, MPs were loaded as described above but 3.6 mg MPs 
were resuspended in a total volume of 50 μL sterile 0.1 wt% BSA PBS solution and 
subsequently loaded into sterile syringes.  1, 7, and 15 days following MMT injury, MPs 
were delivered via intra-articular injection through the infrapatellar ligament and into the 
stifle joint of the left leg.  For soluble TSG-6 controls, 16.7 μg TSG-6 was dissolved in a 
total volume of 50 μL sterile 0.1 wt% BSA PBS solution, loaded into sterile syringes, and 
delivered using the same method as TSG-6 loaded MPs.  Overall, in vivo experimental 
groups included TSG-6 loaded MPs (18 μg TSG-6 loaded onto 10.8 mg MPs delivered 
over 3 time points; n = 4), soluble TSG-6 (50 μg TSG-6 delivered over 3 time points; n = 
4) or injury only (no TSG-6 or MPs; n = 3).  The same animals were used for all 
subsequent outcome measures.  Contralateral tibiae served as uninjured controls.  
4.2.9 MICROCT ANALYSIS 
21 days following MMT injury, rats were euthanized and tibiae were harvested and fixed 
in 10% neutral buffered formalin (EMD Chemicals) for 7 days.  Tibiae were then 
immersed in a 30% Hexabrix (Covidien) PBS solution at 37°C for 30 mins and scanned 
using a μCT40 (Scanco Medical) at 45 kVp, 177 µA, 200 ms integration time, and 16 µm 
voxel size.  
For cartilage assessment via µCT, Equilibrium Partitioning of an Ionic Contrast 
agent-µCT (EPIC-µCT) and Scanco evaluation software (Scanco µCT evaluation 
software V6.5-3) was used as described previously [132].  First, raw scan data were 
automatically reconstructed to 2D grayscale tomograms, which were subsequently rotated 
to sagittal sections.  Next, cartilage (gray in images) was manually contoured on the head 
of the tibiae to separate it from trabecular bone (white in images) and surrounding area 
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(black in images).  Fixed threshold values were used to separate cartilage from air and 
bone: a lower threshold of 458 mg HA/cm3 was used to separate cartilage from air and a 
higher threshold of 635 mg HA/cm3 was used to separate cartilage from bone.  The 
threshold values were globally applied for both the left and right tibiae of all animals.  
After manually defining the cartilage region of interest (ROI), Scanco evaluation 
software was used to measure cartilage thickness (distance transformation of stacked 2D 
images), volume (# of voxels * voxel volume), attenuation (inversely proportional to 
proteoglycan content), osteophyte volume, and lesion volume within the medial third of 
the medial tibial plateau, which is the characteristic region of damage in MMT injuries; n 
= 3-4 [38,127,131]. 
4.2.10 HISTOLOGY 
Following μCT, tibiae were decalcified in Cal-Ex II (Fisher) for 10 days, then processed 
for frozen histology sectioning as described previously [266].  Sections were stained in 
0.1% fast green (Sigma) and 0.25% safranin-O solution (Sigma) and imaged at 20x 
magnification with a Nikon Eclipse 80i; n = 3-4. 
4.2.11 STATISTICAL ANALYSIS 
All data are presented as mean ± standard deviation. One-way analysis of variance 
(ANOVA) and Tukey’s post hoc multiple comparison test (significance value of p ≤ 
0.05) were run using Prism software. 
 
4.3 RESULTS 
4.3.1 MATERIALS CHARACTERIZATION 
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1H NMR indicated that PEGDA was ~55% functionalized while Hep-N MAm was 
between 20-28% functionalized (Figure B.1). 
4.3.2 PLASMIN INHIBITION ASSAY WITH SOLUBLE HEPARIN DERIVATIVES 
Hep and Hep-N both significantly enhanced TSG-6 anti-plasmin activity (57.3 ± 1.2% and 
66.1 ± 1.7% plasmin activity compared to plasmin control, respectively) compared to 
TSG-6 alone (74.6 ± 0.2%), though Hep enhanced TSG-6 activity significantly more than 
Hep-N.  In contrast, Hep- had no significant effect (69.6 ± 1.2%) compared to TSG-6 
alone (Figure 4.1). 
 
Figure 4.1. Degree of heparin sulfation affects TSG-6 bioactivity in vitro.  (A-B) Fully 
sulfated and N-desulfated heparin significantly enhanced TSG-6 anti-plasmin activity 
whereas (C) fully desulfated heparin had no effect on TSG-6 activity compared to soluble 
TSG-6 controls.  *Significantly different than all other groups; p ≦0.05. #Not 
significantly different from each other but significantly different than all other groups; p 
≦0.05; n = 3; data shown as mean ± SD. 
 
4.3.3 MICROPARTICLE FABRICATION, LOADING, AND RELEASE  
Degradable 10 wt% Hep-N MPs were found to be 80 ± 60 μm in diameter (Figure 4.2) 
and have previously been shown to degrade within 10-16 days in vitro [266]. In vitro, 6.0 
μg TSG-6 was loaded onto MPs and over 1-3 days ~1 μg TSG-6 was released (Figure 
4.3A). Therefore, over 3 injections in vivo, 18.0 μg TSG-6 was originally added to MPs 
and ~3 μg TSG-6 was released.  In comparison, for soluble TSG-6 treatment, 16.7 μg 
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TSG-6 was delivered per injection, resulting in a total dosage of 50.0 μg soluble TSG-6 
over three injections.  Importantly, TSG-6 released from MPs after 1 day exhibited 
significantly greater anti-plasmin activity (65.7 ± 3.0% plasmin activity compared to 




Figure 4.2.  Degradable, 10 wt% N-desulfated heparin microparticles were fabricated via 
Michael type addition and free radical polymerization.  (A) Microparticles were 
fabricated with 10 wt% N-desulfated heparin methacrylamide, 90 wt% linear poly 
(ethylene glycol) diacrylate and 35 mM dithiothreitol (DTT). (B) Phase image analysis 
indicated that microparticles were 80±60 μm in diameter; black arrows indicate 





Figure 4.3. 10 wt% Hep-N MPs released TSG-6 over ~3 days and enhanced TSG-6 
bioactivity. (A) Over 5 days, ~1.0 µg TSG-6 was released from MPs; n = 3-4 ± SD. (B) 
TSG-6 released from MPs exhibited significantly more anti-plasmin activity than soluble 
TSG-6 at the same concentration. *Significantly lower than all other groups; p  0.05; n 
= 3-4; data shown as mean ± SD. 
 
4.3.4 MICROCT ANALYSIS 
μCT images 21 days following MMT injury were quantified to assess changes in 
cartilage thickness, volume, and attenuation (Figure 4.4E-H).  After 21 days following 
MMT injury, cartilage thickness (1.9 ± 0.4X compared to uninjured control) and volume 
(2.0 ± 0.6X) increased significantly compared to uninjured contralateral controls (Figure 
4.4I-J).  Soluble TSG-6 treated samples also exhibited significantly increased cartilage 
thickness (1.5 ± 0.2X) and volume (1.9 ± 0.5X) as well as increased attenuation (1.6 ± 
0.2X) (Figure 4.4I-K) compared to uninjured controls.  In contrast, neither cartilage 
thickness, volume, nor attenuation were increased in the TSG-6 loaded MP group 
compared to uninjured controls (Figure 4.4I-K).  Osteophyte volume, focal lesion 
volume, and surface roughness were not significantly different between each 




Figure 4.4. TSG-6 loaded MPs reduce cartilage damage 3 weeks following MMT injury. 
(A-D) Safranin-O stained coronal sections of tibiae 3 weeks following injury and 
treatment indicated that GAG loss was observed in the (A) injured and (B) soluble TSG-
6, but not in the (C) TSG-6 loaded MP group. (E-H) Contrast-enhanced μCT imaging of 
the same samples indicated that cartilage fibrillation was present in the (E) injured and 
(F) soluble TSG-6 groups but was not present in the (G) TSG-6 loaded MP group. Scale 
bars are 500 μm; n = 3-4 ± SD. (I-K) Quantified evaluation of articular cartilage indicated 
that (I) cartilage thickness and (J) volume were significantly increased compared to 
uninjured controls after injury and soluble TSG-6 treatment, and (K) cartilage attenuation 
was significantly increased after soluble TSG-6 treatment. In contrast, no significant 
increase in cartilage thickness, volume, or attenuation was observed in the TSG-6 loaded 
MP group compared to uninjured controls. *Significantly different than contralateral 
control; p ≦0.05; n = 3-4; data shown as mean ± SD. 
 
4.3.5 HISTOLOGY 
Safranin-O staining of GAG within cartilage was observed in TSG-6 loaded MP treated 
tibiae (Figure 4.4C) and in uninjured controls (Figure 4.4D).  Qualitatively, less intense 
safranin-O staining was observed in the medial one-third of the injured and soluble TSG-





The objectives of this work were to elucidate the effect of heparin sulfation on TSG-6 
bioactivity and, utilizing this information, to develop heparin-based biomaterials for the 
intra-articular delivery of TSG-6.  To this end, soluble heparin derivatives including Hep, 
Hep-N, and Hep-, found to have 100%, ~80% and ~0% sulfation compared to natively 
sulfated heparin [14,21], were incubated with TSG-6 and results indicated that Hep and 
Hep-N significantly enhanced TSG-6 anti-plasmin activity compared to soluble TSG-6 
alone, whereas Hep- had no effect (Figure 4.1).  For Hep specifically, these results 
parallel previous work, and it is hypothesized that the ability for Hep to maintain TSG-6 
in a “closed” conformation upon binding, unlike other GAGs such as HA, may have 
contributed to the enhanced anti-plasmin activity observed [22,23].  Secondly, as Hep can 
bind to both TSG-6 and IalphaI, it is possible that Hep increased the proximity of the two 
proteins, thereby enabling TSG-6 to potentiate IalphaI-mediated plasmin inhibition [22]. 
In comparison to Hep, Hep-N enhanced TSG-6 activity to a significantly less degree, 
whereas Hep- showed no enhancement over soluble TSG-6, indicating that heparin 
desulfation reduced heparin-mediated enhancement of TSG-6 anti-plasmin activity 
(Figure 4.1).  One possible explanation may be that the sulfate groups removed from Hep-
N and Hep-, the N sulfate group for Hep-N as well as the 2O and 6O sulfate groups for 
Hep-, are necessary for complete heparin binding to TSG-6 and the subsequent 
enhancement of TSG-6 bioactivity.  In a study with derivatives of another GAG, 
chondroitin sulfate, with varying sulfation patterns, it was found that chondroitin-4-
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sulfate (C4S) could bind to TSG-6 while chondroitin-6-sulfate (C6S) could not,[88] 
suggesting that specific sulfate groups may significantly affect GAG binding to TSG-6.  
Alternatively, as Hep- is ~0% sulfated, it is possible that Hep- bound to TSG-6 in a 
similar manner as HA, a naturally non-sulfated GAG which binds to TSG-6 at a distinct 
and non-overlapping binding site from heparin, and which did not enhance TSG-6 
bioactivity in previous work [22,23]. 
Finally, more sulfated heparin derivatives have also been shown to protect 
proteins from denaturation, providing an additional mechanism by which Hep and Hep-N 
may have maintained TSG-6 bioactivity in this study.  For example, when Hep, Hep-N, 
and Hep- were incubated with bone morphogenetic protein-2 (BMP-2) and exposed to 
65°C heat treatment for 15 mins, Hep was significantly more effective in protecting 
BMP-2 than all other desulfated heparin derivatives [14,21].  As our in vitro studies were 
conducted at 37°C over ~4 hours, it is possible that Hep and Hep-N, due to binding with 
TSG-6, could protect TSG-6 from denaturation over this time course, thereby protecting 
TSG-6 bioactivity.   In summary, these findings indicate that Hep and Hep-N can enhance 
TSG-6 anti-plasmin activity, potentially due to interactions with specific sulfate groups 
which may enable binding to TSG-6, through the protection of TSG-6 from denaturation 
when bound to heparin, or through a combination of mechanisms.  Ultimately, given its 
diminished anti-coagulant properties compared to Hep, Hep-N-based MPs were chosen as 
the biomaterial carrier for intra-articular delivery of TSG-6. 
To determine the ability for Hep-N-based MPs to enhance TSG-6 treatment in 
vivo, we first assessed the effect of soluble TSG-6 and injury alone via EPIC-μCT, an 
analysis technique which utilizes a contrast agent to better distinguish cartilage from bone 
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in μCT images [132,267].  Our results following injury alone parallel previous findings 
whereby cartilage thickness, volume, and attenuation (which is inversely proportional to 
proteoglycan content) were all significantly increased after 21 days following MMT 
injury in rats (Figure 4.4I-K) [127].  Furthermore, these results also parallel findings from 
human OA joints, where chondrocytes have been shown to proliferate, produce ECM, 
and undergo hypertrophy potentially resulting in increased cartilage thickness and 
volume, whereas the upregulation of proteinases in OA patients is known to cause 
cartilage proteoglycan loss [38,127,130,268].   
However, our results also indicate that soluble TSG-6 was unable to improve 
cartilage degeneration following injury (Figure 4.4B,F,I-K).  In contrast, in a recent study 
the intra-articular injection of soluble TSG-6 link modules, a portion of TSG-6 that has 
been shown to retain certain TSG-6 anti-inflammatory properties [269],  over 3 weeks 
within a rat OA model led to a significant reduction in cartilage fibrillation and ulceration 
when analyzed via histology [135].  It is important to note, however, that several 
differences exist between this study and our work, including the OA animal model, which 
included both anterior cruciate ligament transection and MMT compared to MMT alone 
in our work, and the methods for analyzing cartilage degeneration, which included only 
histology.  Furthermore, the doses of TSG-6 used in the study were not reported, which 
may be an explanation for the results of soluble TSG-6 treatment observed in this case. 
In our experiments, in contrast to injury and soluble TSG-6, EPIC-μCT revealed that 
neither cartilage thickness, volume, nor attenuation were increased in the TSG-6 loaded 
MP group compared to uninjured controls (Figure 4.4G,I-K), indicating that cartilage 
swelling and proteoglycan loss were reduced by TSG-6 loaded MP treatment.  
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Histological analysis similarly showed that cartilage safranin-O staining remained 
qualitatively similar to uninjured controls, again suggesting that proteoglycan loss was 
reduced by TSG-6 loaded MP treatment (Figure 4.4C).  As TSG-6 treatment was only 
effective when delivered with Hep-N-based MPs, even with a 3X lower dose than soluble 
TSG-6, our results indicate that the Hep-N-based carrier played a significant role in the 
efficacy of TSG-6 in vivo.  Combining these findings with our in vitro studies, it is 
possible that Hep-N MPs enhanced TSG-6 anti-plasmin activity, thereby reducing 
plasmin-mediated MMP activation and ECM degradation, or protected TSG-6 against 
denaturation, further improving the efficacy of TSG-6 treatment.  Importantly, our 
findings indicate that Hep-N-based MPs may reduce the amount of TSG-6 required for 
therapeutic effect by at least 3-fold, providing a more efficacious approach to TSG-6-
mediated OA treatment.   
However, in our system TSG-6 is still released from MPs over a relatively short 
period of time, within 1-3 days after loading (Figure 4.3A).  Moreover, given the 
relatively fast degradation rate of MPs (between 9-16 days in vitro [266]), we delivered 
TSG-6 loaded MPs in weekly injections which is unsuitable for direct clinical translation.  
Thus, future optimization of this carrier may include extending the degradation rate of 
MPs over several weeks by decreasing the concentration of DTT within MPs [14,17,266], 
potentially extending the release of TSG-6 from MPs.  Furthermore, in other work, by 
increasing the heparin content within heparin-PEG hydrogels from 3 to 6 wt%, a ~20% 
reduction in the amount of protein released after the first 7 days was observed [270], 
suggesting that increasing heparin content may provide another mechanism to prolong 
the release of TSG-6 from our MPs.  
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Ultimately, in this system, TSG-6 loaded onto Hep-N-based MPs was significantly 
more chondroprotective than a 3X dosage of soluble TSG-6. While, based on our soluble 
GAG experiments, TSG-6 anti-plasmin activity is likely one potential mechanism 
through which TSG-6 displayed a chondroprotective effect following MMT injury, TSG-
6 has also been shown to interact with a number of cell populations potentially found 
within the injured joint space, including leukocytes [269],  neutrophils [43], macrophages 
[271], and MSCs [272,273].  Thus, in the future, additional studies designed to fully 
elucidate which functions of TSG-6 are responsible for the results seen in these 
experiments and how Hep-N may enhance these capabilities may further improve TSG-6-
mediated OA treatment. 
 
4.5 CONCLUSIONS 
In this chapter, we assessed the effect of heparin sulfation on TSG-6 bioactivity to inform 
the development of heparin-based MPs for the intra-articular delivery of TSG-6 in post-
traumatic osteoarthritis.  More sulfated heparin derivatives (Hep and Hep-N) significantly 
enhanced TSG-6 anti-plasmin activity in vitro, whereas fully desulfated heparin (Hep-) 
had no effect, indicating that heparin sulfation plays a significant role in modulating 
TSG-6 bioactivity.  Based on this data, hydrolytically degradable TSG-6 loaded Hep-N-
based MPs were delivered via intra-articular injection following MMT injury.  After 21 
days, EPIC-µCT analysis indicated that TSG-6 loaded MPs reduced cartilage damage 
following MMT injury, whereas a 3X higher dose of soluble TSG-6 did not.  These 
results suggest that Hep-N can enhance TSG-6 bioactivity in vivo and, ultimately, that 
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Hep-N-containing MPs may be an effective method for delivery of TSG-6 for OA 
























LOCALIZED SDF-1 DELIVERY INCREASES PRO-HEALING BONE MARROW-
DERIVED CELLS IN THE SUPRASPINATUS MUSCLE FOLLOWING SEVERE 




The chemotactic protein stromal cell-derived factor-1alpha (SDF-1), primarily through 
its G protein-coupled receptor, CXC chemokine receptor type 4 (CXCR4), has previously 
shown to attract a myriad of cell populations including immune cells such as monocytes 
[28,29] and lymphocytes [29,219], stem cells such as hematopoietic [30] and 
mesenchymal stem cells (MSCs) [31], and progenitor cell populations [12,32], among 
others [33,34].  Previously in our laboratory, we subcutaneously implanted SDF-1 
loaded hydrogels into a murine dorsal skinfold window chamber model to enable the 
visualization of cell recruitment and vascular remodeling [9,274].  After 2-3 days 
following implantation, more bone marrow-derived cells [9] and significantly more anti-
inflammatory monocytes were detected near the SDF-1 loaded hydrogels [9,10] 
compared to unloaded gels.  Moreover, after 7 days significantly more anti-inflammatory, 
M2-like macrophages, were observed near SDF-1 loaded gels compared to unloaded 
controls [10].  Thus, as SDF-1 can recruit certain potentially pro-regenerative cell 
populations, including MSCs and anti-inflammatory monocytes and macrophages, SDF-
1 delivery may be an effective approach to modulate the cellular milieu during disease 
states involving tissue degeneration. 
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Despite these prior findings, SDF-1 treatment has yet to be explored in the 
unique context of muscle degeneration following rotator cuff tear.  Though rotator cuff 
tear begins primarily as a tendon injury, significant muscle degeneration often 
accompanies rotator cuff tears, which can include muscle atrophy as well as fatty and 
fibrous infiltration into the muscle  [149,150].   To fully understand the degenerative 
changes in muscle following rotator cuff tear, several laboratories have investigated the 
cellular milieu within rotator cuff muscles following injury [159,175,176,275].  In our 
work, significantly more mononuclear phagocytes, monocytes, and M2 macrophages, 
among others, were detected in the supraspinatus muscle 7 days following transection of 
two rotator cuff tendons in mice [275].  Furthermore, using a rat model with a similar 
tendon transection approach, it was found that macrophages were specifically observed 
near areas of fat accumulation [176] and, in patients with chronic full-thickness tears, 
lipid-laden macrophages were observed surrounding muscle fibers [159].  Collectively, 
these results suggest that specific inflammatory cell populations may play a role in 
muscle degeneration following rotator cuff tear, and further investigation and 
manipulation of these cell populations through the delivery of SDF-1 may enable a 
better understanding of the muscle degeneration observed as well as potential treatment 
strategies following rotator cuff tear. 
 For the facile delivery of SDF-1 to muscle following rotator cuff injury, we have 
developed a degradable, injectable microparticle platform.  First, our laboratory and 
others have developed biomaterials containing heparin, a highly sulfated 
glycosaminoglycan (GAG) that can bind and interact with a myriad of proteins to 
maintain or enhance protein bioactivity, including SDF-1 [9,14,17–19].  Second, as 
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natively sulfated heparin possesses potent anti-coagulant properties and may present 
safety issues in vivo, we have incorporated N-desulfated heparin (Hep-N) within our 
biomaterials, which exhibits diminished anti-coagulant properties while maintaining the 
ability to bind protein and protect protein bioactivity [14,96].  Lastly, though heparin and 
heparin derivatives have been successfully incorporated within bulk hydrogels for SDF-
1 delivery [9–12], we and others have developed heparin-based microparticles (MPs) 
[13–16] as an injectable protein delivery method without exposure to free radicals that 
are required for in situ radically-polymerized hydrogels [46–48].  Furthermore, building 
on our previous work [17], we have incorporated dithiothreitol (DTT) within the MPs to 
vary the rate of hydrolytic degradation [276] and ultimately allow for more complete 
release of protein over time. 
In the present study, we have developed SDF-1 loaded 10 wt% Hep-N MPs 
comprised of Hep-N methacrylamide, poly (ethylene glycol) diacrylate (PEGDA), and 
DTT and injected them into the supraspinatus muscle immediately following rotator cuff 
tendon transection and denervation in rats.  Based on previous results [14,261],  10 wt% 
Hep-N MPs due to their ability to efficiently release protein, protect protein bioactivity, 
and degrade within 1-2 weeks in vitro.  The tendon transection and denervation model 
utilized in these studies recapitulates many hallmarks of muscle degeneration exhibited in 
the human condition of rotator cuff tear in as little as 3 weeks following injury 
[171,176,177] and thus provides an excellent platform to investigate and modulate the 
cellular milieu via SDF-1 treatment.  Specifically, after 3 and 7 days, the supraspinatus 
muscles were harvested and analyzed for changes in cellular composition by quantifying 
the number of myeloid cells, macrophages, macrophage subpopulations and MSCs 
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present via flow cytometry.  We hypothesized that significantly more pro-regenerative 
bone marrow-derived cells would be observed in muscle treated with SDF-1α loaded 
Hep-N MPs than untreated muscle after rotator cuff tendon transection. 
 
 
5.2 MATERIALS AND METHODS 
5.2.1 HEPARIN MODIFICATIONS 
N-desulfated heparin (Hep-N) was prepared as described previously [14,21,254,255].  
Briefly, heparin sodium salt (Hep) from porcine intestinal mucosa (Sigma) was dissolved 
at 10 mg/mL in dH2O and passed through Dowex 50WX4 resin (mesh size 100-200, 
Sigma).  Pyridine was added drop-wise to the heparin until the solution reached pH 6 and 
the solution was placed on a rotatory evaporator (Buchi) to remove excess dH2O and 
pyridine.  Heparin pyridinium salt solution was frozen in liquid nitrogen, lyophilized, and 
then dissolved at 1 mg/mL in 9:1 v/v dimethyl sulfoxide (DMSO)/ dH2O at 50°C for 2 
hours.  Following the reaction, the Hep-N was cooled on ice and precipitated with 95% 
ethanol saturated with sodium acetate, then collected by centrifugation.  The resulting 
material was dissolved in dH2O, dialyzed for 3 days, lyophilized, frozen in liquid 
nitrogen, and stored at -20°C. 
For methacrylamide (MAm) functionalization, 1.1 mM Hep-N, 83.0 mM N-
hydroxysulfosuccinimide (sulfo-NHS, Sigma), 101.0 mM N-(3-Aminopropyl) 
methacrylamide hydrochloride (APMAm, Polysciences Inc.), and 156.0 mM (N-3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC, Sigma) were 
dissolved in 10 mL phosphate buffer saline (PBS, Teknova) solution.  After stirring on 
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ice for 6 hours, the Hep-NMAm was dialyzed for 2 days, lyophilized, frozen in liquid 
nitrogen, and stored at -20°C. 
 To fluorescently label Hep-NMAm, Hep-NMAm was dissolved at 10 mg/mL in 0.1 
M Na2HPO4 solution at pH 6.  Next, 10 mM EDC and 5.7 μM AlexaFluor633 hydrazide 
(AF633, Invitrogen) were added and the reaction proceeded in the dark for 90 mins at 
RT.  AF633 Hep-NMAm was dialyzed for 2 days, frozen in liquid nitrogen, lyophilized, 
and stored at -20°C. 
5.2.2 POLY (ETHYLENE GLYCOL) DIACRYLATE SYNTHESIS 
Poly (ethylene glycol) (PEG, 3.4 kDa, Sigma) was reacted with acryloyl chloride (AcCl, 
Sigma) in an 8:1 AcCl to PEG molar ratio in dichloromethane (DCM) solution [276]. 
Triethylamine (TEA, Sigma) was added drop-wise in a 1:1 TEA to AcCl molar ratio as a 
catalyst to yield linear PEG-diacrylate (PEGDA). 
5.2.3 PROTON NUCLEAR MAGNETIC RESONANCE 
Proton nuclear magnetic resonance (1H NMR) was performed to determine the degree of 
PEGDA and Hep-NMAm functionalization, whereby each material was dissolved at 10 
mg/mL in deuterated H2O (Sigma), run on a Bruker Avance III spectrometer at 400 Hz, 
and analyzed using iNMR software [21,261]. 
5.2.4 STRONG ANION EXCHANGE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
Strong anion exchange high performance liquid chromatography (SAX-HPLC) was 
performed at the University of Georgia Complex Carbohydrate Research Center (CCRC) 
to determine the disaccharide composition of Hep and Hep-N.  Hep and Hep-N were 
dissolved at 12.5 mg/mL in a heparinase mixture of 0.5 U/mL heparinases I, II, and III 
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for 24 hours at 37°C.  The reaction was then quenched by heating the mixture for 2 mins 
at 100°C. 
SAX-HPLC was carried out on an Agilent system using a Waters Spherisorb 
analytical column (4.6250 mm; 5 m particle size) at 25°C. Analytes were detected by 
their UV absorbance at 232 nm using a buffer system consisting of 2.5 mM sodium 
phosphate (Na3PO4) and pH 3.5, which was gradually transitioned from 0 to 1.2 M NaCl. 
The flow rate was 1.0 mL/min and detection was performed by post-column 
derivatization and fluorescence detection.  Commercial standard disaccharides (Dextra 
Laboratories) were used for identification of each disaccharide based on elution time and 
calibration. 
5.2.5 SIZE EXCLUSION CHROMATOGRAPHY 
Size exclusion high performance liquid chromatography (SEC-HPLC) was performed at 
the University of Georgia CCRC to analyze the average molecular weight and desulfation 
characteristics of Hep and Hep-N.  Hep and Hep-N were dissolved at 20 mg/mL in a 0.5 M 
lithium nitrate buffer.  Separations were carried out using two TSKGel G2000SWXL 
columns (7.8 mm ID x 30 cm), connected in series, on an Agilent 1200 LC instrument 
using refractive index detection and a sample flow rate and injection volume of 0.6 
mL/min and 10 μL, respectively.  Cirrus GPC software was used to construct 3rd order 
polynomial standard curves with the molecular weights and elution times of USP 
enoxaparin sodium molecular weight calibrants and broad standard USP heparin 
molecular weight calibrants.  Weight molecular weights were calculated in Cirrus using 
the raw chromatograms exported from the SEC-HPLC instrument software. 
5.2.6 MICROPARTICLE FABRICATION 
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10 wt% Hep-N microparticles (MPs) were fabricated via water-and-oil emulsion.  First, 
50.0 mg PEGDA and 0.92-1.85 mg dithiothreitol (DTT, 20-40 mM, Sigma) were added 
to 273 μL 10 wt% bovine serum albumin (BSA, Thermo) PBS solution, consistent with 
previous studies in our laboratory [9,10], and incubated at ~ pH 7 and 37°C for 30 mins 
to allow for Michael Type addition between PEGDA and DTT.  Next, 5.6 mg Hep-
NMAm was added and the aqueous phase was incubated for an additional 30 mins.  For 
fluorescently tagged Hep-N MPs (AF633 Hep-N MPs), a 1:1 ratio of AF633 Hep-NMAm to 
Hep-NMAm was used and for non-degradable MPs, no DTT was added during 
fabrication. 
 After 27 μL of 0.05 wt% Irgacure 2959 photo initiator (Ciba) was added, the 
aqueous phase described above was added drop-wise to an oil phase of 5 mL mineral oil 
(Amresco) with 3.0-3.2 μL Span80 (TCI) and allowed to homogenize at 4000 RPM 
(Polytron PT 3100, Kinematica) for 5 mins.  The amount of Span80 in the oil phase was 
varied to ensure that MPs with different DTT concentrations were maintained at the same 
average diameter.  The water-and-oil emulsion was nitrogen purged for 1 min then placed 
into a petri dish under UV (~15 mW/cm2) for 10 mins to allow for free radical 
polymerization between PEGDA and Hep-NMAm.  Finally, the MP solution was added to 
35 mL dH2O, centrifuged at 4000 RPM for 5 mins, and the oil phase was removed.  MPs 
were washed once more with dH2O, then pipetted through 40 μm cell strainers to remove 
most MPs under 40 μm in diameter.   
 Once fabricated, MPs were sterilized in 70% ethanol on rotary at 4°C for 30 mins, 
followed by 3 30-min washes in sterile PBS.  MPs were imaged via phase microscopy 
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and size distribution was measured using ImageJ software.  MPs were stored in sterile 
PBS at 4°C and used within 2 weeks of fabrication. 
5.2.7 IN VITRO SDF-1 LOADING AND RELEASE FROM MICROPARTICLES 
To load SDF-1 onto MPs, 1.0-1.2 μg sterile human SDF-1 (R&D Systems) was added 
to 0.6 mg MPs in 50 μL 0.1 wt% sterile BSA solution.  SDF-1 and MPs were incubated 
for 2 hours at 4°C, after which time MPs were rinsed by adding an additional 450 μL 0.1 
wt% sterile BSA solution.  The MPs were centrifuged for 3 mins at 10,000 RCF and 495 
μL supernatant was removed.   
 For in vitro SDF-1 release studies, the removed supernatant was replaced with 
495 μL fresh 0.1 wt% sterile BSA solution and samples were incubated at 37°C.  MPs 
were centrifuged and 495 μL supernatant was removed and replaced 3 hours, 1, 3, 7, 10 
and 15 days following SDF-1 loading.  SDF-1 protein levels were quantified with a 
human SDF-1 ELISA kit (R&D Systems) using the manufacturer’s protocol, except for 
standard curves which were made with recombinant human SDF-1 rather than the 
provided standard.  To ensure equivalent cumulative SDF-1 release for each in vivo 
study, an in vitro SDF-1 release study from MPs was conducted prior to each individual 
surgery; n = 3-5 per release study. 
5.2.8 IN VIVO FLUORESCENTLY-TAGGED MICROPARTICLE INJECTION AND IMAGING 
Non-degradable (0 mM DTT) and degradable (35 mM DTT) AF633 Hep-N MPs were 
suspended in 120 μL sterile dH2O (4.3 mg MPs) and subsequently loaded into sterile 
syringes with 20-gauge 1.5 in. hypodermic needles (BD Precision Glide).  Immediately 
following tendon transection and denervation, the MPs were injected into the 
supraspinatus muscle located posterior to the scapula.  Uninjured contralateral 
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supraspinatus muscles were not injected with MPs and served as negative controls.  After 
3 and 7 days, supraspinatus muscles were dissected from the scapula, sliced in half 
length-wise, stained with a 1:1000 dilution Hoechst cellular stain (Thermo) in PBS for 5 
mins, and remained unfixed for imaging.  Muscles were whole-mounted and single 
fluorescent images were obtained using a Zeiss LSM 700 confocal microscope with a 20x 
objective to visualize AF633 Hep-N MPs (red) within the muscle tissue (blue); n = 2 
animals per group per time point. 
5.2.9 ROTATOR CUFF INJURY MODEL 
Rotator cuff injury was induced using a similar method to previously established 
protocols [177].  Male Sprague-Dawley rats (250-300 g initial weight and 8-10 weeks 
old) were used in accordance with protocols approved by the Georgia Institute of 
Technology Institutional Animal Care and Use Committee.  Prior to surgery animals 
were anesthetized by 5% isoflurane (Isothesia), followed by 2-3% isoflurane during 
surgery and were administered sustained release buprenorphine as an analgesic.  The left 
chest and arm were shaved, wiped with alcohol/chlorhexidine, and a ~2 cm incision was 
made through the skin and deltoid, parallel to and just below the clavicle.  To induce 
injury, a ~5 mm portion of the suprascapular nerve was resected and, after orienting the 
humerus to expose the supraspinatus and infraspinatus tendon insertions, both tendons 
were sharply transected.  The deltoid and skin were closed using Vicryl 4-0 absorbable 
sutures (Ethicon) and wound clips, respectively.  The right rotator cuff of each animal 
served as an internal uninjured contralateral control. 
5.2.10 IN VIVO SDF-1 LOADED MICROPARTICLE INJECTION 
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For in vivo SDF-1 loaded MP delivery, we based our dosage of SDF-1α on previous 
results in mouse models whereby 15-20 ng SDF-1α released from 10 wt% Hep-N 
hydrogels over ~7 days resulted in significant cell recruitment after 7 days [9].  As male 
Sprague Dawley rats used in our studies were approximately 10X the weight of the mice 
used in previous studies, we used a dosage of ~155 ng SDF-1α released from 0.6 mg 10 
wt% Hep-N MPs.  For in vivo injection, MPs were loaded with SDF-1 as described 
above but after centrifugation, MPs were resuspended in a total volume of 120 μL sterile 
0.1 wt% BSA solution.  MPs were then loaded into sterile syringes with 20-gauge 1.5 in. 
hypodermic needles and injected into the supraspinatus muscle immediately following 
tendon transection and denervation.  Unloaded MPs were prepared in the same way, 
except that the maximum concentration of MPs that could be delivered in 120 uL was 
used (4.3 mg, 36 mg/mL). 
5.2.11 FLOW CYTOMETRY 
For flow cytometry experiments, groups included SDF-1 loaded MPs (0.6 mg MPs 
which released ~155 ng SDF-1 in vitro), unloaded MPs (4.3 mg MPs), and injury only 
(no SDF-1 or MPs).  Supraspinatus muscles were harvested 3 and 7 days following 
injury and treatment, digested with collagenase 1A (Sigma) for 45 mins at 37º C, and 
passed through a 40 μm cell strainer (Corning).  One-half of each sample was stained 
with the inflammatory cell panel that included FITC-conjugated anti-CD11b (AbD 
Serotec), PE-conjugated anti-CD163 (BioRad), and APC-conjugated anti-CD68 (BioRad) 
and the other one-half was stained with the MSC panel that included PE-conjugated anti-
CD29 (BioLegend), APC-conjugated anti-CD44 (BioLegend), and BV421-conjugated 
anti-CD90 (BioLegend).  Samples were stained for 30 mins with the appropriate 
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antibodies and fixed in 2% PFA for 20 mins, then analyzed using a FACS-AriaIIIu flow 
cytometer (BD Biosciences).  Inflammatory cells were identified as CD11b+ myeloid 
cells, CD11b+CD68+ macrophages, and CD163 was used to differentiate M2-like 
(CD11b+CD68+CD163+) from M1-like macrophages (CD11b+CD68+CD163-) 
[277,278]. MSCs were identified as triple positive for CD29, CD44, and CD90 [279]; n = 
4-9 animals per group per time point.  For data analysis, each cell population was first 
calculated as a percentage of single cells:  
 
% of single cells = # of cells in subpopulation 
                           # of single cells 
 
Then, each % of single cell value was divided by the % of single cells in the uninjured 
contralateral control of the same animal: 
 
Fold-change over contralateral control = % of single cells in experimental group 
                 % of single cells in contralateral control  
 
5.2.12 VASCULAR STAINING OF WHOLE-MOUNTED SUPRASPINATUS MUSCLE 
After 7 days following injury and treatment, supraspinatus muscles were fixed in 4% 
PFA for 30 mins at RT, rinsed in PBS, permeabilized in 0.2% saponin (Sigma) PBS 
solution for 24 hours at 4ºC, and blocked in 10% BSA solution for 24 hours at 4ºC.  For 
vascular staining, muscles were incubated in 5 µg/mL anti-mouse/rat CD31/PECAM-1 
primary antibody (R&D Systems) in a 1.0% BSA, 0.3% Triton X-100 (Amresco), 0.01% 
sodium azide solution (incubation buffer) overnight at 4ºC, followed by 4 30-min washes 
in 0.2% saponin solution.  Muscles were then stained in a 1:200 dilution of NL557-
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conjugated anti-goat IgG secondary antibody (R&D Systems) in incubation buffer for 4 
hours at RT, then washed in 0.2% saponin solution and PBS twice each for 30 mins.  As 
a negative control, samples were stained using the same protocol but with polyclonal goat 
IgG isotype control (R&D Systems) in place of the primary antibody.  Finally, muscles 
were incubated in a 1:1000 dilution of Hoechst cellular stain in PBS for 5 mins.  Muscles 
were whole-mounted and single fluorescent images were obtained using a Zeiss LSM 700 
confocal microscopy with a 10x objective to visualize vasculature (green) within muscle 
tissue (blue); n = 2 animals per group.  
5.2.13 STATISTICAL ANALYSIS 
All data are presented as mean ± standard deviation. One-way analysis of variance 
(ANOVA) and Tukey’s post hoc multiple comparison test with a significance value set at 
p ≤ 0.05 were used to identify significant differences. Statistical analysis was performed 
with Prism software. 
 
5.3 RESULTS 
5.3.1 MATERIALS CHARACTERIZATION 
Using 1H NMR analysis, PEGDA was determined to be ~55% functionalized and Hep -N 
methacrylamide was determined to be 22-28% functionalized [261].  SAX-HPLC 
analysis was also used to assess Hep and Hep-N disaccharide composition.  Disaccharide 
elution patterns showed evidence of N-desulfation when comparing Hep-N against Hep 
samples (Table 5.1).  Finally, using SEC-HPLC, the weight average molecular weight 
was determined to be ~13.5 kDa for Hep-N compared to ~18.4 kDa for Hep. 
5.3.2 MICROPARTICLE FABRICATION 
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Degradable 10 wt% Hep-N MPs were found to be 62 ± 65 μm in diameter (Figure 5.1B 
and C.1).  Additionally, by varying DTT concentration within MPs, MP degradation 
ranged between 30 days for 20 mM DTT to 8 days for 40 mM DTT (Figure C.3).  MPs 
used in all subsequent studies contained 35 mM DTT, which degraded within 16 days in 
vitro (Figure C.3). 
Figure 5.1. Degradable 10 wt% N-desulfated heparin microparticles released SDF-1α 
over 24 hours in vitro.  (A) Microparticles were fabricated with 10 wt% N-desulfated 
heparin methacrylamide, 90 wt% linear poly (ethylene glycol) diacrylate and 35 mM 
dithiothreitol (DTT). (B) Phase image analysis indicated that microparticles were ~62±65 
μm in diameter; black arrows indicate microparticles; scale bar is 100 μm. (C) 
Microparticles released ~155 ng SDF-1α over ~3 days in vitro; n = 3-5 ± SD. 
 
5.3.3 IN VITRO SDF-1 LOADING AND RELEASE FROM MICROPARTICLES 
For all MP batches, 370 ± 50 ng was loaded onto MPs and 155 ± 10 ng SDF-1 was 
released from MPs over ~24 hours in vitro (Figure 5.1C).  Using the ~155 ng dose of 
SDF-1, a small in vivo pilot study was conducted and results indicated that ~155 ng 
SDF-1 induced significant cell recruitment compared to injury alone.  Once ~155 ng 
SDF-1 was determined to be an effective dose, we ensured that ~155 ng SDF-1 was 
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released from all subsequent batches of MPs by varying the initial mass of SDF-1 added 
to each batch of MPs between 1.0-1.2 µg SDF-1 and by conducting an in vitro release 
study prior to each surgery.  The pilot study and additional data was combined and is 
shown in Figure 5.3 and 5.4. 
5.3.4 IN VIVO INJECTION OF MICROPARTICLES 
Intact, non-degradable AF633 Hep-N MPs (red) were visible within the supraspinatus 
muscle (blue) 3 and 7 days following injection (Figure 5.2Bi-ii), whereas degradable 
AF633 Hep-N MPs were present at day 3 but no longer detectable by day 7 (Figure 
5.2Biii-iv). 
 
Figure 5.2. Injected 10 wt% Hep-N microparticles were retained within the supraspinatus 
muscle for up to 7 days. (A) Experimental design: AlexaFluor633 tagged Hep-N was 
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crosslinked within 10 wt% Hep-N microparticles and injected into the supraspinatus 
muscle immediately following injury, then tracked at day 3 and 7 via confocal 
microscopy. (Bi-ii) Non-degradable microparticles (red) remained within the muscle 
(nuclei in blue) for at least 7 days while (Biii-iv) degradable microparticles appeared to 
have degraded by day 7; white arrow heads indicate microparticles; scale bar is 100 μm. 
 
5.3.5 INFLAMMATORY CELL ANALYSIS 
Supraspinatus muscles were analyzed for inflammatory cell infiltration via flow 
cytometry at days 3 and 7.  For unloaded MPs, there was small but significant elevation 
in total myeloid cells (1.8 ± 0.6X compared to contralateral control) and macrophages 
(1.7 ± 0.6X) compared to the uninjured contralateral controls after 3 days (Figure 5.3A-
B).  For all other groups, there were no significant differences in myeloid cells (1.3-
2.1X), macrophages (1.2-1.9X), or macrophage subpopulations (1.1-2.6X) between the 
experimental groups and the uninjured contralateral controls after 3 days (Figure 5.3A-
D).  There were also no differences between any of the experimental groups including 
SDF-1 loaded MPs, unloaded MPs, and injury only at the day 3 time point. 
 
Figure 5.3. SDF-1α loaded microparticles recruited significantly more M2-like 
macrophages 7 days following injury and treatment.  (A-D) No significant increase in cell 
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recruitment was observed after 3 days except in (A) total myeloid cells and (B) total 
macrophages after treatment with unloaded microparticles compared to uninjured 
controls. (E-F) By day 7, significantly more total myeloid cells and macrophages were 
recruited to all experimental groups compared to uninjured controls.  (G) While there 
were no differences in M1-like macrophage recruitment between any of the experimental 
groups, (H) SDF-1α loaded microparticles recruited significantly more M2-like 
macrophages than all other groups. #Significantly greater than contralateral control at that 
time point; *Significantly different; p ≦ 0.05; n = 4-9 ± SD. 
 
In contrast, 7 days following injury, significantly more M2-like macrophages were 
observed in muscle treated with SDF-1 loaded MPs than uninjured controls (4.3 ± 
1.9X), unloaded MPs (1.4 ± 0.4X) and injury alone (2.2 ± 1.2X, Figure 5.3H). There 
were also no significant differences in M1-like macrophages between groups (Figure 
5.3G). Notably, significantly more total myeloid cells (2.0-2.3X) and macrophages (1.6-
2.1X) were detected in each experimental group compared to the respective uninjured 
contralateral controls (Figure 5.3E-F), though experimental groups were not significantly 
different from each other.  Background fluorescence from antibody binding to 
inflammatory cell Fc receptors was tested by incubating separate samples with Fc blocker 
(CD16/32, BioLegend), and no significant differences were observed with any 
inflammatory cell population between Fc blocked and non-Fc blocked samples (Figure 
C.6).  Therefore, Fc blocking was not used for the experiments and data presented in 
Figure 5.3. 
5.3.6 MESENCHYMAL STEM CELL ANALYSIS 
Similar to the trends seen in inflammatory cell analysis, there were no significant 
differences in MSC recruitment between any experimental group or between each 
experimental group and the uninjured contralateral controls at day 3 (1.1-1.4X, Figure 
5.4A).  However, by day 7 there were significantly more MSCs in both the SDF-1 
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loaded MP group (3.0 ± 0.8X) and the unloaded MP group (1.7 ± 0.6X) compared to their 
respective uninjured contralateral controls, and significantly more MSCs were recruited 
to the SDF-1 loaded MP group than unloaded MPs and injury alone (Figure 5.4B). 
Figure 5.4. SDF-1α loaded microparticles recruited significantly more mesenchymal stem 
cells 7 days following injury and treatment.  (A) No significant increase in mesenchymal 
stem cell (MSC, CD29+CD44+CD90+) recruitment was observed after 3 days but (B) by 
day 7, significantly more MSCs were recruited to the SDF-1α loaded microparticle group 
than all other groups.  #Significantly greater than contralateral control; *Significantly 
different; p ≦ 0.05; n = 4-11 ± SD. 
 
5.3.7 VASCULAR STAINING OF WHOLE-MOUNTED SUPRASPINATUS MUSCLE 
Compared to uninjured contralateral controls that had little CD31+ vascular staining 
(Figure 5.5A), CD31+ vascular staining was present in the injury only control (Figure 
5.5B).  Furthermore, CD31+ vascular looping, a product of rapid angiogenesis whereby 
vessels elongate and form loops of vasculature [280], also appeared to be present in 
muscles treated with SDF-1 loaded MPs (Figure 5.5C).  No staining was observed in 
samples prepared with isotype controls (data not shown). 
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Figure 5.5. Vascular looping was observed in SDF-1α loaded MP treated supraspinatus 
muscle. Supraspinatus muscles treated with SDF-1α loaded MPs (C) appear to exhibit 
CD31+ vascular looping 7 days following injury and treatment compared to uninjured 
(A) or injured (B) controls; blue = Hoechst stained nuclei, green = CD31+ vasculature; 




Despite the well-documented ability for SDF-1 to induce chemotaxis of pro-
regenerative cell populations, SDF-1 treatment has yet to be explored in the unique 
cellular context of muscle degeneration following rotator cuff tear.  Furthermore, as 
current standard-of-care reattachment surgery for rotator cuff tear largely neglects the 
muscle tissue, leading to further degeneration and an increased likelihood of re-tear 
[149,150], SDF-1 may be a promising strategy to recruit pro-regenerative cell 
populations to the degenerating muscle for improved rotator cuff repair prognoses in the 
future.  We therefore developed injectable 10 wt% Hep-N MPs capable of releasing 
bioactive SDF-1 and subsequently degrading within 1-2 weeks (Figure 5.1A-B) to 
enable further investigation and manipulation of cell populations within the rotator cuff 
muscle. 
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By incorporating varying concentrations of DTT within the MP crosslinking 
network, it is thought that the thioether group established between PEGDA and DTT 
increases the atomic charge of the carbonyl carbon within the PEGDA molecule, thereby 
increasing its reactivity with water and ultimately resulting in ester hydrolysis [17,281].  
Thus, DTT concentrations of 20-40 mM, all of which were previously shown to be non-
toxic in in vitro studies [282], were incorporated within 10 wt% Hep-N MPs and resulted 
in degradation within 8 to 30 days in vitro (Figure C.3).  Furthermore, while non-
degradable MPs (0 mM DTT) remained intact over 7 days in vivo, degradable MPs (35 
mM DTT) were no longer observable 7 days following injection in the supraspinatus 
muscle (Figure 5.2).  Though we observed that MPs with 35 mM DTT degraded within 
16 days in vitro, MP degradation rate can be concentration-dependent (data not shown) 
which may account for the differences observed between our in vitro and in vivo results.  
Furthermore, upon activation following injury or biomaterial implantation, cells 
including macrophages may secrete acids which reduce pH and accelerate ester 
hydrolysis [283], reactive oxygen intermediates which promote oxidation-mediated 
cleavage of the PEG ether backbone [284], and enzymes including esterases which 
catalyze the cleavage of PEGDA ester bonds [285], all which may have contributed to the 
accelerated MP degradation observed in vivo.  Ultimately, 10 wt% Hep-N MPs with 35 
mM DTT degraded within 16 days in vitro and 7 days in vivo, and these particles were 
utilized in all subsequent in vivo studies to enable release of SDF-1. 
Next, we assessed in vitro and in vivo SDF-1 release from the Hep-N-based MPs.  
In our system, though MP degradation occurred over 1-2 weeks in vitro, most of the ~155 
ng SDF-1 released from MPs within 3 days in vitro (Figure 5.1C).  In vivo, 
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fluorescently labelled SDF-1 was observed for at least 3 days following SDF-1 loaded 
MP injection, whereas little to no SDF-1 signal was observed after 3 days following 
soluble SDF-1 injection (Appendix A), which may indicate that MPs can retain SDF-1 
at the site of injury for a longer period of time than soluble SDF-1 alone.  It is important 
to note, however, that since the dose of MPs required for the in vivo tracking study was 
significantly higher due to sensitivity of the instrument, direct comparison with in vitro 
studies is not possible.  Overall, this general release profile is similar to many other SDF-
1 hydrogel and MP delivery systems, whereby more than 60% of all SDF-1 released 
over the time course of the experiment occurred within the first 1-3 days in all but one of 
these systems [11,12,19,31,34,286].  However, to improve the release kinetics of SDF-1 
in future studies, one method may be to adjust the heparin-SDF-1 molar ratio, as 
increasing the heparin-to-protein molar ratio has previously been shown to reduce the 
release rate of basic fibroblast growth factor (bFGF) in a theoretical model of bFGF and 
heparin-containing biomaterials [67]. 
To assess the ability for SDF-1 loaded MPs to modulate the cellular milieu 
within the supraspinatus muscle, we first assessed how injury alone affected the muscle 
and its inflammatory cell and MSC populations.  First, a significant decrease in 
supraspinatus muscle weight was observed after 6 weeks and a significant increase in 
fibrous infiltration was observed after only 3 weeks, both of which mimic symptoms of 
the human condition and indicate that significant muscle degeneration was induced 
within our animal model (Figure C.4) [149,150].  Concurrently, we assessed changes in 
the cellular milieu following injury and while no significant differences in the 
inflammatory cell populations were observed at day 3, significantly more myeloid cells 
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and macrophages were observed in the muscle from injured rotator cuffs compared to 
uninjured controls by day 7 (Figure 5.3E-F).  Similar findings were also observed in our 
previous characterization of rotator cuff injury in mice, where significantly more 
mononuclear phagocytes, monocytes, macrophages, and dendritic cells were observed in 
the muscle from injured rotator cuffs compared to uninjured controls after 7 days [275].  
Similar to injury alone, significantly more myeloid cells and total macrophages were also 
recruited following unloaded MP treatment at day 3 and day 7 (Figure 5.3A-B, E-F), and 
in no case was the unloaded MP group significantly different from the injury only group, 
which indicates that unloaded MPs did not elicit an additional inflammatory response.  
Overall, tendon transection and denervation resulted in significant total myeloid cell and 
macrophage recruitment after 7 days, and this characterization provided a baseline to 
further interrogate effect of SDF-1 release on the supraspinatus cellular milieu. 
In this injury model, after SDF-1 loaded MP treatment, little change to 
inflammatory cell populations was observed after 3 days and, while significantly more 
total myeloid cells and macrophages were detected compared to uninjured controls after 7 
days, this cell recruitment was not significantly different from unloaded MPs or injury 
alone (Figure 5.3).  In analyzing macrophage subpopulations, however, significantly 
more M2-like macrophages were present at day 7 in muscle treated with SDF-1 loaded 
MPs than all other groups, including uninjured, injured, and unloaded MPs (Figure 5.3H). 
To understand the timing of cell recruitment observed, it is important to note that while 
much of the SDF-1 was released over 1-3 days, additional time may be required for a 
significant cellular response to be observed.  For example, monocyte migration to sites of 
muscle injury typically peaks 7 days following injury [287] and monocyte to macrophage 
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differentiation can require up to 10 days depending on the microenvironment [288,289].  
Furthermore, our present findings parallel our previous work using a mouse backpack 
model, whereby significantly more M2-like macrophages were located near a 
subcutaneously implanted SDF-1α loaded hydrogel after 7 days compared to unloaded 
hydrogels [10].  Finally, as our in vivo study of SDF-1 release from MPs indicates that a 
small percentage of SDF-1 may remain near the site of injection for at least 3 days, it is 
possible that this residual SDF-1 observed at later time points may have contributed to 
the significant differences in cell recruitment observed at day 7. 
The selective recruitment of M2 macrophages in this system may be explained by 
the fact that studies have found that as monocytes underwent in vitro macrophage 
differentiation, CXCR4 (the primary SDF-1 receptor) gene expression increased 10-fold 
after 7 days [290], and in our recent work, anti-inflammatory monocytes exhibited higher 
CXCR4 surface expression than inflammatory monocytes [9].  In the same study, SDF-
1 loaded 10 wt% Hep-N hydrogels enabled a shift in monocyte composition, whereby 
significantly more anti-inflammatory monocytes and fewer pro-inflammatory monocytes 
were present compared to unloaded gels.  Thus, it is possible that while SDF-1 release 
was unable to significantly affect the broader, more heterogeneous population of 
leukocytes, SDF-1 loaded MP treatment could lead to significant enrichment of high 
CXCR4-expressing M2-like macrophages.   
In the context of muscle regeneration, it is important to note that M1 and M2 
macrophages, which exist on a spectrum between pro and anti-inflammatory phenotypes, 
possess unique and critical functions to muscle repair.  While M1 macrophages have been 
shown to infiltrate quickly following muscle injury and act to phagocytose cellular debris 
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and secrete pro-inflammatory proteins [277,291], M2 macrophages secrete anti-
inflammatory proteins [277,292] and enhance the proliferation and differentiation of 
satellite cells [293], a muscle-derived stem cell subpopulation and the primary contributor 
to the reparative phase of muscle regeneration [199].  Thus, while significantly more anti-
inflammatory, M2-like macrophages were observed in the muscle following SDF-1 
loaded MPs treatment, additional studies are required to fully elucidate the optimal 
balance between M1 and M2 macrophages for muscle regeneration following rotator cuff 
injury. 
SDF-1 loaded MPs also recruited significantly more MSCs compared to 
unloaded MPs, injury only, and uninjured contralateral controls 7 days following 
treatment (Figure 5.5).  As MSCs have been previously utilized as a potential therapeutic 
in a variety of muscle injury types, several studies have investigated the potential 
mechanisms by which MSCs exhibit their muscle-regenerating capacity.  Among these 
studies, some have shown that MSCs undergo myogenic differentiation in vivo [196], 
while others suggest that the MSC protein secretion profile may be primarily responsible 
for the regenerative effects of MSCs [294].  Specifically, MSCs possess many 
immunomodulatory functions, such as secreting proteins that mediate macrophage 
recruitment, mitigating the inflammatory response to injury, and promoting the 
polarization of pro-inflammatory, M1 macrophages into a more anti-inflammatory, M2 
macrophage phenotype [295].  This immunomodulatory relationship is reciprocal as well, 
as macrophages have been shown to regulate MSC differentiation and promote MSC 
secretion of anti-inflammatory proteins such as TNF- stimulated gene-6 (TSG-6) and 
pro-angiogenic proteins such as angiopoietin-1 [295,296].  Thus, while SDF-1 loaded 
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MPs may have initiated the enrichment of M2-like macrophages and the recruitment 
MSCs, it is possible that the reciprocal and synergistic relationship between these cell 
populations will enable additional modulation of the cellular milieu toward a more pro-
regenerative microenvironment. 
Both MSCs and M2 macrophages have previously shown to facilitate vascular 
remodeling and, in addition, it is well known that SDF-1 can recruit other pro-
angiogenic cells including HSCs and smooth muscle cell progenitors [297] which can 
lead to collateralization, sprouting, looping, and splitting of new microvasculature 
[280,298,299].  In our studies, whole-mount imaging of the supraspinatus muscle 7 days 
following injury suggested that while CD31+ vascular staining was present in injured 
muscle, CD31+ vascular looping appeared present in the SDF-1 loaded MP group 
(Figure 5.5).  As vascular looping is known to be a step of mature vessel formation, 
which can in turn support the regeneration of injured tissue [300,301] including muscle 
[214], the recruitment of pro-regenerative and pro-angiogenic cells to the supraspinatus 
muscle via SDF-1 loaded MPs may ultimately improve muscle healing in the context of 
rotator cuff injury.   
 
5.5 CONCLUSIONS 
In this aim, we developed a heparin-based microparticle platform to recruit pro-
regenerative cells to the supraspinatus muscle following severe rotator cuff injury.  To 
locally present SDF-1, degradable 10 wt% Hep-N microparticles were fabricated and 
subsequently injected within the supraspinatus muscle.  After 7 days, significantly more 
anti-inflammatory, M2-like macrophages (4.3X increase compared to no injury) and 
 106 
MSCs (3.0X increase compared to no injury) were detected in muscle treated with SDF-
1 loaded MPs compared to unloaded MPs or injury alone.  While no prior studies have 
investigated the use of chemotactic therapeutics such as SDF-1 to treat muscle 
following rotator cuff injury, our results indicate that SDF-1 loaded MPs can shift the 
cellular composition of the supraspinatus muscle, which may provide a platform to 




















INTRA-MUSCULAR CHEMOKINE RELEASE AND SYSTEMIC BONE MARROW 
MOBILIZING AGENT DELIVERY ENHANCES EARLY SUPRASPINATUS MUSCLE 




In Chapter 5, SDF-1 loaded microparticles (MPs) were found to recruit significantly 
more anti-inflammatory M2-like macrophages and mesenchymal stem cells (MSCs) to 
the supraspinatus muscle 7 days following rotator cuff injury.  Still, it has yet to be 
determined what amount or what timescale of endogenous cell recruitment may be 
required for muscle regeneration in this unique context of supraspinatus muscle 
degeneration [141,144,145,159]. Therefore, delivering therapeutics that synergize with 
SDF-1 may be, first, a method to further modulate the inflammatory cellular milieu and 
recruit pro-regenerative cells to muscle and, second, a platform to examine how cell 
recruitment may result in muscle regeneration following rotator cuff tear. 
Bone marrow mobilizing agents, including clinically approved granulocyte 
colony stimulating factor (G-CSF) and AMD3100, are most commonly used to treat 
neutropenia or lymphopenia following chemotherapy treatment [220–223].  Through 
indirect signaling, G-CSF has been shown to promote chemotaxis of hematopoietic stem 
and progenitor cells (HSPCs) from the bone marrow into circulation, and mice lacking G-
CSF demonstrate chronic neutropenia which highlights its biological significance in cell 
mobilization [221].  Furthermore, through initial studies utilizing AMD3100 as a human 
immunodeficiency virus (HIV) inhibitor, significantly more circulating leukocytes were 
also observed in treated patients, leading to the approval of AM3100 as a hematopoietic 
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cell mobilization agent in 2008 [222].  Among other mechanisms of actions, both G-CSF 
and AMD3100 have shown to antagonize CXC chemokine receptor type 4 (CXCR4), an 
essential mediator of cell trafficking [33], which may also disrupt CXCR4 signaling with 
stromal cell-derived factor 1- (SDF-1/CXCL12) [221].  Despite these promising 
effects, G-CSF and AMD3100 can lead to significant complications and specifically 
through CXCR4 inhibition, AMD3100 has shown to impair the ability for cells to return 
to the bone marrow niche.  Thus, bone marrow mobilizing agents with non-CXCR4 
targets may be advantageous [36,225,226].   
Sphingosine-1-phosphate (S1P) is a structurally simple lipid with a class of 
corresponding G-protein coupled receptors (GPCRs) S1PR1-5, found in abundance in the 
plasma and serum [226].  During homeostasis, a gradient of S1P is maintained between 
the blood and bone marrow (Schematic 6.1) [227], and the disruption of this gradient 
leads to the sequestration of HSPCs, indicating the importance of S1P in the mobilization 
of bone marrow-derived cell populations.  Though structurally similar, S1PR1-5 possess 
unique functions, and even play opposing roles in cell mobilization.  For example, S1PR1 
agonism is required for the egress of lymphocytes from bone marrow and lymphoid 
organs (Schematic 6.1) [35,228–230], while antagonism of S1PR3 has been shown to 
promote egress of HSPCs from bone marrow to blood, ultimately suggesting that S1PR1 
agonists and S1PR3 antagonists may be methods to promote cell mobilization. 
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Schematic 6.1 S1P gradient at steady state and after S1PR1 agonism.  At steady state, a 
higher concentration of S1P is present in blood compared to bone marrow and tissue. 
S1PR1 agonism in blood promotes egress of cells into circulation.  Figure adapted from 
Golan et al [302]. 
 
 
Among a host of drugs targeting S1P receptors, VPC01091 (VPC) is both an 
S1PR1 agonist and S1PR3 antagonist [35,231].  In vitro, VPC induced a reduction in LSK 
(LinnegSca-1+c-Kit+, early hematopoietic stem cells) cell adhesion and an increase in LSK 
cell migration.  Furthermore, when delivered via intraperitoneal (I.P.) injection in rats, 
significantly more mesenchymal stem cells (MSCs, CD29+CD44+CD90+Sca1+) were 
observed in blood 1.5 and 24 hours after delivery [232] while in mice, significantly more 
circulating LSK cells were observed in blood 1.5 hours after delivery [36].  Interestingly, 
of the mobilized LSK cells, significantly more cells were CXCR4+ (the primary receptor 
for SDF-1), compared to untreated controls [36]. 
 SDF-1, primarily through its GPCR, CXCR4, has previously shown in our work 
and others to attract a myriad of cell populations including immune cells such as 
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monocytes [9,10,28,29] and lymphocytes [29,219,266], stem cells such as hematopoietic 
[30] and mesenchymal stem cells (MSCs) [31], and progenitor cell populations [12,32], 
among others [33,34].  Most recently, we have shown that SDF-1 loaded microparticles 
(MPs) delivered to the supraspinatus muscle following severe rotator cuff injury could 
recruit significantly more M2-like macrophages and MSCs 7 days following injury and 
treatment [266].  Building from these findings and previous work indicating that VPC can 
mobilize CXCR4+ cells responsive to SDF-1 we hypothesized that the co-delivery of 
VPC via systemic I.P. injection and SDF-1 loaded MPs via intra-muscular injection, 
would synergistically increase the number of pro-regenerative cell populations in the 




6.2.1 ANIMAL MODEL 
Rotator cuff injury was induced using a similar method to previously established 
protocols [177,266].  Male Sprague-Dawley rats (250-300 g initial weight and 8-10 
weeks old) were used in accordance with protocols approved by the Georgia Institute of 
Technology Institutional Animal Care and Use Committee.  Prior to surgery animals 
were anesthetized by 5% isoflurane (Isothesia), followed by 2-3% isoflurane during 
surgery and were administered sustained release buprenorphine as an analgesic.  The left 
chest and arm were shaved, wiped with alcohol/chlorhexidine, and a ~2 cm incision was 
made through the skin and deltoid, parallel to and just below the clavicle.  To induce 
denervation, a ~0.5 mm portion of the suprascapular nerve was resected. Next, after 
orienting the humerus to expose the supraspinatus and infraspinatus tendon insertions, 
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both tendons were sharply transected, then encased in a 0.3 mm portion of PharMed BPT 
tubing (Tygon, 1.6 mm inner diameter) to prevent spontaneous reattachment of either 
tendon.  The deltoid and skin were closed using Vicryl 4-0 absorbable sutures (Ethicon) 
and wound clips, respectively.  The right rotator cuff of each animal served as an internal 
uninjured contralateral control. 
6.2.2 MICROPARTICLE FABRICATION 
10 wt% Hep-N microparticles (MPs) were fabricated via water-and-oil emulsion as 
previously described [266].  Briefly, 50.0 mg PEGDA and 35 mM dithiothreitol (DTT) 
were added to 273 μL 10 wt% BSA PBS solution and incubated at ~ pH 7 and 37°C for 
30 mins.  Next, 5.6 mg Hep-NMAm was added and the aqueous phase was incubated for 
an additional 30 mins.  After 27 μL of 0.05 wt% Irgacure 2959 photo initiator (Ciba) was 
added, the aqueous phase described above was added drop-wise to an oil phase of 5 mL 
mineral oil (Amresco) with 3.0-3.2 μL Span80 (TCI) and allowed to homogenize at 4000 
RPM (Polytron PT 3100, Kinematica) for 5 mins. The water-and-oil emulsion was 
nitrogen purged for 1 min then placed into a petri dish under UV (~15 mW/cm2) for 10 
mins to allow for free radical polymerization between PEGDA and Hep-NMAm.  Finally, 
the MP solution was added to 35 mL dH2O, centrifuged at 4000 RPM for 5 mins, and the 
oil phase was removed.  MPs were washed once more with dH2O, then pipetted through 
40 μm cell strainers to remove most MPs under 40 μm in diameter.  MPs were sterilized 
in 70% ethanol on rotary at 4°C for 30 mins, followed by 3 30-min washes in sterile PBS.  
MPs were imaged via phase microscopy and size distribution was measured using ImageJ 
software.  MPs were stored in sterile PBS at 4°C and used within 2 weeks of fabrication. 
6.2.3 SDF-1 LOADED MICROPARTICLE ADMINISTRATION 
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To load SDF-1 onto MPs, 1.0-1.2 μg sterile human SDF-1 (R&D Systems) was added 
to 0.6 mg MPs in 50 μL 0.1 wt% sterile BSA solution.  SDF-1 and MPs were incubated 
for 2 hours at 4°C, after which time MPs were rinsed by adding an additional 450 μL 0.1 
wt% sterile BSA solution.  The MPs were centrifuged for 3 mins at 10,000 RCF and 495 
μL supernatant was removed.  MPs were then resuspended in a total volume of 120 μL 
sterile 0.1 wt% BSA solution, loaded into sterile syringes with 20-gauge 1.5 in. 
hypodermic needles, and injected into the supraspinatus muscle immediately following 
rotator cuff injury.  
6.2.4 VPC01091 ADMINISTRATION 
VPC (Avanti Polar Lipids) was dissolved at 1 mg/mL in 2% 2-hydroxypropyl-B-
cyclyodextrin H2O solution and placed in a sonicating bath for 1 hr to fully dissolve.  
VPC was then filtered sterilized and stored at -20°C until use.  Immediately following 
rotator cuff injury, VPC was administered via intraperitoneal (I.P.) injection at either 1 
mg or 5 mg/kg animal weight using a 1 mL leur lock syringe and 25-guage 1.5 in. 
hypodermic needle. 
6.2.5 COLLECTION AND FLOW CYTOMETRY ANALYSIS OF BLOOD 
To avoid disruption of the cell populations within blood, animals remained awake but 
restrained for blood collection.  After 1.5 hrs, 3 hrs, 1, 3, and 7 days following rotator 
cuff injury and treatment, a scalpel was used to create a small incision perpendicular to 
the tail, ~3 cm from the tail tip.  No more than 150 μL blood was collected in a 1.7 mL 
low binding tube containing 10 μL 500 AU/mL heparin to prevent blood coagulation.  
Next, erythrocytes were lysed by adding 10x ammonium chloride by volume compared to 
the volume of blood for 10 mins at RT.  Samples were centrifuged for 5 mins at 500 
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RCF, and supernatant was removed.  One-half of each sample was stained with the 
inflammatory cell panel that included FITC-conjugated anti-CD11b (AbD Serotec), PE-
conjugated anti-CD163 (BioRad), and APC-conjugated anti-CD68 (BioRad) and the 
other one-half was stained with the MSC panel that included PE-conjugated anti-CD29 
(BioLegend), APC-conjugated anti-CD44 (BioLegend), BV421-conjugated anti-CD90 
(BioLegend), and APC/Fire750 anti-CD45 (BioLegend).  Samples were stained for 30 
mins with the appropriate antibodies and fixed in 2% PFA for 10 mins, then analyzed 
using a FACS-AriaIIIu flow cytometer (BD Biosciences).  Inflammatory cells were 
identified as CD11b+ myeloid cells, CD11b+CD68+ macrophages, and CD163 was used 
to differentiate M2-like (CD11b+CD68+CD163+) from M1-like macrophages 
(CD11b+CD68+CD163-) [277,278]. MSCs were identified as negative for CD45 and 
triple positive for CD29, CD44, and CD90 [279]; n = 6. For data analysis, each cell 
population was calculated first as a percentage of single cells:  
 
% of single cells = # of cells in subpopulation 
                           # of single cells 
 
Then, each % of single cell value was divided by the % of single cells at the 1.5 hour 
time point from the same animal: 
 
Fold-change over 1.5 hour time point:   % of single cells at each time point 
  % of single cells at 1.5 hours 
 
6.2.6 FLOW CYTOMETRY ANALYSIS OF MUSCLE 
Supraspinatus muscles were harvested 3 and 7 days following injury and treatment, 
digested with collagenase 1A (Sigma) for 45 mins at 37º C, and passed through a 40 μm 
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cell strainer (Corning).  One-half of each sample was stained with the inflammatory cell 
panel described in Methods Section 6.2.3; n = 5-7.  For data analysis, each cell 
population was first calculated as a percentage of single cells:  
% of single cells = # of cells in subpopulation 
                           # of single cells 
 
Then, each % of single cell value was divided by the % of single cells in the uninjured 
contralateral control of the same animal: 
 
Fold-change over contralateral control = % of single cells in experimental group 
                  % of single cells in contralateral control 
 
 
6.2.7 PROTEIN PRODUCTION IN MUSCLE 
Portions of muscle harvested at day 7 were digested with Tissue Extraction Reagent 1 
(Invitrogen) and stored at -80ºC prior to use for Luminex analysis with the MILLIPLEX 
MAP rat cytokine/chemokine immunology magnetic bead panel (EMD Millipore).  First, 
12.5 µL of sample and standard (EMD Millipore) was combined with 12.5 µL assay 
buffer (EMD Millipore) and 12.5 µL pre-mixed magnetic beads (EMD Millipore) in a 
96-well plate.  The plate was incubated overnight at 4ºC on a 750rpm shaker plate.  Next, 
the plate was washed 3 times by placing the plate on a magnet for 2 mins, decanting the 
plate, adding 200 µL wash buffer (EMD Millipore), and allowing the plate to shake at RT 
for 2 mins.  After washing was repeated 3 times, 12.5 µL of detection antibody (EMD 
Millipore) was added and the plate was incubated for 1 hr shaking at 750 RPM in RT.  
Next, 12.5 µL strep-phyco (EMD Millipore) was added and the plate was incubated for 
30 mins shaking at 750 RPM in RT.  After washing 3 times, 110 µL drive fluid was 
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added, the plate was shaken for 5 mins at RT, and then analyzed on the Luminex System 
(MAGPIX Instruments).  Individual samples were normalized to total protein content (in 
mg/mL) which was determined using a BCA assay (Thermo Scientific); n = 4-6. 
6.2.8 VASCULAR STAINING OF MUSCLE 
After 7 days following injury and treatment, supraspinatus muscles were fixed in 4% 
PFA for 30 mins at RT, rinsed in PBS, permeabilized in 0.2% saponin (Sigma) PBS 
solution for 24 hours at 4ºC, and blocked in 10% BSA solution for 24 hours at 4ºC.  For 
vascular staining, muscles were incubated in 5 µg/mL anti-mouse/rat CD31/PECAM-1 
primary antibody (R&D Systems) in a 1.0% BSA, 0.3% Triton X-100 (Amresco), 0.01% 
sodium azide solution (incubation buffer) overnight at 4ºC, followed by 4 30-min washes 
in 0.2% saponin solution.  Muscles were then stained in a 1:200 dilution of NL557-
conjugated anti-goat IgG secondary antibody (R&D Systems) in incubation buffer for 4 
hours at RT, then washed in 0.2% saponin solution and PBS twice each for 30 mins.  As 
a negative control, samples were stained using the same protocol but with polyclonal goat 
IgG isotype control (R&D Systems) in place of the primary antibody.  Finally, muscles 
were incubated in a 1:1000 dilution of Hoechst cellular stain in PBS for 5 mins.  Muscles 
were whole-mounted and single fluorescent images were obtained using a Zeiss LSM 700 
confocal microscopy with a 10x objective to visualize vasculature (green) within muscle 
tissue (blue).  First, CD31+ vascular loops were quantified manually in 3 10x images per 
animal.  CD31+ vasculature was then quantified using ImageJ and color thresholding; n = 
5-7: 
 
% CD31+ vasculature = total green fluorescent signal 
   total area of muscle 
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6.2.9 HISTOLOGY OF MUSCLE 
After 7 days following injury and treatment, supraspinatus muscles were harvested and 
incubated in 10% v/v optimum cutting temperature (OCT, Sakura Finetek) PBS solutions 
with 0, 10, and 20% sucrose for 10 mins each.  Muscles were placed in histology blocks 
with 100% OCT under vacuum overnight and then frozen in 190 proof ethanol cooled by 
liquid nitrogen.  Muscles were sectioned with a cryostat (Thermo Scientific CryoStar 
NX70) into 10 μm sections perpendicular to the muscle to create tissue cross-sections. 
Prior to hematoxylin and eosin (H&E) staining, muscle cross-sections were rinsed in 
distilled water (dH2O) for 2 minutes then stained in hematoxylin (Fisher) for 2 
mins.  Subsequently, slides were rinsed in dH2O until excess stain was removed, dipped 
in 0.5% acid alcohol once, rinsed in dH2O for 1 min, Scott’s tap water (Electron 
Microscope Science) for 30 seconds, dH2O for 2 mins, and 95% ethanol for 1 
min.  Sections were then stained in eosin (VWR) for 30 seconds.  Following eosin 
staining, slides were rinsed in 95% ethanol for 30 seconds, dehydrated in 100% ethanol 3 
times for 1 min, and cleared in xylene 3 times for 1 min.  Sections were then covered 
with cytoseal (Richard Allen Scientific) and coverslipped for imaging via phase contrast 
imaging (Nikon i80 microscope); n = 5-7. 
6.2.10 IMMUNOHISTOCHEMISTRY OF EMHC, DYSTROPHIN, AND CD163+ MACROPHAGES IN MUSCLE 
 Muscle cross-sections were first prepared as described in Methods Section 6.2.7. 
For immunohistochemical staining, sections were outlined using a hydrophobic pen, then 
blocked with blocking buffer (2% bovine serum albumin, 0.5% goat serum, 0.5% Triton 
X in PBS solution) for 30 mins at RT.  Between each step, slides were washed 3 times for 
2 mins each with 0.1 wt% Tween20 PBS solution.  Primary antibodies included 
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embryonic myosin heavy chain (eMHC) primary antibody (Developmental Studies 
Hybridoma Bank, 1:10 dilution), dystrophin (Abcam, 1:200), PE-conjugated anti-CD163 
(BioRad, 1:10), and APC-conjugated anti-CD68 (BioRad, 1:10) in blocking buffer.  
Primary antibodies were pipetted onto slides, allowed to incubate for 1 hr at RT, then 
washed.  Secondary antibody for eMHC (Goat anti-mouse AlexaFluor555, Thermo 
Fisher) and for dystrophin (Goat anti-rabbit AlexaFluor 488) were diluted 1:250 in 
blocking buffer, pipetted onto slides, allowed to incubate in the dark for 30 mins at RT, 
then washed.  Finally, Hoechst cellular stain was diluted 1:1000 in PBS, pipetted onto 
slides, allowed to incubate for 5 mins, and washed.  Sections were fixed with 4% 
paraformaldehyde (PFA) for 10 mins at RT, washed, then mounted with cytoseal 
(Richard Allen Scientific) and coverslipped for imaging using a Zeiss LSM 700 confocal 
microscopy with a 10x objective to visualize eMHC (red) and CD163+ macrophages 
(yellow) within outlined muscle fibers (dystrophin, green) with cell nuclei (blue); n = 5-7. 
6.2.11 MUSCLE WEIGHT 2 AND 3 WEEKS POST-INJURY AND TREATMENT 
To assess muscle degeneration at later time points following rotator cuff tear, injury was 
induced following Methods Section 6.2.1.  SDF-1 loaded MPs and VPC were 
administered as described in Methods Section 6.2.3 and 6.2.4 at day 0, but were also 
administered weekly such that SDF-1 loaded MPs, injected via percutaneous injection, 
and VPC were delivered at day 0 and 7 for 2 week animals and day 0, 7, and 14 for 3 
week animals.  At each designated time point, supraspinatus muscles were harvested, 
weighed, and its mass was divided by the mass of the uninjured contralateral control; n = 





6.3.1 INFLAMMATORY CELL ANALYSIS IN BLOOD AND MUSCLE 
After 3 hrs, 24 hrs, 3 and 7 days following injury and treatment, VPC+SDF-1 treatment 
resulted in significantly more myeloid cell mobilization in blood than injury alone 
(Figure 6.1A).  VPC alone significantly increased the number of circulating myeloid cells 
at 3 and 24 hrs, whereas SDF-1 alone was significantly higher than injury at day 7.  
After 3 days, both VPC+SDF-1 and VPC significantly increased the number of myeloid 
cells in muscle compared to SDF-1 and injury, whereas by day 7 all treated muscles had 
significantly more myeloid cells than injury alone (Figure 6.1B-C). 
 Though no significant differences were observed at 3 and 24 hours in blood, after 
3 days VPC+SDF-1 treatment resulted in significantly more monocyte mobilization 
than all other groups, and after 7 days both VPC+SDF-1 and SDF-1 treatment resulted 
in significantly more monocyte mobilization than VPC and injury (Figure 6.1D).  In 
muscle, significantly more macrophages were observed in VPC+SDF-1 and VPC 
treated groups after 3 days, whereas significantly more macrophages were presented in 





Figure 6.1. Mobilization of myeloid cells and monocytes in blood corresponds to an 
increase in myeloid cells and macrophages in muscle.  (A) VPC+SDF and VPC treatment 
exhibited significantly more myeloid cell recruitment after 3 hrs, 24 hrs, and 3 days 
compared to injury, (B-C) leading to a significant increase in myeloid cells in muscle 
after 3 and 7 days with VPC+SDF and VPC compared to injury.  (D) VPC+SDF 
treatment exhibited significantly more monocyte mobilization after 3 days compared to 
all groups, whereas both VPC+SDF and SDF exhibited more monocyte mobilization at 
day 7.  (E-F) At day 3, significantly more macrophages were observed in VPC+SDF and 
VPC treated muscle compared to injury, whereas at day 7 VPC+SDF and SDF treated 
groups were significantly higher than injury.  $VPC+SDF significantly different than 
injury at designated time point; Significantly different than: #uninjured; * injury; **SDF 
and injury; **VPC and injury; ***VPC, SDF, and injury; p ≤ 0.05; n = 6 in blood; n = 4-
6 in muscle. 
 
 
When assessing macrophage subpopulations in muscle, VPC+SDF-1 and VPC 
treatment resulted in significantly more M2-like and M1-like macrophages compared to 
injury (Figure 6.2A-B), and a significantly higher M2:M1 macrophage ratios than both 
SDF-1 and injury (Figure 6.2C).  By day 7, all treatments significantly increased the 
number of M2 macrophages in muscle, though no significant differences were observed 
in M1 macrophages, except between SDF-1 and VPC treatment (Figure 6.2D-E).  
However, only VPC+SDF-1 and VPC treatments significantly increased the M2:M1 
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ratio at day 7, a ~5x increase from uninjured controls (Figure 6.2F).  Parallel to our flow 
cytometry findings, after 7 days more CD163+ staining was observed in treated muscles 




Figure 6.2. More M2-like macrophages were observed in all treated muscles at day 7 
compared to injury, but only VPC+SDF and VPC treatment increased the M2:M1 ratio at 
day 3 and 7 compared to SDF and injury.  (A-C) After 3 days, more M2-like and M1-like 
macrophages were observed with VPC+SDF and VPC treatment compared to injury, 
resulting in a significantly higher M2:M1 macrophage ratio compared to SDF and injury.  
(D-F) By 7 days, more M2-like macrophages were observed in all treatment groups 
compared to injury, though the M2:M1 ratio was only increased in the VPC+SDF and 
VPC groups compared to SDF injury.  ^SDF is significantly different than VPC; 
Significantly different than: #uninjured; * injury; **SDF and injury; p ≤ 0.05. (G-J) 











































































































































































































muscle via immunohistochemistry; white arrows indicate example CD163+ cells; scale 
bar is 100 µm; n = 4-6. 
 
6.3.2 MESENCHYMAL STEM CELL ANALYSIS IN BLOOD AND MUSCLE 
After 3 hrs, significantly more MSCs were observed in blood with VPC treatment 
compared to SDF-1 treatment and injury, and with VPC+SDF-1 treatment compared 
to injury (Figure 6.3A).  By 24 hrs, significantly more MSCs were mobilized in 
VPC+SDF-1 and SDF-1 treated animals compared to VPC treatment and injury, while 
VPC treatment was only significantly greater than injury alone.  At day 3, similar trends 
were observed as at 24 hrs, whereby VPC+SDF-1 and SDF-1 treated animals 
exhibited the greatest MSC mobilization.   MSC mobilization was significantly higher in 
SDF-1 treatment compared to VPC treatment and injury, whereas VPC+SDF-1 was 
only significantly higher than injury.  Finally, by day 7 in blood, MSC mobilization via 
VPC+SDF-1 and SDF-1 treatment was no longer significantly different from injury, 
and was only significantly higher than VPC treatment alone. 
 In muscle, after 3 days significantly more MSCs were observed with VPC+SDF-
1 and VPC treatment (Figure 6.3B), whereas all treatments, VPC+SDF-1, VPC, and 





Figure 6.3. Increased MSC mobilization in blood by all treatment groups after 3 hours to 
3 days compared to injury led to significantly more MSCs in VPC+SDF and VPC treated 
muscle after 3 days and all treated muscles at day 7. (A) MSC mobilization was greater 
than injury with VPC+SDF and VPC after 3 hrs, all treatments after 24 hrs, and 
VPC+SDF and SDF 3 days.  (B) In muscle, MSC recruitment was greater than injury 
with VPC+SDF and VPC after 3 days, and all treatments after 7 days. $VPC+SDF 
significantly different than injury at designated time point; Significantly different than: 
#uninjured; * injury; **SDF and injury; **VPC and injury; ***VPC, SDF, and injury; p 
≤ 0.05; n = 6 in blood; n = 4-6 in day 3 muscle; n = 3-6 in day 7 muscle. 
 
6.3.3 INFLAMMATORY PROTEIN PRODUCTION IN MUSCLE 
Principal component analysis (PCA) was first utilized to assess the muscle secretome 
after 7 days.  Treated, injured, and uninjured groups were not well-discriminated from 
each other using PCA, suggesting that the global secretome was not significantly altered 
by injury or treatment at day 7 (Figure D.1).  We also analyzed significant differences 
between groups with each analyte.  Due to injury, the pro-inflammatory protein IL-5 was 
significantly increased compared to all groups, IL-18 and RANTES were significantly 
increased compared to uninjured controls, and LIX was significantly increased compared 
to VPC (Figure 6.4A-D).  In contrast, analyzing muscles with VPC+SDF-1, VPC, or 
SDF-1 treatment, average production of IL-5, IL-18, and RANTES were not 
significantly different from uninjured muscle.  Leptin, an adipogenic mediator, was also 
significantly increased in injured muscle compared to uninjured, while Leptin production 
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Finally, VEGF, a pro-angiogenic factor, was significantly decreased in injured compared 
to uninjured muscles, while VEGF production in treated muscles were not significantly 
different than uninjured muscles (Figure 6.4F). 
 
Figure 6.4. Pro-inflammatory mediators were increased in injured muscles compared to 
uninjured controls after 7 days. (A) Pro-inflammatory protein IL-5 was significantly 
increased compared to all groups, (B-C) IL-18 and RANTES were significantly increased 
compared to uninjured controls, and (D) LIX was significantly increased compared to 
VPC.  (E) Leptin production, an adipogenic mediator, was significantly higher in injured 
muscle than all others and (F) VEGF production, an angiogenic mediator, was 
significantly lower in injured than uninjured muscle.  ****Significantly different than all 
other groups; *Significantly different than designated group; p ≤ 0.05; n = 3-6. 
 
 On a single analyte basis, certain treatments also significantly altered protein 
production.  SDF-1 treated significantly increased IP-10 production compared to 
VPC+SDF-1 and uninjured muscle, whereas VPC and SDF-1 treatment significantly 
reduced IL-13 production compared to uninjured muscles (Figure 6.5). 
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Figure 6.5. VPC and SDF significantly modulated the production of chemoattractive and 
macrophage polarizing proteins compared to uninjured controls. (A) IP-10 production 
was significantly higher in SDF treated muscle than SDF+VPC and uninjured, (B) while 
IL-13 production was significantly decreased in VPC and SDF groups compared to 
uninjured muscle. *Significantly different than designated group; p ≤ 0.05; n = 4-6. 
 
6.3.4 VASCULAR STAINING OF MUSCLE 
After 7 days, significantly more CD31+ vasculature was observed in VPC+SDF-1 
treated muscles compared to uninjured controls, while no other groups were significantly 
different from each other (Figure 6.6).  Vascular looping, indicative of rapid angiogenesis 
was also quantified but high variance was observed and no significant differences were 
found between groups (Figure 6.7). 
 
Figure 6.6. Significantly more CD31+ vasculature was present in VPC+SDF treated 
muscle compared to uninjured controls after 7 days.  (A) Whole-mounted muscles were 
stained for CD31+ vasculature (green) and nuclei (blue); scale bar is 100 µm. (B) Image 

































































treated muscles compared to uninjured controls; &Significantly different than uninjured; p 




Figure 6.7. CD31+ vascular looping was present in all muscle after 7 days.  (A) Whole-
mounted muscles were stained for CD31+ vasculature (green) and nuclei (blue) and two 
images were included per group to accurately portray variability of CD31+ vascular 
looping; white arrows indicate example CD31+ vascular loops; scale bar is 100 µm. (B) 
Image analysis indicated that no significant differences were observed between groups; n 
= 6-7. 
 
6.3.5 EMBRYONIC MYOSIN HEAVY CHAIN (EMHC) AND DYSTROPHIN STAINING OF MUSCLE 
After 7 days, supraspinatus muscle cross-sections were stained for eMHC+ regenerating 
muscle fibers (Figure 6.8).  With all treatments, significantly more eMHC+ muscle fibers 
were observed than in untreated injury muscles (Figure 6.8B).  However, significantly 
more eMHC+ fibers were observed in muscles treated with VPC+SDF-1 than either 




Figure 6.8. Significantly more eMHC+ regenerating muscle fibers were observed in 
VPC+SDF treated muscles than all other groups after 7 days. (A) Representative images 
of muscle cross-sections stained with eMHC (red), dystrophin (green), and DAPI (blue) 
on top, and hematoxylin & eosin on bottom.  White arrows indicate example eMHC+ 
muscle fibers; Scale bar is 100 µm. (B) Quantification of eMHC images indicated that 
more eMHC+ fibers were observed in VPC+SDF muscle compared to all groups, and 
more eMHC+ fibers were observed in VPC and SDF muscle than injury.  Significantly 
different than: * injury; ***VPC, SDF, and injury; p ≤ 0.05; n = 5-7. 
 
 
6.3.6 MUSCLE WEIGHT 2 AND 3 WEEKS POST-INJURY AND TREATMENT 
After 1 week, no significant decrease in muscle weight was observed with VPC+SDF-1 
muscles or injured muscles (Figure 6.9).  However, by 2 and 3 weeks a significant 
reduction in muscle weight was observed in injured muscles untreated or treated with 
VPC+SDF-1 compared to uninjured controls.  No significant difference was observed at 
any time point between VPC+SDF-1 treated muscles and injured muscles. 
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Figure 6.9. Muscle weight was not significantly different between VPC+SDF treated 
muscle and injured muscles 1, 2, and 3 weeks post-injury.  # Significantly different than 




Combining the results of previous work that identified the ability for VPC to mobilize 
CXCR4+ cells [232] and the ability for SDF-1 loaded MPs to recruit CXCR4+ cells to 
the supraspinatus muscle, we hypothesized that the co-delivery of VPC via systemic 
injection and SDF-1 loaded MPs via intra-muscular injection would synergistically 
increase the number of pro-regenerative cell populations in muscle following rotator cuff 
injury more than either treatment alone.  Therefore, we investigated the ability for VPC 
and SDF-1 to mobilize inflammatory cells and MSCs within blood and, subsequently, 
to increase these cell populations in muscle to promote regeneration following rat tendon 
transection and denervation. 
 We first investigated inflammatory cell mobilization and recruitment in blood and 
muscle, respectively, following rotator cuff injury.  In blood, the fold-change in myeloid 





















































for injury alone, indicating that cell mobilization generally decreased after the initial 
response to injury (Figure 6.1A,D).  In muscle at day 3, a 1.2 to 1.3-fold increase in 
myeloid cells, macrophages, and macrophage subpopulations was observed in injury 
compared to uninjured controls, which increased to a 1.4 to 1.5-fold increase for all 
inflammatory cell populations by day 7 (Figure 6.1).  Furthermore, at both day 3 and 7 
the M2:M1 macrophage ratio was ~1.1, though overall no significant differences were 
observed between injury and uninjured controls.  These results parallel our previous 
findings in mice, where monocytes and macrophages were only slightly skewed toward a 
more anti-inflammatory phenotype 7 days after rotator cuff injury [275].  In other skeletal 
muscle injuries, a typical inflammatory response includes an initial influx of neutrophils, 
then pro-inflammatory M1 macrophages and finally, within 7 to 14 days, recruitment and 
polarization toward a more anti-inflammatory M2 macrophage phenotype [303,304].  At 
day 3 and 7 in our work, however, no substantial shift in the M2:M1 ratio was observed, 
which may indicate that the inflammatory response is dysregulated and may ultimately 
contribute to the muscle degeneration observed following rotator cuff tear.   
Following treatment with VPC and SDF-1, we investigated the timeline of cell 
mobilization in blood and recruitment in muscle.  VPC+SDF-1 and VPC treatment 
generally elicited more myeloid cell and monocyte mobilization in blood between 3 and 
24 hours after treatment and, subsequently, significant increases in these cell populations 
were observed in muscle after 3 days compared to SDF-1 or injury alone (Figure 
6.1B,E).  Similarly, VPC+SDF-1 treatment elicited more myeloid cell and monocyte 
mobilization at day 3 in blood, though SDF-1 alone induced similar levels of cell 
mobilization by day 7, resulting in greater myeloid cell populations in VPC+SDF-1 and 
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SDF-1 treated muscle by day 7 (Figure 6.1C,F).  As expected, these results collectively 
indicate that inflammatory cell mobilization in blood precedes the increase in these same 
cell populations in muscle.  Additionally, the ability for VPC+SDF-1 and VPC to elicit 
cell mobilization in blood in as little as 3 hours and increase cell populations in muscle 
after only 3 days may indicate that VPC can evoke a cellular response more rapidly than 
SDF-1 treatment, which required ~7 days to elicit significant cell recruitment in muscle.  
One possible explanation for these differences is the method of delivery, whereby VPC 
was injected systemically while SDF-1 loaded MPs were delivered locally to the 
supraspinatus muscle.  Additionally, as SDF-1 was previously shown to release from 
MPs over ~1-3 days in vivo, this may have delayed the cellular response to SDF-1 
treatment as well [266].  Ultimately, these findings suggest that cell mobilization in blood 
precedes the increase of these cell populations in muscle, and that modulating bone 
marrow cell mobilization may be a method to increase pro-regenerative cell populations 
in injured rotator cuff muscle. 
We further analyzed how VPC and SDF-1 treatment could modulate 
macrophage subpopulations and found that after 3 days, VPC+SDF-1 and VPC 
treatment significantly increased the number of M2-like and M1-like macrophages in 
muscle compared to injury, which resulted in a significant increase in the M2:M1 ratio 
compared to SDF-1 and injury (Figure 6.2A-C).  By day 7, significantly more M2-like 
macrophages were observed in all treatment groups compared to injury, which was 
determined quantitatively via flow cytometry (Figure 6.2D) and observed via 
immunohistochemistry (Figure 6.2G-J).  However, only VPC+SDF-1 and VPC 
treatments significantly increased the M2:M1 ratio compared to SDF-1 and injury 
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(Figure 6.2F).  In understanding how VPC may increase the M2:M1 macrophage ratio, 
S1P has shown to induce mouse macrophage IL-4 and IL-13 gene expression [305] and 
downregulate TNF-, IL-12, and MCP-1 [306], resulting in M2 macrophage polarization 
in vitro.  FTY720 treatment, an S1PR1 and S1PR3 agonist, has also shown to reduce M1 
macrophage-associated cytokines and increase IL-1–receptor antagonists, a marker of M2 
macrophage activation in mice [307] and in the Botchwey lab, too, FTY720 treatment led 
to significantly more anti-inflammatory monocytes (AMs) after 3 days in blood and 
tissue, while inflammatory monocyte (IM) migration was unaffected [308].   
Lastly, while most inflammatory cells express S1PR1 [309], certain 
subpopulations have shown to express these S1PRs to different magnitudes; AMs have 
shown to exhibit higher S1PR3 expression than IMs, while M2 macrophages exhibit 
higher S1PR1 and S1PR3 expression than M1 macrophages [308].  In fact, FTY720 
further increased the expression of S1PR3 in monocytes and macrophages [308].  Thus, 
the inherent differences in S1PR expression by inflammatory cells and the potential for 
VPC to modulate anti-inflammatory monocyte/macrophage polarization may account, in 
part, for the increased M2:M1 macrophage ratio with VPC treatment in our studies.   
Additionally, the selective recruitment of M2-like macrophages with SDF-1 
loaded MPs may be explained by previous findings showing that as monocytes 
underwent in vitro macrophage differentiation, CXCR4 (the primary SDF-1α receptor) 
gene expression increased 10-fold after 7 days [290], and in our recent work, AMs 
exhibited higher CXCR4 surface expression than IMs [9].  Thus, SDF-1 may be able to 
recruit high CXCR4 expressing cell populations, including anti-inflammatory M2 
macrophages, which would in turn increase the M2:M1 macrophage ratio, though not to 
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the same magnitude as VPC+SDF-1 treatment.  Overall, it is possible that VPC, through 
S1PR1 agonism and S1PR3 antagonism, promoted M2-like macrophage polarization to 
increase the M2:M1 macrophage ratio, whereas SDF-1 recruited significantly more high 
CXCR4-expressing M2-like macrophages to the muscle. 
MSCs were also quantified, and significantly more MSCs were observed in 
muscle treated with VPC+SDF-1 and VPC than SDF-1 and injury after only 3 days 
whereas by day 7, all treatment groups recruited significantly more MSCs than injury 
alone, between ~3 to 4-fold change over uninjured controls (Figure 6.3).  These results 
parallel previous work, where VPC treatment induced acute MSC migration in blood 1.5 
hours after administration, and loss of the S1PR3 altogether induced MSC circulation as 
well [232].  Though VPC treatments significantly affected both the M2:M1 macrophage 
ratio and MSC population, these cell populations exhibit significantly different S1PR 
expression patterns which may have altered their interaction with VPC.  It has been 
previously shown that VPC is a potent S1PR3 antagonist with an EC50 similar to S1P, 
whereas VPC is only a partial S1PR1 agonist and is about 50% as effective as S1P [231].  
In the Botchwey lab, while LSK HSPCs and MSCs have both shown to express S1PR1 
and S1PR3 to some extent, LSK HSPCs expressed significantly more S1PR3 than MSCs, 
while MSCs expressed significantly more S1PR1 [36].  In other work, too, S1PR1 and 
S1PR2 were found to be critical in MSC migration whereas S1PR3 inhibition had no 
effect on MSC migration in vitro [310].  Given these differences, it is plausible that VPC 
acted on inflammatory cell populations through both S1PR1 and S1PR3 to enable cell 
recruitment and polarization, whereas VPC was only able to act on MSCs primarily 
through S1PR1.   
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We next sought to understand how the modulation of cell populations affected 
protein secretion within muscle using a multiplex protein assay, but no global differences 
were observed between groups when using principal component analysis (Figure D.1).  
To more fully interpret these results, secretome analysis at additional time points both 
before and after day 7 may help to capture the time course of protein expression due to 
injury and treatment.  Supervised multivariate analysis such as partial least squares 
discriminate analysis (PLSDA) and multivariate analyses that are coupled with our other 
outcome measures such as the quantity of eMHC+ muscle fibers may also help to 
discriminate between groups.  Through individual protein analysis, it was observed that 
IL-18 [311], RANTES [312], LIX [313], and Leptin [314], all of which have shown to 
play a role in the acute inflammatory response to injury, were upregulated in injured 
muscle but not in treated or uninjured muscle (Figure 6.4), which may suggest that VPC 
and SDF-1 can modulate the initial pro-inflammatory response to injury.  Additionally, 
SDF-1 significantly increased IP-10 production, a chemoattractant for monocytes and 
macrophages, while VPC and SDF-1 significantly decreased IL-13 production 
compared to uninjured muscle, which plays a role in M2 macrophage polarization (Figure 
6.5) [315].  As VPC and SDF-1 treatments have shown to modulate inflammatory cell 
recruitment and polarization in our work, these findings generally coincide with our 
current findings and ultimately, additional multivariate analysis may allow us to further 
elucidate if these factors, or others, are critical to modulating the muscle 
microenvironment. 
We next assessed angiogenesis in muscle after 7 days, and observed significantly 
more CD31+ vasculature in VPC+SDF-1α treated muscle than uninjured controls (Figure 
 133 
6.6A-B).  The highest number of vascular loops, a marker of rapid angiogenesis 
[214,300], was also observed in VPC+SDF-1α treated muscle but no significant 
differences were observed given the variability within each group (Figure 6.7).  VEGF 
production was also significantly reduced in injured muscle, though not in treated 
muscles, compared to uninjured controls (Figure 6.4F).  It is known that M2 macrophages 
and MSCs can secrete VEGF and facilitate vascular remodeling, and these cell 
populations likely played a role in the angiogenesis observed in VPC+SDF-1α muscles 
[316,317].  However, VPC and SDF-1α have shown to contribute to vascular remodeling 
and angiogenesis through mechanism independent of M2 macrophages and MSCs as 
well.  For example, S1PR1 agonism has led to increased endothelial cell and smooth 
muscle cell (SMC) proliferation and migration, thereby increasing vascular diameter and 
length [274] and VPC treatment has shown to increase SMC proliferation leading to 
increased arterial thickening [318].  SDF-1α has also shown to mobilize pro-angiogenic 
cells such as hematopoietic cells, endothelial progenitor cells, and SMCs [297] and can 
also retain and localize cell populations near vasculature, which may further promote 
angiogenesis [9,297].  Overall, markers of angiogenesis were observed in treated muscle, 
which has previously shown to support further cell recruitment and, ultimately, the 
regeneration of injured muscle [214,298,299,301]. 
 Towards understanding how the modulation of the cellular and vascular 
microenvironment may affect muscle regeneration, we observed significantly more 
eMHC+ regenerating muscle fibers in VPC+SDF-1 treated muscle compared to all 
other groups, though significantly more regenerating muscle fibers were observed in VPC 
and SDF-1 treated muscle than injury alone as well (Figure 6.8).  Given our collective 
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findings, it is possible that the increased angiogenesis observed in VPC+SDF-1 treated 
muscles as well as the recruitment of MSCs by all treatments contributed to the muscle 
regeneration observed. MSCs have shown in many studies to undergo myogenic 
differentiation in vitro [319,320] and contribute to regenerating muscle fibers in vivo 
[197].  In fact, in previous studies, the MSC secretome alone reduced fatty infiltration 
and increased muscle weight after 8 weeks following rotator cuff injury, possibly due to 
the MSC secretion of pigment epithelium-derived factor (PEDF) and follistatin which 
have shown to induce satellite cell proliferation [321].   
But in addition, the modulation of the inflammatory profile within muscle due to 
VPC+SDF-1 treatment may have played an important role in muscle regeneration as 
well.  Along with the significantly increased M2:M1 macrophage ratio that was observed 
due to VPC+SDF-1 and VPC treatment, individual analyte protein analysis suggested 
that most treatments may reduce the production of early pro-inflammatory mediators 
such as IL-18, RANTES [322], LIX [313], some of which have shown to be increased 
following skeletal muscle and tendon injury [322,323].  Furthermore, M2 macrophages 
have shown to localize with regenerating skeletal muscle fibers [324], and secrete IL-1 
which promotes muscle fusion and MyoD expression [325] and IL-10 which promotes 
myoblast proliferation [326].  In our work, we observed more CD163+ M2-like 
macrophages within regenerating muscle, although analysis is ongoing to determine if 
these macrophages co-localize with eMHC+ regenerating muscle fibers.  Furthermore, 
though we did not observe a significant increase in IL-1 or IL-10 with treatment at day 7, 
VPC+SDF-1 and VPC treatment significantly increased the M2:M1 macrophage ratio 
as early as 3 days after injury, so it is possible that production of these factors peaked at 
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an earlier time point.  Overall, it is possible that MSCs, M2-like macrophages, and 
CD31+ vasculature within muscle all partly contributed to the early muscle regeneration 
observed with VPC+SDF-1 treated muscle, and future work could focus on elucidating 
the specific role of each factor, and others, in this context. 
Though neither VPC nor SDF-1 have been utilized to mobilize or recruit cells to 
degenerating muscle, cell recruitment has been observed and employed to promote 
muscle regeneration through other methods.  For example, ß-catenin overexpression in 
mice resulted in, among other outcomes, significant angiogenic progenitor mobilization 
to injured skeletal muscle, which may have contributed to the muscle regeneration 
observed [327].  Additionally, IGF-1 is known to promote anti-inflammatory cell 
recruitment and in one case, local IGF-1 expression promoted expression of chemokines 
responsible for monocyte/macrophage recruitment and muscle regeneration was 
ultimately observed after CTX-induced tibilias anterior injury [322].  It is important to 
note, however, that many other mechanisms of regeneration were activated in these 
studies, and in this work and our own, further investigation would be required to 
determine the specific role of cell recruitment in promoting muscle regeneration.   
It is also important to note that we have yet to investigate the effect of VPC and 
SDF-1 treatment on the satellite cell population within muscle.  In previous studies of 
rotator cuff injury, satellite cell proliferation was decreased in patients with rotator cuff 
tears [45,328], and satellite cell differentiation capacity was reduced with increasing tear 
size in another study [329].  In mice with rotator cuff tears, while the satellite cell 
population with the supraspinatus muscle initially increased and was transiently 
activated, the population size returned to baseline levels by 14 weeks after injury [174].  
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In contrast, it has previously been shown in mice that SDF-1 can enhance satellite cell 
migration [28], and though VPC has not been explored in the context of satellite cells, 
S1P has shown to enhance satellite cell proliferation in an S1PR2-dependent manner in 
mdx mice [330], whereas S1P promoted the mitogenic and migratory activities of 
satellite cells in an S1PR2/S1PR4 and S1PR1/S1PR4-dependent manner, respectively 
[331]. 
Beyond the direct signaling between S1P and SDF-1, immune cells including 
M2 macrophages which were recruited to muscle in the present work, have also shown to 
interact with and affect satellite cell behavior.  Immune cells have been shown to secrete 
growth factors and ECM chemoattractive fragments which help satellite cells escape 
from the basal lamina of myofibers and protect satellite cells from apoptosis [332]. M2 
macrophages in particular, through secretion of IL-10 among other factors, can promotes 
satellite cell commitment to terminal differentiation, cell fusion, and formation of large 
myotubes [324,333].  Interestingly, satellite cell progeny have also shown to migrate 
more efficiently toward M2 macrophages compared to M1 macrophages  [324] and 
satellite cell progeny have even shown to attract monocytes themselves, which further 
highlights the cross-talk between satellite cells and immune cells [325].  Thus, it is 
evident that satellite cell activity may be dysregulated following rotator cuff injury, and 
that our co-delivery treatment may directly or, through the modulation of the M2:M1 
macrophage ratio, indirectly impact satellite cell behavior to promote muscle 
regeneration.  As Pax7 is becoming increasingly more commonplace as a marker for rat 
satellite cells, a future direction of this work may be investigating the localization and 
activity of satellite cells following VPC and SDF-1 treatment. 
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 Though we have now observed early muscle regeneration 1 week following 
injury, studies are ongoing to examine the efficacy of weekly VPC and SDF-1 
injections in promoting muscle regeneration over time.  After 2 and 3 weeks, no 
significant differences in muscle weight, indicative of muscle atrophy, were observed in 
injured muscles that were untreated or treated with VPC and SDF-1 (Figure 6.9).  
However, given that this model of rotator cuff injury is degenerative and does not include 
reattachment of the tendons, it is understandable that muscle atrophy may have continued 
despite VPC and SDF-1 treatment.  Instead, it is possible that other aspects of muscle 
quality may be affected by VPC and SDF-1 treatment, and ongoing work will analyze 
regenerating muscle fibers via image analysis of eMHC+ muscle fibers and centrally 
located nuclei within fibers, muscle fibrosis via histology and Masson’s trichrome 
staining, and muscle function via muscle twitch or tetanic force testing 2 and 3 weeks 
post-injury.  Ultimately, these studies will evaluate whether VPC and SDF-1, 
potentially due to the modulation of the cellular milieu, angiogenesis, and early muscle 
fiber regeneration, can result in functional recovery of muscle following severe rotator 
cuff injury. 
Current standard of care for severe rotator cuff injury involves reattachment of the 
torn tendons, resulting in continued muscle degeneration and an increased likelihood of 
re-tear.  Our current results indicate that systemic delivery of VPC and local injection of 
SDF-1 loaded MPs may stimulate endogenous healing mechanisms, leading to 
increased MSC recruitment, polarization of macrophages toward an anti-inflammatory 
phenotype, increased angiogenesis and early muscle regeneration in the context of rotator 
cuff injury.  Thus, a promising application of our treatment strategy could be improving 
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muscle quality following reattachment surgery, potentially reducing the likelihood of re-
tear.  In realizing the translation of this approach to the clinic, however, it is important to 
note that the animal model used in this work did not include tendon reattachment, 
meaning that the muscle degeneration and response to treatment observed in our studies 
may differ from that of a patient following surgical repair.  Nevertheless, our results 
indicate that harnessing endogenous healing mechanisms may be a novel approach to 
promote muscle regeneration and could be employed in the future to improve patient 
prognoses after rotator cuff repair. 
 
6.5 CONCLUSIONS 
In this work, the synergy between systemic delivery of the bone marrow mobilizing agent 
VPC and intra-muscular delivery of the chemokine SDF-1 was assessed in the 
supraspinatus muscle following severe rotator cuff tear in rats.  Co-delivery of VPC and 
SDF-1 loaded MPs led to significant mobilization of inflammatory cells and MSCs in 
blood, which was followed by a significant increase in the M2:M1 macrophage ratio and 
number of MSCs in muscle 3 and 7 days following injury.  After 7 days, VPC+SDF-1 
treatment resulted in significantly more CD31+ vasculature than uninjured controls, 
indicative of angiogenesis, and significantly more eMHC+ muscle fibers compared to all 
other groups, indicative of early muscle regeneration.  Collectively, these results suggest 
that the combination of VPC to induce bone marrow cell mobilization and SDF-1 
loaded MPs to recruit these bone marrow-derived cell populations to muscle stimulated 
early endogenous repair processes, and may be a promising method to promote rotator 
cuff muscle regeneration and improve patient prognoses following repair in the future. 
 139 
CHAPTER 7 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
7.1 SUMMARY 
In this work, a tunable heparin-based microparticle (MP) system was developed for the 
delivery of regenerative therapeutics for musculoskeletal tissues including bone, 
cartilage, and muscle.  Though biomaterial-based drug delivery systems exist, MPs are 
advantageous for injection to a wide range of injury locations.  Furthermore, due to 
heparin’s ability to bind via electrostatic interactions carbohydrate sequence-specific 
interactions to positively-charged proteins, heparin was employed to load and release 
proteins of interest in a controlled manner, and to protect and even enhance protein 
bioactivity.  Ultimately, heparin-based MP tunability was validated by modulating 
heparin content, heparin sulfation, and hydrolytic degradation of MPs, and subsequently 
investigating the effect of these variable on loading, release, and bioactivity of an 
osteoinductive growth factor in vitro.  Subsequently, a single MP formulation was 
validated as a method to deliver bioactive heparin-binding proteins in vivo for the 
ultimate purpose of regenerating musculoskeletal tissues in two unique injury contexts.  
These findings were delineated in 4 chapters of this thesis: 
In Chapter 3, hydrolytically-degradable, heparin-based MPs were fabricated 
containing heparin derivatives with varying levels of sulfation.  First, it was shown that 
MP degradation could be modulated between 7-14 days in vitro.  Furthermore, most MP 
formulations loaded equivalent amounts of an osteoinductive protein, BMP-2, whereas 
more sulfated Hep and Hep-N MPs released significantly more BMP-2 than more 
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desulfated heparin MPs.  Similarly, BMP-2 bioactivity was enhanced by more sulfated 
Hep and Hep-N MPs compared to soluble BMP-2.  Collectively, 10 wt% Hep and Hep-N 
MPs were selected as viable therapeutic carrier capable of efficient loading and release of 
bioactive BMP-2, and this work ultimately demonstrated that heparin sulfation level may 
be an important consideration for any future heparin-based biomaterials approach for 
bioactive therapeutic delivery. 
In Chapter 4, the effect heparin sulfation on TSG-6 bioactivity was first 
determined to inform the development of heparin-based MPs for TSG-6 intra-articular 
delivery.  More sulfated Hep and Hep-N derivatives significantly enhanced TSG-6 anti-
plasmin activity in vitro, whereas fully desulfated heparin (Hep-) had no effect, indicating 
that heparin sulfation plays a significant role in modulating TSG-6 bioactivity.  Next, 
hydrolytically degradable TSG-6 loaded 10 wt% Hep-N-based MPs were delivered via 
intra-articular injection in a rat model of post-traumatic osteoarthritis (OA).  After 21 
days, EPIC-µCT analysis indicated that TSG-6 loaded MPs reduced cartilage damage 
following post-traumatic OA injury, whereas a 3X higher dose of soluble TSG-6 did not.  
These results suggest that Hep-N can enhance TSG-6 bioactivity in vivo and, ultimately, 
that Hep-N-containing MPs may be an effective method to deliver a chondroprotective 
protein for cartilage regeneration. 
In Chapter 5, the same formulation selected in Chapter 3 and utilized in Chapter 
4, hydrolytically degradable 10 wt% Hep-N MPs, were utilized and injected within the 
supraspinatus muscle of rats with severe rotator cuff injury to modulate the cellular 
milieu within muscle.  First, MPs were tracked in vivo and were found to be retained 
within muscle for at least 3 days and appeared to have degraded by day 7.  Furthermore, 
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tracking of SDF-1 released from MPs in vivo indicated that SDF-1 may be retained at 
the site of injection for at least 1-3 days when delivered to the supraspinatus muscle.  
After 7 days following rotator cuff injury and SDF-1 loaded MP treatment, significantly 
more anti-inflammatory, M2-like macrophages and MSCs were detected in muscle 
treated with SDF-1 loaded MPs compared to unloaded MPs or injury alone.  As no prior 
studies have investigated the use of chemotactic therapeutics such as SDF-1 to treat 
muscle following rotator cuff injury, our results indicate that SDF-1 loaded MPs can 
shift the cellular composition of the supraspinatus muscle, which may provide a platform 
to improve muscle repair after rotator cuff injury in the future. 
Finally, in Chapter 6, building on the findings of Chapter 5, SDF-1 loaded MPs 
were delivered via intra-muscular injection to the supraspinatus muscle in combination 
with systemic injection of a bone marrow mobilizing agent, VPC01091 (VPC), to further 
modulate the supraspinatus muscle cellular milieu.  Co-delivery of VPC and SDF-1 led 
to significant mobilization of inflammatory cells and MSCs in blood, which was followed 
by a significant increase in the M2:M1 macrophage ratio and number of MSCs in muscle 
3 and 7 days following injury.  After 7 days, VPC+SDF-1 treatment resulted in 
significantly more CD31+ vasculature than uninjured controls, indicative of 
angiogenesis, and significantly more eMHC+ muscle fibers compared to all other groups, 
indicative of early muscle regeneration.  Collectively, these results suggest that the 
combination of VPC to induce cell mobilization and SDF-1 loaded MPs to recruit these 
cell populations to muscle stimulated endogenous healing processes, and may be a 





Overall, the long term goal of this research was to develop a tunable biomaterial-
based system for the delivery of regenerative therapeutics for musculoskeletal tissue 
including bone, cartilage, and muscle.  This goal was first achieved through the 
engineering of a heparin-based microparticle system with tunable hydrolytic degradation, 
heparin content, and heparin sulfation.  To first tune MP degradation, we developed 
heparin-based MPs with varying concentrations of dithiothreitol (DTT), which 
accelerates the hydrolytic degradation of the ester linkage within PEGDA molecules.  As 
the concentration of DTT was increased within MPs, MP degradation accelerated, and 
overall MPs could be fabricated to degrade between 7 to 30 days in vitro, and ~7 days 
within muscle in vivo.  Interestingly, in studies with heparin of varying degradation rates, 
between 7-14 days in vitro, BMP-2 release rates were unaffected by the degradation rate 
of MPs, which may indicate that BMP-2 release was governed more by diffusion than 
MP degradation.  It is also important to note that several confounding variables existed 
within these studies.  First, the heparin MPs in this study were composed of varying 
heparin derivatives making direct comparisons of BMP-2 release rate challenging and 
second, BMP-2 denaturation likely reduced the ability for the BMP-2 ELISA to detect all 
released BMP-2 from MPs.  In contrast to this study, in previous work it has been found 
that 10 wt% heparin hydrogels could release the more stable small molecule, crystal 
violet, with varying release kinetics through modulation of hydrogel degradation [17].  
Nevertheless, this work collectively validated the ability to modulate hydrolytic 
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degradation of heparin MPs, which can be adjusted to accommodate the specific in vivo 
application in the future. 
MPs were also developed with varying heparin content to further modulate 
protein loading and release.  In collaboration with other laboratories, we previously 
developed 100% heparin MPs, but due to the high heparin content, 100% heparin MPs 
sequestered protein and only released up to ~10% of the originally loaded protein in vitro 
[15].  In contrast, we found that though heparin content did not affect BMP-2 loading, 
10% heparin MPs released up to 60% of the originally loaded protein while 1% heparin 
MPs released up to 30% in vitro.  As heparin has previously shown to protect BMP-2 
from denaturation, it is postulated that greater heparin content within 10% heparin MPs 
protected more BMP-2 than 1% heparin MPs, thereby enabling more BMP-2 release in 
this study. 
 Finally, heparin sulfation has shown to play a critical role in protein binding and, 
in certain cases, bioactivity.  Therefore, we synthesized heparin derivatives of varying 
sulfation level, between 0 to 100% total sulfation, to further tune protein release, and 
bioactivity.    In in vitro studies with BMP-2, more sulfated heparin MPs, Hep and Hep-N 
which are 100 and 80% sulfated, respectively, released more BMP-2 and enhanced BMP-
2 bioactivity compared to more desulfated heparin derivatives, Hep6O,N and Hep- which 
are 20% and 0% sulfated, respectively.  It has been found that heparin sulfate groups are 
involved, and potentially even required, for complete binding to BMP-2 [62,84].  When 
desulfated heparin derivatives were incubated with TSG-6, similar results were observed 
whereby Hep and Hep-N enhanced TSG-6 anti-plasmin activity compared to Hep- and to 
soluble TSG-6 controls.  Heparin has previously shown to enhance TSG-6 plasmin 
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activity, and it has previously been hypothesized that this is due to heparin’s ability to 
maintain TSG-6 is a “closed” conformation.  Ultimately, these results indicate that 
heparin MPs can be fabricated and utilized to modulate protein release and bioactivity. 
 Following the validation of the heparin-based MP platform, the system was then 
employed to deliver therapeutics to musculoskeletal tissues in two injury contexts.  Given 
our in vitro findings whereby more sulfated heparin derivatives could release more 
protein and enhance protein bioactivity, and due to the diminished anti-coagulant 
properties of desulfated heparin derivatives, 10 wt% Hep-N MPs were chosen for further 
in vivo drug delivery application in this thesis.  First, in Chapter 4 the anti-inflammatory 
protein TSG-6 was loaded onto MPs, which were then delivered via intra-articular 
injection using standard needles and syringes for treating cartilage in the context of post-
traumatic osteoarthritis.  Second, the chemokine SDF-1 was loaded onto MPs via intra-
muscular injection to the supraspinatus muscle following severe rotator cuff injury.  
Following intra-muscular injection, MPs were visualized in vivo over time, and it was 
determined that non-degradable MPs were retained within the muscle for at least 7 days, 
whereas degradable MPs were retained within MPs for at least 3 days and appeared to 
have degraded by day 7.  Furthermore, SDF-1 loaded MPs were shown to release SDF-
1 over at least 1-3 days in vivo.  Lastly, unloaded MPs were also delivered to the 
supraspinatus muscle after rotator cuff injury and did not elicit any significant 
inflammatory cell response compared to injury alone, indicating a lack of any undesired 
immune response at the MP concentration and injection location studied in this work.  
Thus, MPs were validated as a method to locally deliver therapeutics to degenerating 
musculoskeletal tissues. 
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 Once it was determined that MPs could be delivered via injection to the joint 
space and muscle to release therapeutics of interest, MPs were assessed for their ability to 
enhance the efficacy of these therapeutics to promote musculoskeletal tissue 
regeneration.  First, TSG-6 loaded heparin-based MPs were delivered via intra-articular 
injection in a rat model of post-traumatic osteoarthritis.  In this work, TSG-6 loaded onto 
MPs was significantly more chondroprotective than a 3x dose of soluble TSG-6, which 
indicates the ability for MPs to enhance therapeutic efficacy in this context.  First, it is 
possible that MPs were able to retain TSG-6 within the joint space for a longer period of 
time than soluble TSG-6, which was likely cleared from the joint space rapidly.  
Secondly, given that heparin could enhance TSG-6 bioactivity in vitro, it is possible that 
heparin-based MPs enhanced the TSG-6 released in vivo as well.  Ultimately, for the first 
time, heparin-based MPs were used to more effectively deliver TSG-6 to an osteoarthritic 
joint, which subsequently protected cartilage from OA-induced degeneration. 
 Apart from the development of heparin-based MPs, another significant 
component of this work was the first, elucidation of the cellular milieu in muscle and 
subsequently, the degenerative state of muscle following severe rotator cuff injury.  
Though nearly 300,000+ rotator cuff repairs occur annually [45], current standard of 
surgical repair involves only tendon reattachment, allowing for continued muscle 
degeneration and an increased likelihood of re-tear.  Thus, understanding and altering the 
cellular milieu within muscle following rotator cuff injury may be a method to improve 
patient prognoses following rotator cuff repair.  After injury in blood, the fold-change in 
myeloid cells and monocytes compared to the 1.5 hour time point was less than 1 at all 
time points for injury alone, indicating that cell mobilization generally decreased after the 
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initial response to injury.  In muscle at day 3, a 1.2 to 1.3-fold increase in myeloid cells, 
macrophages, and macrophage subpopulations was observed in injury compared to 
uninjured controls, which increased to a 1.4 to 1.5-fold increase for all inflammatory cell 
populations by day 7.  Furthermore, at both day 3 and 7 the M2:M1 macrophage ratio 
was ~1.1, though overall no significant differences were observed between injury and 
uninjured controls.  Following skeletal muscle injuries, a typical inflammatory response 
includes an initial response by neutrophils in the first several hours, followed by an influx 
of pro-inflammatory M1 macrophages and finally, within 7 to 14 days, a shift toward an 
anti-inflammatory M2 macrophage-dominant cellular milieu [303,304].  However, at the 
day 3 and 7 time point in our work, no substantial shift in the M2:M1 ratio was observed, 
which may indicate that the inflammatory response in muscle following rotator cuff tear 
may be unique or dysregulated compared to other muscle injuries.  Additionally, rotator 
cuff injury begins primarily as a tendon injury, so the inflammatory response in muscle 
may be delayed compared to other direct muscle injuries.  Overall, these results suggest 
that treatments designed to modulate the M2:M1 macrophage ratio may be a method to 
significantly alter the regenerative state of muscle following rotator cuff injury. 
As a measure of muscle degeneration, we also assessed muscle atrophy and 
fibrosis 1, 3, and 6 weeks following tendon transection and denervation.  Though no 
differences were apparent after 1 week following rotator cuff injury, supraspinatus 
muscle weight significantly decreased by 50-60% compared to uninjured controls after 3 
and 6 weeks.  Similarly, Masson’s trichrome staining showed that fibrous infiltration was 
significantly greater in the injured supraspinatus muscles compared to uninjured controls 
at both 3 and 6 weeks as well.  These results confirm that this is a model of degenerative 
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muscle injury and thus is an appropriate in vivo platform to test effects of release of SDF-
1α on altering the cellular milieu in a degenerative environment.  These results 
collectively indicate that a unique inflammatory response occurs in muscle occurs within 
1 week following rotator cuff injury, which leads to significant muscle degeneration as 
early as 3 weeks following tendon transection and denervation in rats. 
 MPs were also utilized to deliver the chemokine SDF-1 to the supraspinatus 
muscle alone and in combination with systemic delivery of the bone marrow mobilizing 
agent, VPC01091, to enhance the pro-regenerative cellular milieu within muscle after 
rotator cuff injury.  SDF-1 loaded MPs significantly increased the number of anti-
inflammatory M2-like macrophages and MSCS within muscle compared to injury, and 
when co-delivered with VPC01019, the M2:M1 ratio was also significantly increased as 
early as 3 days following injury and treatment.  After 7 days, co-delivery of VPC01091 
and SDF-1 loaded MPs led to significantly more regenerating muscle fibers within the 
supraspinatus than any other treatment and injury alone.   
With this foundation, we then modulated the muscle’s cellular composition with 
the chemokine SDF-1 and bone marrow mobilizing agent VPC.  Co-delivery of 
VPC+SDF-1 resulted in a significantly increased M2:M1 macrophage ratio and MSC 
population compared to SDF-1 and injury alone as early as 3 days following injury and 
treatment.  After 7 days, VPC+SDF-1 treatment resulted in significantly more CD31+ 
vasculature than uninjured controls and significantly more eMHC+ regenerating muscle 
fibers compared to all other groups.  Though cell recruitment has been observed in 
several muscle injury contexts, few treatment strategies have harnessed endogenous cell 
recruitment as a method to regenerate muscle.  In one case, ß-catenin overexpression 
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resulted in, among other outcomes, significant angiogenic progenitor mobilization to 
injured skeletal muscle, which may have contributed to the muscle regeneration observed 
[327].  Additionally, local IGF-1 expression promoted expression of chemokines 
responsible for monocyte/macrophage recruitment, and muscle regeneration was 
ultimately observed after CTX-induced tibilias anterior injury [322].   It is important to 
note, however, that many other mechanisms of healing and regeneration were activated in 
these studies, and in this work and ours, further investigation would be required to 
determine the specific role of cell recruitment in promoting muscle regeneration.  
Overall, as SDF-1 and VPC have never before been utilized in the context of muscle 
regeneration following rotator cuff injury, these results indicate a novel approach to 
enhancing musculoskeletal tissue regeneration may be the modulation of endogenous cell 
recruitment, which may ultimately improve patient outcomes following rotator cuff repair 
in the future. 
 
7.3 FUTURE DIRECTIONS 
7.3.1 TSG-6 LOADED MPS IN THE CONTEXT OF OSTEOARTHRITIS 
In Chapter 4, TSG-6 was implemented as a chondroprotective anti-inflammatory 
protein capable of reducing cartilage degeneration within the context of post-traumatic 
osteoarthritis.  In particular, it was found that TSG-6 delivered via heparin-based MPs 
was significantly more chondroprotective than a 3x dose of soluble TSG-6.  In analyzing 
these results, it was postulated that heparin-based MPs may have retained TSG-6 within 
the intra-articular joint space for a longer period of time than soluble TSG-6 and/or 
heparin within MPs was able to enhance TSG-6 bioactivity compared to soluble TSG-6 
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alone in vivo.  To test the first hypothesis, in vivo fluorescent imaging could be employed 
to track both fluorescently-tagged heparin MPs and fluorescently-tagged TSG-6 once 
delivered via intra-articular injection.  By comparing the release kinetics and subsequent 
clearance rate of both MPs and TSG-6 to a soluble TSG-6 control, we may better 
understand the importance of heparin MPs in retaining TSG-6 locally within the intra-
articular joint space.   To test the second hypothesis, in two in vitro studies it was 
previously observed that soluble heparin derivatives, including Hep and Hep-N, could 
enhance TSG-6 anti-plasmin activity and that TSG-6 released from Hep-N-based MPs 
exhibited significantly more anti-plasmin activity than soluble TSG-6 at the same 
concentration.  Despite these results, however, we have yet to validate that TSG-6 
delivered to an osteoarthritic joint in vivo exhibits anti-plasmin activity to, in turn, reduce 
cartilage degeneration in this context.  Therefore, to probe this hypothesis, synovial fluid 
samples could be collected from treated and untreated knees of rats with post-traumatic 
osteoarthritis to determine if TSG-6 loaded MP delivery impacts the plasminogen 
activation pathway within the joint space.  Overall, by more fully understanding the 
mechanism of action by which TSG-6 loaded MPs reduce cartilage degeneration, we may 
also elucidate specific pathways to explore for effective treatment of cartilage 
degeneration in osteoarthritic joints in the future. 
7.3.2 CELL BEHAVIOR FOLLOWING VPC AND SDF-1 LOADED MP TREATMENT 
 In Chapter 5 and 6, the cellular milieu within muscle was modulated with the 
chemokine SDF-1 and bone marrow mobilizing agent VPC.  It was found that co-
delivery of SDF-1 loaded MPs and systemic delivery of VPC treatment led to a 
significant increase in the M2:M1 macrophage ratio and the MSC population after 3 and 
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7 days post-injury and treatment.  Furthermore, by day 7 VPC+SDF-1 treated muscles 
exhibited significantly more eMHC+ regenerating muscle fibers than all other groups and 
significantly more CD31+ vasculature than uninjured controls.  Though it is known that 
cell populations including anti-inflammatory M2 macrophages and MSCs may play a role 
in angiogenesis and muscle regeneration, it remains unclear what specific cell 
populations may be directly involved in the increased muscle regeneration in our studies. 
 One method to further elucidate cell behavior once recruited to the supraspinatus 
muscle could be to sort each cell population of interest for secretome analysis.  We have 
previously established with flow cytometry that M2-like macrophage and MSC 
population are significantly increased following VPC and SDF-1 treatment, though it is 
unclear what proteins and factors these cells are secreting, and if their secretion is 
differentially affected by each treatment.  Therefore, cell populations of interest could be 
sorted as CD11b+CD68+ for macrophages, CD11b+CD68+CD163- for M1-like 
macrophages, CD11b+CD68+CD163+ M2-like macrophages, and CD29+CD44+CD90+ 
MSCs.  In situ hybridization studies could be employed to look at each cell population 
within the muscle, alone with the RNA expression profiles of each cell population.  In 
particular, these studies may elucidate how each individual cell populations contributes to 
the modulation of the inflammatory profile within muscle, as well as to the angiogenesis 
and muscle regeneration previously seen 7 days following rotator cuff injury in our 
studies. 
Additionally, to more fully confirm the role of inflammatory cell mobilization and 
recruitment, monocyte depletion experiments could be conducted by administering 
clondronate liposome to animals prior to rotator cuff tear and treatment.  In previous 
 151 
work, clondronate liposome administration to mice caused complete depletion of blood 
monocytes within 6 hours followed by recovery of some monocyte populations at day 2 
[334].  As we observed VPC-mediated mobilization in blood during this time frame and 
VPC-mediated inflammatory cell changes in muscle at day 3, clondronate liposome 
treatment may eliminate these responses and allow us to decouple the effects of 
inflammatory cell populations from the effects of other cell populations such as MSCs. 
 As described in Chapter 6, in our work we have yet to analyze how satellite cells 
are affected in the context of rotator cuff tear alone and with VPC and SDF-1 treatment.  
In previous studies of rotator cuff injury, satellite cell proliferation was decreased in 
patients with rotator cuff tears [45,328], and satellite cell differentiation capacity was 
reduced with increasing tear size in another study [329].  In mice with rotator cuff tears, 
while the satellite cell population with the supraspinatus muscle initially increased and 
was transiently activated, the population size returned to baseline levels by 14 weeks after 
injury [174].  In contrast, it has previously been shown in mice that SDF-1 can enhance 
satellite cell migration [28], and though VPC has not been explored in the context of 
satellite cells, S1P has shown to enhance satellite cell proliferation in an S1PR2-
dependent manner in mdx mice [330], whereas S1P promoted the mitogenic and 
migratory activities of satellite cells in an S1PR2/S1PR4 and S1PR1/S1PR4-dependent 
manner, respectively [331].  Thus, it is evident that satellite cell activity may be 
dysregulated following rotator cuff injury, and that our co-delivery treatment strategy 
may enable improved satellite cell activity in this context. 
 Until recently, the availability of reliable rat antibodies to identify satellite cells 
have been limited.  However, Pax7 antibodies have become increasingly more available 
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and more readily used as a marker in immunohistochemistry and flow cytometry 
experiments to identify satellite cells in rat samples.  Therefore, Pax7 could be employed 
in future experiments to first, determine how the quantity of satellite cells within muscle 
changes over time with rotator cuff tear.  Next, in situ hybridization could be employed to 
visualize satellite cells and their RNA expression profile.  Finally, immunohistochemistry 
experiments could be employed to observe the co-localization of satellite cells with 
regenerating muscle fibers, newly formed vasculature, and other cell populations that we 
have shown are present in muscle following injury.  As both VPC and SDF-1 have 
shown to affect satellite cell behavior in other contexts, assessing how these treatments 
affect satellite cell population using these same experiments may also elucidate if our 
treatment strategies are a method to improve satellite cell function and enable muscle 
regeneration. 
7.3.3 ADVANTAGES & DISADVANTAGES OF ENDOGENOUS REPAIR 
In Chapter 4, 5, and 6, endogenous repair mechanisms were harnessed to promote 
cartilage and muscle regeneration.  TSG-6 is naturally upregulated in osteoarthritic joints 
as an anti-inflammatory agent, and we therefore employed TSG-6 loaded MPs to prevent 
cartilage degeneration after post-traumatic osteoarthritic injury in rats.  In our studies 
with VPC and SDF-1 loaded MPs, VPC was utilized to mobilize endogenous cell 
populations while SDF-1 loaded MPs were employed to recruit those endogenous cell 
populations to the muscle following rotator cuff injury.  Ultimately, promoting 
endogenous healing mechanisms for tissue regeneration is advantageous compared to 
transplants which may be more costly, more difficult to prepare and deliver, and may be 
rejected once delivered.  Scaffolds are another common approach to replace degenerated 
 153 
tissue, but significant research and development is often required to create materials 
which mimic the properties of natural tissue and these materials may evoke a negative 
immune response once implanted. 
Still, employing endogenous healing mechanisms also has its disadvantages.  For 
instance, these treatment strategies primarily target a single mechanism to promote tissue 
regeneration, such as the recruitment of M2-like macrophages and MSCs to the muscle 
via VPC and SDF-1.  Despite the recruitment of these cell populations, this mechanism 
alone may not enable complete muscle recovery after rotator cuff injury.  Furthermore, in 
injury contexts including osteoarthritis and rotator cuff tear, among many others, 
endogenous healing processes are often dysregulated, which may make these 
mechanisms poor treatment targets.  For example, satellite cell proliferation and 
differentiation has shown to be affected by rotator cuff tear, meaning therapeutics 
targeting satellite cells specifically may be ineffective as the satellite cell population 
decreases or loses function. 
To improve on our current work and to ensure the efficacy of future treatments 
which promote endogenous repair processes, it is important to consider the time course of 
tissue degeneration in each injury context.  In osteoarthritic joints and rotator cuff 
muscles after cuff tear, tissue degeneration progresses over time and may require long-
term treatment to, ideally, return the tissue to a healthy state.  In fact, dependent on the 
injury, it may be that life-long treatment is required to maintain the health of each tissue.  
Therefore, our current work could be improved upon by extending therapeutic delivery in 
a controlled manner that matches the requirements of the disease state.  Though 
therapeutic delivery of biomaterials over a lifetime is unrealistic, a step towards this goal 
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would be utilizing biomaterials to decrease the frequency of injections, which can often 
be inconvenient and costly to patients. 
7.3.4 CLINICAL CONSIDERATIONS FOR TREATING ROTATOR CUFF INJURY 
There are many factors when considering how our treatments may be translated to the 
clinic.  First, significantly larger doses of both VPC and SDF-1 would be required for 
the human rotator cuff, and both therapeutics are currently too costly to be a reasonable 
option for patients.  Large scale production of both products would be required to ensure 
affordability and availability.  Furthermore, especially for VPC which is delivered 
systemically, many side effects may occur due to the increased mobilization of bone 
marrow-derived cells into circulation.  Though this has been studied with other S1PR 
agonists/antagonists, clinical trials focused on the appropriate dosages and the potential 
risks of systemic VPC administration would be necessary.  Finally, the translation of 
manipulated biomaterials can be time-consuming and costly, and would be a significant 
component to the translation of our treatment to the clinic.  Given the ability for our 
microparticle platform to improve release and bioactivity of proteins, it is an important 
component to the treatment strategy, but would likely extend the time and capital 
required for full clinical translation of our technology.  
Beyond the selection and development of therapeutics for musculoskeletal tissue 
regeneration, timing of intervention is a critical component to successful translation of 
these treatment strategies.  In the case of rotator cuff injuries, it is known that muscle 
degeneration continues after surgical intervention, and correlates with an increased 
likelihood of re-tear.  Therefore, a potential timeline of intervention with muscle 
regenerating therapeutics could be immediately following surgical reattachment, thereby 
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promoting muscle regeneration and reducing the likelihood of re-tear.  However, certain 
patients have shown to exhibit such significant muscle degeneration that they become 
ineligible for surgery.  For these patients, earlier intervention may promote muscle 
regeneration and potential improve their eligibility for surgery in the future.  Overall, for 
rotator cuff tears and many other musculoskeletal injuries, exploring the timing of 
intervention is critical for promoting sustained tissue regeneration and improving patient 
prognoses. 
Furthermore, it is important to consider patient to patient variability and how our 
treatments may differentially affect each patient.  As mentioned earlier, when targeting 
endogenous healing mechanisms, it is important to determine the current state or health 
of these healing mechanisms.  For elderly patients who may be in poor health, their 
inflammatory cell or stem cell count in the bone marrow or blood may be low, which 
limits the efficacy of targeting these cell populations to promote muscle regeneration in 
the rotator cuff.  Therefore, prior screening may be required to determine the health of 
each patient and the potential efficacy of our treatment strategy, which would include 
blood analysis for inflammatory and stem cell populations as well as analysis of the 
muscle state within the rotator cuff.  Dependent on these results, we may have a better 
understanding of whether each individual patient is more suited for our treatments 
targeting endogenous healing mechanisms, or if alternative treatment approaches may be 
more effective. 
Lastly, though Chapter 5 and 6 have focused on muscle regeneration following 
rotator cuff injury, other tissue of the joint space including tendon, cartilage, and bone 
have all shown to be significantly affected after severe rotator cuff injury.  Tendon tissue 
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has shown to exhibit an initial inflammatory response, followed by disorganization and 
fragmentation of collagen and overall degeneration [165].  Mankin scoring of cartilage 
tissue has indicated increased structural disorganization, hypocellularity, decreased GAG 
content and tide marks crossed by blood vessels, all of which are indicators of cartilage 
degeneration [148].  For the surrounding bone tissue, the disrupted kinematics of the 
glenohumeral joint after rotator cuff injury can often lead to osteoarthritis, where the 
subchondral bone of the humeral head collapses and the surrounding bone tissue erodes 
[148].  In our previous work, we have shown that drug loaded heparin-based MPs can be 
injected into the intra-articular joint space of rat knees, and in turn prevented cartilage 
degeneration in the context of post-traumatic osteoarthritis.  Therefore, intra-articular 
injection of drug loaded MPs may be a method to treat cartilage, bone, and tendon in this 
context.  Furthermore, we have shown that unloaded MPs can be injected directly into 
tendon tissue, which may offer a method to specifically target degenerating tendon tissue 
as well.  Ultimately, as rotator cuff tear affects many tissues of the joint space, heparin-
based MPs may be a method to treat multiple tissues, thereby improving the condition of 










A.1 PICOGREEN ASSAY FOR DNA QUANTIFICATION OF C2C12 MOUSE MYOBLASTS 
Methods: dsDNA was quantified by Quant-iT dsDNA PicoGreen assay (Invitrogen, 
Grand Island, NY).  After incubating C2C12 cells for 3 days at 37°C, cells were lysed 
with 100 μL lysis buffer and frozen, thawed and sonicated three times to completely 
dissociate the cells.  Cell lysates and standards were incubated in PicoGreen reagent and 
the fluorescence (ex 485 nm, em 528 nm) was measured (n = 3-5).   
Results: After 3 days of incubation, no significant differences in C2C12 dsDNA content 
were seen between any groups. 
Discussion: Treatment with soluble BMP-2, unloaded 10 wt% Hep MPs, or BMP-2 
loaded MPs did not significantly affect the total DNA content of C2C12 cells over 3 
days.  
 
Figure A.1. PicoGreen Assay for DNA quantification of C2C12 mouse myoblasts. No 
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A.2 DETECTED LEVELS OF BMP-2 AFTER INCUBATION WITH SOLUBLE HEPARIN DERIVATIVES. 
Methods: 100 ng BMP-2 was incubated with 0.01 mg soluble Hep, Hep-N, Hep-6O,N, 
Hep-, or PEG-4Ac in 0.5 mL 0.5% v/v BSA PBS solution for 15 minutes or 24 hours at 
4°C.  BMP-2 was then quantified via ELISA (n = 3-5). 
Results: After incubating heparin and BMP-2 for 15 minutes, the ELISA accurately 
detected approximately 100 ng BMP-2 in all heparin samples (Figure A.2A).  After 
incubating for 24 hours at 4°C, the detected levels of BMP-2 remained between 90-100 
ng in Hep and Hep-N samples but decreased to between 40-50 ng in Hep-6O,N, Hep-, and 
no heparin samples, significantly lower than Hep and Hep-N (Figure A.2B).   
Discussion: The ELISA accurately detected approximately 100 ng BMP-2 in samples 
with each heparin derivative after 15 minutes incubation, indicating that no derivative 
significantly interfered with the assay.  After 24 hours incubation, the detected levels of 
BMP-2 were maintained in the more sulfated heparin samples (Hep and Hep-N), 
indicating that these heparin derivatives protected BMP-2 over this timeframe, allowing 
for accurate detection via ELISA.  In contrast, BMP-2 levels were significantly lower in 
the more desulfated heparin and no heparin samples, indicating that BMP-2 was not well 
protected by these derivatives. 
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Figure A.2. Detected levels of BMP-2 after incubation with soluble heparin derivatives. 
(A) After 15-min incubation, there was no difference between heparin groups. (B) After 
24-hr incubation, there was significantly higher detected levels of BMP-2 in more 
sulfated heparin groups. #Significantly different than all other groups at 15 mins; p ≤ 
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APPENDIX B 
B.1 PROTON NUCLEAR MAGNETIC RESONANCE  
Methods: Proton nuclear magnetic resonance (1H NMR) was performed whereby 10 
mg/mL Hep-N MAm and PEGDA samples were each dissolved in deuterated H2O 
(Sigma), run on a Bruker Avance III spectrometer at 400 Hz, and analyzed using iNMR 
software [21].  Percent modification was determined by dividing the integral of the 
methacrylamide peak by the heparin peak for Hep-N MAm and the acrylate peaks by the 
PEG peak for PEGDA. 
Results: Using 1H NMR analysis, PEGDA was determined to be ~55% functionalized 




Figure B.1. 1H NMR of poly (ethylene glycol) diacrylate and N-desulfated heparin 
methacrylamide.  (A) Characteristic peaks for acrylate groups were present in the 
PEGDA spectra and (B) characteristic peaks for methacrylamide peaks were present in 
the N-desulfated heparin methacrylamide. 
 
B.2 MICROPARTICLE SIZE AND MORPHOLOGY BEFORE AND AFTER TSG-6 LOADING 
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Methods: TSG-6 was loaded onto microparticles (MPs) using the same method for all 
other in vitro and in vivo studies.  Briefly, 0.6 mg 10 wt% Hep-N MPs were incubated 
with 1.0 ug TSG-6 for 2 hours at 4°C.  Phase microscopy and ImageJ software were used 
to image and quantify the diameter of microparticles before and after the loading 
protocol. 
Results:  MPs appear to have the same morphology (Figure B.2A-B) and exhibit a 
similar size distribution (Figure B.2C) before and after loading. 
Discussion:  Overall, TSG-6 loading did not affect MP morphology or size, indicating 
that MPs from our previous in vitro and in vivo studies likely remained approximately 80 
± 60 μm in diameter before and after loading. 
 
 
Figure B.2. Microparticle size and morphology before and after TSG-6 loading. (A-B) 10 
wt% Hep-N MPs qualitatively appeared similar in morphology before and after TSG-6 
loading, and (C) were not significantly different in average size distribution. Before 
loading and after loading group were not significantly different; p ≤ 0.05; two-tailed t-







C.1 STRONG ANION EXCHANGE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
Results: SAX-HPLC analysis was used to determine Hep and Hep-N disaccharide 
composition.  For Hep, 74% of the sample was 2-sulfo unsaturated uronic acid 
(∆UA(2S)) / 6-sulfo-N-sulfo glucosamine (GlcNS(6S)), which is likely the common 
disaccharide repeat unit of heparin, 2-O-sulfo-α-L-iduronic acid / 6-O-sulfo-N-sulfo-α-D-
glucosamine (Table C.1).  Additionally, 8% of the Hep sample was ∆UA / GlcNS(6S) 
and 6% was ∆UA(2S) / GlcNS.  In the Hep-N sample, however, the above N-sulfated 
repeat units were not detected and instead appeared to be replaced by the N-desulfated 
equivalents.  Specifically, the Hep-N sample was 72% ∆UA(2S) / 6-sulfo glucosamine 
(Glc(6S)), 10% ∆UA / Glc(6S), and 7% ∆UA(2S) / Glc, indicating that the sample was 
successfully N-desulfated.  One other repeat unit, ∆UA(2S) / GlcNAc(6S) made up 2% of 
the Hep sample but was no longer detected in the Hep-N sample which may indicate that a 
small amount of acetyl groups were also removed in the N-desulfation process. 
 
Table C.1. Heparin and N-desulfated heparin disaccharide composition as determined by 
SAX-HPLC analysis. ∆UA=∆4,5-unsaturated uronic acid; Glc= glucosamine; NS= N-
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C.2 MICROPARTICLE SIZE DISTRIBUTION 
Methods: Prior to all in vitro and in vivo experiments, MPs were filtered with 40 μm cell 
strainers to remove most MPs under 40 μm in diameter.  Therefore, MP sizing was 
completed on the filtered microparticles using phase microscopy and ImageJ analysis of 
MP diameter.   
Results and Discussion: MPs were 62 ± 65 μm in diameter and an image of the MPs can 
be found in Figure C.1. 
 
Figure C.1. Histogram of microparticle size distribution. Microparticles were found to be 
62 ± 65 μm in diameter using ImageJ analysis; n > 50 microparticles. 
 
C.3 MICROPARTICLE DEGRADATION 
Methods: MP degradation in vitro was monitored by incubating 0.5 mg MPs in 0.5 mL 
0.1 wt% BSA solution at 37°C.  30 μL of each sample was removed and imaged via 
phase microscopy every 2 days until complete degradation; n = 3 per MP formulation.  
 164 
MP degradation was defined as the time point at which no MP were found across the 
entire microscope slide, at which point no image was taken. 
Results and Discussion: MPs degradation varied by DTT concentration, whereby 20 
mM DTT MPs degraded in 30 days, 25 mM DTT MPs degraded within 10-16 days, and 
40 mM DTT MPs degraded within 8 days (Figure C.2).  The incorporation of DTT within 
10 wt% Hep-N MPs accelerates ester hydrolysis within the PEGDA molecules [276].   
Therefore, by increasing the concentration of DTT within MPs allowed for tunable 
degradation from within 30 days for 20 mM DTT MPs to 8 days for 40 mM DTT MPs. 
 
Figure C.2. 10 wt% Hep-N microparticles degraded between 8 to 30 days in vitro. 
Microparticle degradation time course in vitro was dependent on the concentration of 
dithiothreitol (DTT) crosslinked within microparticles.  Microparticle degradation was 
defined as the time point at which no microparticles were found, at which time no image 
was taken.  Black arrows indicate microparticles; scale bar is 100 μm. 
 
C.4 SUPRASPINATUS MUSCLE WEIGHT AND FIBROUS INFILTRATION FOLLOWING INJURY 
Methods:  After 1, 3, and 6 weeks following injury and treatment, animals were 
euthanized and the supraspinatus muscles were dissected, weighed, and fixed in 2% 
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paraformaldehyde solution (PFA, J.T. Baker) for 45 mins, followed by incubations in 
10% v/v optimum cutting temperature (OCT, Sakura Finetek) PBS solutions with 0, 10, 
and 20% sucrose for 10 mins each.  Muscles were placed in histology blocks with 100% 
OCT under vacuum overnight and then frozen in 190 proof ethanol cooled by liquid 
nitrogen.  Muscles were sectioned with a cryostat (Thermo Scientific CryoStar NX70) 
into 7 μm sections perpendicular to the muscle to create tissue cross-sections. Masson’s 
trichrome (Sigma, Fisher) was used to identify fibrous infiltrate and following staining, 
slides were mounted with Cytoseal 60 (Richard Allen Scientific) and cover slipped.  
Sections were imaged with a Nikon Eclipse 80i and analyzed using ImageJ software and 
color thresholding; n = 4-5 per experimental group per time point.  To quantify fibrous 
infiltration:  
 
% of fibrous infiltration =           blue pixel count     x 100 
                                red pixel count + blue pixel count 
 
Results and Discussion: Though no differences were apparent after 1 week following 
tendon injury, supraspinatus muscle weight significantly decreased by 40 ± 9% compared 
to uninjured controls at week 6 (Figure C.3).  Masson’s trichrome showed that fibrous 
infiltration was significantly greater in the injured supraspinatus muscles compared to 
uninjured controls at both the 3 and 6 week time points (Figure C.3B-C).  These results 
confirm that this is a model of degenerative muscle injury and thus is an appropriate in 




Figure C.3. Supraspinatus muscle weight significantly decreased after 6 weeks and 
fibrosis significantly increased after 3 weeks following injury compared to uninjured 
control. (A) Injured supraspinatus muscle weight was ~40% the weight of the uninjured 
contralateral control 6 weeks following injury; #Significantly different than uninjured 
control; p ≦ 0.05; n = 5 ± SD. (B) Masson’s trichrome staining was used to identify 
fibrous infiltrate (blue) within the supraspinatus muscle (red); scale bar is 100 μm. (C) 
Image analysis indicated that fibrosis was significantly greater in the injured muscle 
compared to the contralateral control after 3 and 6 weeks; **Significantly different than 3 
and 6 week injury; p ≦ 0.05; ***Significantly different than 1, 3, and 6 week injury; p 
≦ 0.05; n = 4-5 ± SD. 
 
C.5 FLOW CYTOMETRY GATING SCHEMES 
Methods: Single cells were identified first by gating for all cells (forward scatter vs. side 
scatter) followed by identifying the single cell population with forward scatter area vs. 
forward scatter height (Figure C.4A-B).  Fluorescence minus one (FMO) controls were 
used to gate for all markers, including CD11b, CD68, CD163 (Figure C.5C-E), CD90, 
CD29, and CD44 (example not shown) and were applied to all samples, including one 
sample shown in Figure C.5F-H.  Cell populations were identified as follows: leukocytes 
(CD11b+), macrophages (CD11b+CD68+), M1-like macrophages 
(CD11b+CD68+CD163-), M2-like macrophages (CD11b+CD68+CD163+), and MSCs 
(CD29+CD44+CD90+). 
Results and Discussion:  Overall results from these studies can be found in the main text 
and in Figure 5.3-4. 
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Figure C.4. Flow cytometry gating scheme for inflammatory cell populations.  (A) Cells 
were first gated through forward scatter (FSC) area vs. side scatter (SSC) area plot, (B) 
then further gated through FSC-area vs. FSC-height plot to identify single cells.  
Fluorescence minus one (FMO)s were used to create gates for (C) CD11b+, (D) CD68+, 
and (E) CD163+ cells.  Example data from supraspinatus muscle shows the identification 
of (F) leukocytes, CD11b+, (G) macrophages, CD11b+CD68+, and (H) M1 or M2 
macrophages, CD11b+CD68+CD163-/+. 
 
C.6 FC BLOCKING OF FLOW CYTOMETRY SAMPLES 
Methods: To ensure that nonspecific binding of antibodies to Fc receptors on leukocytes 
and macrophages did not significantly affect our flow cytometry results, infraspinatus 
muscles from the rotator cuff of Sprague Dawley rats that underwent tendon transection 
and denervation were harvested, digested with collagenase 1A (Sigma) for 45 mins at 37º 
C, and passed through a 40 μm cell strainer (Corning).  Fc blocker (CD16/32, 
BioLegend) was then added to half of each sample according to the manufacturer’s 
protocol.  Briefly, 10 ug/mL Fc blocker was added to each sample and allowed to 
incubate for 5-10 mins on ice.  Subsequently, all samples were stained with the 
inflammatory cell panel that included FITC-conjugated anti-CD11b (AbD Serotec), PE-
conjugated anti-CD163 (BioRad), and APC-conjugated anti-CD68 (BioRad).  Samples 
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were stained for 30 mins and fixed in 2% PFA for 20 mins, then analyzed using a FACS-
AriaIIIu flow cytometer (BD Biosciences).  The cell populations of interest are presented 
as a percentage of single cells. 
Results and Discussion: No significant differences were observed in total myeloid cells, 
total macrophages, M2-like macrophages, or M1-like macrophages between the Fc 
blocked and non-Fc blocked samples (Figure C.5).  As Fc blocking did not affect the 
inflammatory cell staining and subsequent analysis, we did not use Fc blocking for any 
other flow cytometry experiments presented in Chapter 5 or 6. 
 
 
Figure C.5. Fc blocking of flow cytometry samples.  No significant difference in total 
myeloid cells, total macrophages, M2-like macrophages, or M1-like macrophages was 








D.1 PCA ANALYSIS OF MUSCLE SECRETOME  
Methods: Portions of muscle harvested at day 7 were utilized for Luminex analysis with 
the MILLIPLEX MAP rat cytokine/chemokine immunology magnetic bead panel (EMD 
Millipore).  After acquisition of analyte concentrations within each sample, individual 
samples were normalized to total protein content (in mg/mL) which was determined 
using a BCA assay (Thermo Scientific).  Principal component analysis (PCA) was then 
completed using JMP software; n = 4-6. 
Results: PCA was utilized to determine if unsupervised multivariate analysis could 
distinguish between groups based on protein production.  However, PCA was unable to 
distinguish between treatment, injured, or uninjured groups (Figure E.1). 
 
Figure D.1. Principal component analysis did not separate treated, injured, or uninjured 









E.1 EX VIVO SDF-1 LOADED MICROPARTICLE AND SOLUBLE SDF-1 DELIVERY 
Methods: For ex vivo imaging of SDF-1 loaded MPs, infraspinatus muscles from 3 
male, Sprague Dawley rats were cut in half, and one half of each muscle was used for 
either the SDF-1 loaded MP or soluble SDF-1 group.  Each portion of muscle was 
weighed to ensure the same size muscles were used for each group.  As the muscles were 
imaged ex vivo, 1 µg SDF-1 was loaded onto 0.6 mg MPs, the same dose used for cell 
recruitment studies, which was sufficient to detect the fluorescent signal using IVIS.  For 
the soluble SDF-1 group, the same amount of SDF-1 that loaded onto 0.6 mg MPs 
was used.  The SDF-1 loaded MPs and soluble SDF-1 were imaged prior to injection 
into muscles, as well as at day 0, 1, 3, and 7 after injection into the infraspinatus muscles 
using IVIS (Ex: 621, Em: 639). 
Results: Prior to injection, the soluble SDF-1 signal was ~1.3x brighter than the SDF-
1 MPs (Figure E.1A).  Once injected into the muscle, the soluble SDF-1 signal was 
~1.4x brighter than the SDF-1 MPs (Figure E.1B). 
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Figure E.1. Soluble SDF-1 is brighter than SDF-1 loaded MPs before and after 
injection into muscle; n = 3. 
 
Between day 0 to 7, the SDF-1 signal increased in the SDF-1 loaded MP group, 
indicating that SDF-1 was released from MPs and subsequently diffused to the surface 
of the muscle (Figure E.2). 
 
 
Figure E.2. SDF-1 is released from MPs within infraspinatus muscle over 7 days; n = 3. 
  
E.2 IN VIVO SDF-1 LOADED MICROPARTICLE AND SOLUBLE SDF-1 RELEASE 
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Methods: For in vivo imaging of SDF-1 loaded MPs, 9 µg AlexaFluor633-labelled 
SDF-1 was loaded onto 5.4 mg MPs (9x dose compared to cell recruitment studies) to 
ensure that the fluorescent signal was detectable using the In Vivo Imaging System (IVIS, 
Perkin Elmer).  For the soluble SDF-1 group, the same amount of SDF-1 that loaded 
onto 5.4 mg MPs was used.  To track AF633 SDF-1 release over time, longitudinal in 
vivo imaging (Ex: 621, Em: 639) was performed with IVIS on day 0, 1, 3, and 7 
following injury and injection.  Radiant efficiency (photons/second * steradia * µW) was 
evaluated using the same-sized circular region of interest (ROI) at each time point.  
Background fluorescence from the skin was evaluated for each animal at each time point 
and subtracted from each respective ROI measurement. Fluorescent signal at each time 
point was normalized to the day 0 time point; n = 3. 
Results: Similar to the results from our ex vivo study, the soluble SDF-1 signal was 
~1.5x brighter than the SDF-1 MPs when injected and imaged in the supraspinatus 
muscles (Figure D.2A).  However, the difference in fluorescent signal from each group 
was not statistically significant.  For the SDF-1 MP group, on average the highest SDF-
1 signal was observed 1 day following injury and SDF-1 MP injection (Figure D.2Ai-
iv and S2B).   
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Figure E.3. SDF-1α released from MPs remained near the supraspinatus muscle for at 
least 3 days following injury and injection.  (A) Representative images showing (i-iv) 
fluorescently-tagged SDF-1α released from MPs or (v-vii) soluble fluorescently-tagged 
SDF-1α in the supraspinatus muscle over time; red and black circles indicate the region 
of interest used for quantification. (B) For SDF-1α loaded MPs, the highest fluorescently-
tagged SDF-1α signal was observed at day 1, and SDF-1α was still detected after at least 
3 days.  For soluble SDF-1α, no signal was detected by day 3 following injection. 
*Significantly different SDF-1α signal at designated time point; p ≦ 0.05; n = 3 ± SD. 
 
Between 20-60% of the SDF-1 signal observed at day 0 was still observed by day 3, 
whereas little to no SDF-1 signal was observed by day 7.  For the soluble SDF-1 
group, the highest SDF-1 signal was observed at day 0 (Figure E.3v-viii and E.3B).  By 
day 1, only 30-50% of the SDF-1 signal observed at day 0 was still present and by day 
3, little to no SDF-1 signal was observed.  Ultimately, significantly more SDF-1 signal 




Discussion: At day 0, it appeared that the soluble SDF-1 group was brighter than SDF-
1 MPs, which was corroborated by our ex vivo findings (Figure E.1 and 2A).  
Collectively, these results suggest that MPs may be interfering with the fluorescent SDF-
1 signal in these studies.  For SDF-1 loaded MPs, the greatest AF633 SDF-1 signal 
was generally exhibited 1 day following injury and MP injection, which may be due to 
the release of AF633 SDF-1 from MPs within ~1 day (Figure E.3i-iv).  Furthermore, 
because a high dose of MPs was used for IVIS imaging compared to our cell recruitment 
studies, it is also possible that the MPs shifted within the muscle over the first 24 hours, 
possibly resulting in the increased fluorescent signal.  Despite most SDF-1 being 
released from MPs after ~24 hours, however, some AF633 SDF-1 was still detected 
near the supraspinatus muscle at least 3 days following injury and injection (Figure E.3A-
B).  In contrast, with soluble SDF-1, AF633 SDF-1 signal began to decrease as early 
as 1 day following injection, and no AF633 SDF-1 signal was observed at day 3, 
indicating that at this concentration, MPs retained SDF-1 near the site of injection over 
a longer period of time than soluble SDF-1 alone (Figure E.3B).  It is important to note, 
however, that due to limits in the in sensitivity of the imaging equipment, the dose 
employed in the IVIS imaging studies was 9x greater than the dose used for cell 
recruitment, meaning that the release kinetics observed may differ from the release 
kinetics during the cell recruitment studies (see Chapter 5 and 6).  Nevertheless, our 
results indicate that with SDF-1 loaded MPs, SDF-1 signal was observed localized 
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